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List of abbreviations
ApM1  Adipose most abundant gene transcript 1
APOA5  Apolipoprotein A5 gene
APOAII  Apolipoprotein AII
APOAV  Apolipoprotein AV
ApoB  Apolipoprotein B
ASP  Acylation stimulatory protein 
B2M  Beta-2-microglobulin
BMI  Body mass index
CETP  Cholesteryl ester transfer protein
Ct  Threshold cycle
CVD  Cardiovascular disease
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FBAT  Family-based association test
FCH  Familial combined hyperlipidemia
FFA  Free fatty acid
GEE  Generalized estimating equations
HBAT  Haplotype-based association test
HDLc  High-density lipoprotein cholesterol 
HL  Hepatic lipase
HOMA-index Homeostasis model assessment-index
HSL  Hormone-sensitive lipase
HyperapoB Hyperapobetalipoproteinemia
IMT  Intima-media thickness
IR  Insulin resistance
LDLc  Low-density lipoprotein cholesterol 
LEPR  Leptin receptor 
LPL  Lipoprotein lipase
MnSOD  Manganese superoxide dismutase
mRNA  Messenger ribonucleic acid
NL relatives Normolipidemic relatives
PBAT  Pedigree-based association test
PBMCs  Peripheral blood mononuclear cells
PCR  Polymerase chain reaction
PCR-RFLP Polymerase chain reaction restriction fragment length polymorphism
Q-PCR  Real-time quantitative PCR
QTL  Quantitative trait linkage analyses
RLPc  Remnant-like particle cholesterol
sdLDL  Small dense LDL
SNP  Single nucleotide polymorphism
SOLAR  Sequential oligogenic linkage analysis routines
TC  Total cholesterol
TDT  Transmission disequilibrium association tests
TG  Triglycerides
TRL  Triglyceride-rich lipoproteins
TXNIP  Thioredoxin interacting protein
USF1  Upstream stimulatory factor 1
UTR  Untranslated region
VLDL  Very low-density lipoprotein 
WHR  Waist-hip ratio
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Introduction and outline of thesis
Cardiovascular disease
Since many years, cardiovascular diseases (CVD) are the most frequent cause of death in western 
civilization. In the Netherlands, 45.445 individuals died of CVD in 2004, representing 33% of 
the total number of deaths that year 1. Many risk factors for CVD have been identiﬁed, including 
smoking, diabetes mellitus, high blood pressure, obesity, lack of exercise and a disturbed lipid 
proﬁle. Obesity (body mass index > 25 kg/m2) is an important risk factor for CVD, because it 
is present in approximately 48% of the Dutch population. Obesity is responsible for 4% of the 
newly diagnosed CVD patients 2, 3. The relation of hyperlipidemia with CVD is stronger, since 
20% percent of the total incidence of CVD is attributable to elevated serum total cholesterol 
levels 3. Approximately 10% of the Dutch population of 20 years and older, has elevated total 
cholesterol levels (>6.5 mmol/L) and/or takes cholesterol-lowering drugs 2. 
Familial combined hyperlipidemia
Familial Combined Hyperlipidemia (FCH; OMIM144250) is the most common heritable 
lipid disorder, aﬀecting 1-5% of the general population and up to 20% of the survivors of a 
premature myocardial infarction 4. 
The disturbed lipid proﬁle of FCH is characterized by elevated levels of total cholesterol (TC), 
triglycerides (TG) and apolipoprotein B (apoB) 5. Furthermore, increased levels of low-density 
lipoprotein cholesterol (LDLc), decreased levels of high-density lipoprotein cholesterol (HDLc) 
and the presence of small dense LDL (sdLDL) are characteristic features of patients with FCH 6, 
7. Besides a disturbed lipid proﬁle, FCH patients are often obese and insulin resistant. So, several 
cardiovascular risk factors are present in patients with FCH, thereby contributing to the two- to 
ﬁvefold increased risk of premature CVD (before the age of 60 years) in FCH patients 8-11.
Because of this increased risk of CVD, it is of great importance to correctly identify the patients 
with FCH and treat them appropriately. The diagnosis of FCH is, however, diﬃcult because of 
the complex phenotypic heterogeneity and the highly variable expression of FCH, as genetic, 
metabolic and environmental factors inﬂuence its expression 12, 13. 
In 1973, FCH was ﬁrst described by Goldstein et al., based on elevated plasma TC and/or TG 
levels above the 90th percentile adjusted for age and gender, within a family with multiple types 
of hyperlipidemia and the presence of premature CVD 14, 15.
A major problem in the diagnosis of FCH is, however, that the pattern of hyperlipidemia 
within one individual may vary over time, leading to a non-consistent diagnosis of FCH within 
a person over time 16. This makes the traditional diagnostic criteria less suitable for the diagnosis 
of a genetic lipid disorder like FCH. To establish a more consistent diagnosis of FCH, we have 
recently evaluated potential new diagnostic criteria for FCH, including sdLDL and apoB, in 
our 5-year follow-up data of 32 FCH families. A nomogram was developed to calculate the 
probability of being aﬀected with FCH, based on plasma TC and TG levels, adjusted for age and 
gender, and absolute apoB levels, as recently published 17. When this probability is greater than 
60% the subject is deﬁned aﬀected by FCH when also at least one ﬁrst-degree relative exhibits 
the FCH phenotype and at least one individual in the family has premature CVD.
14
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The genetic origin of familial combined hyperlipidemia
Despite more than 30 years of research the complex genetics of FCH is still not fully 
understood. Originally, FCH was thought to be a homogeneous single-gene disorder with a 
major eﬀect on triglyceride levels and a secondary eﬀect on cholesterol levels 14. Segregation 
analyses, however, have implicated major genes in FCH that control TG levels, apoB levels, 
sdLDL and insulin resistance 13, 18-23. Furthermore, environmental factors, like diet, exercise and 
smoking, are known to play a role in the expression of FCH 24. So, at present FCH is known as 
a multifactorial heterogeneous disorder with numerous genetic, metabolic and environmental 
factors contributing to its complex phenotype. 
Diﬀerent strategies can be used to identify genetic factors contributing to FCH, including 
linkage analyses and association studies. For linkage analyses, genome-wide scans are performed 
within families containing two or more aﬀected individuals by testing many evenly spaced 
microsatellite markers covering the whole genome. The co-segregation of these markers and FCH 
is analyzed, resulting in the identiﬁcation of a chromosomal region that may contain gene(s) 
involved in the pathophysiology of FCH 25. 
The aim in association studies is to detect disease alleles in candidate genes that are more 
(or less) common in aﬀected subjects than in the general population. Candidate genes include; 
1) genes located in a region of interest identiﬁed with linkage analyses, 2) genes with a biological 
action known to be involved in the development or physiology of the disease, and 3) genes 
involved in similar phenotypes in animal models. The association of the variations in candidate 
genes with FCH can be tested in a case-control design or family based association studies. When 
more than one variant is genotyped in a candidate gene, haplotype analyses can be performed. 
Haplotype analyses are in general more powerful to identify assocation, as the complete genomic 
region included by the genotyped variants is taken into account.
Linkage analyses
To identify chromosomal regions, containing candidate gene(s) for FCH, linkage analyses 
have been performed in seven FCH study populations. These linkage analyses have resulted in 
the identiﬁcation of multiple loci for FCH, as depicted in ﬁgure 1. One locus, on chromosome 
1q21-23 has been identiﬁed as a major locus for FCH in Finnish FCH families and has 
subsequently been replicated in four other FCH study populations 26-30. Another repeatedly 
identiﬁed locus for FCH in Finnish, Dutch and British FCH families, is located on the long 
arm of chromosome 11, a region including the apolipoprotein A1/C3/A4/A5 gene cluster 31-33. 
Furthermore, loci on seven other chromosomes have been identiﬁed for FCH 29, 34-36. Linkage 
analyses for the separate traits of FCH, including elevated levels of TC, TG and apoB, decreased 
levels of HDLc and the presence of sdLDL, resulted in the identiﬁcation of more than 20 loci 
spread over the entire genome 27, 29, 31, 33, 36-43.
Candidate genes
Based on mice studies, the thioredoxin interacting protein (TXNIP) has been proposed as 
a candidate gene for FCH underlying the linkage signal on chromosome 1q21-23 44. TXNIP 
is a major regulator of the cellular redox state in mice and humans; by binding and inhibiting 
thioredoxin, TXNIP inhibits the insulin reducing activity of thioredoxin 45. 
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More recently, a second candidate gene on chromosome 1q21-23, the upstream stimulatory 
factor 1 (USF1) gene, has been suggested as the prime candidate gene for FCH 46. Two SNPs 
in the USF1 gene showed linkage and association with FCH and multiple phenotypes of FCH, 
including elevated levels of TG, TC, apoB and sdLDL, suggesting that USF1 contributes to the 
complex pathophysiology of FCH. Supportive evidence for these associations have been found 
in two other independent study populations 42, 47. USF1 regulates the transcriptional activation of 
more than 40 important enzymes, which are involved in glucose and lipid metabolism, adipose 
tissue metabolism and blood pressure control, thereby potentially important in the development 
of atherosclerosis 46, 48. 
The repeatedly identiﬁed locus on chromosome 11q, includes the apolipoprotein 
 A1-C3-A4-A5 gene cluster 49. By combined linkage and association analysis, the apolipoprotein 
Figure 1
Presented are all 22 autosomal chromosomes and 2 sex chromosomes present in humans. The arrows indi-
cate previously identiﬁed loci for FCH in Finnish (1), Dutch (2) and Brittish (3) FCH study populations. 
* The locus on chromosome 1q21-23 is replicated in the Mexican, German, Chinese and American FCH 
populations.
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A5 (APOA5) gene, encoding the apolipoprotein AV (APOAV), has been shown to contribute to 
FCH and its related lipid phenotypes 33, 50, 51. Based on mice studies, it has been suggested that the 
APOAV modulates TG levels by inﬂuencing VLDL production and secretion 52, 53.
Based on linkage analyses, biological function and animal models several other candidate 
genes for FCH have been evaluated for their contribution to the FCH phenotype (Table 1). 
Investigated candidate genes are genes involved in lipid, adipose tissue and glucose metabolism. 
The most recently investigated candidate gene contributing to FCH is the functional acylation 
stimulating protein (ASP) receptor C5L2, which is involved in fatty acid uptake in adipose 
tissue 54.
Table 1     Investigated candidate genes for FCH
Gene Chromosome Associated with FCH References
Lipid metabolism
     Apolipoprotein A1 11q23 +/- 51, 56-62
     Apolipoprotein A4 11q23 + 63, 64
     Apolipoprotein B 2p24 - 65, 66
     Apolipoprotein C3 11q23 + 32, 51, 56, 58, 
60-62, 67-69
     Apolipoprotein E 19q13 + 65, 70-72
     Hepatic lipase 15q21-23 + 73, 74
     Lipoprotein lipase 8p22 +/- 59, 75-83
Adipose tissue / FFA metabolism
     ASP receptor C5L2 19q13 + 55
     FABP2 4q28-31 - 75, 84
     Hormone sensitive lipase 19q13 - 85
     PPARα 22q12-13 + 86
     PPARγ 3p25 - 87, 88
     TNFRSF1B 1p36 + 89
     Uncoupling protein 1 4q31 - 69, 90
Glucose metabolism
     Beta3-adrenergic receptor 8p12-11 - 75, 90
      Insulin receptor substrate 1 2q36 - 75
Other
     Alpha-adducin 4p16 + 91
ASP receptor C5L2, an acylation stimulating protein receptor; FABP2, Fatty-acid binding protein2; PPAR, 
Peroxisome proliferator-activated receptors; TNFRSF1B, Tumour necrosis factor receptor 2; +, The candi-
date gene was associated with FCH; +/-, The association of the candidate gene with FCH is still controver-
sial; -, No association of the candidate gene with FCH was found.
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The metabolic origin of familial combined hyperlipidemia
Although several metabolic abnormalities have been suggested to be important for the 
development of FCH, the exact pathophysiology of FCH is still unknown. Generally, it is thought 
that FCH is associated with an overproduction of very low-density lipoprotein (VLDL) by the 
liver, combined with a delayed clearance of atherogenic triglyceride-rich lipoproteins 91, 92. This 
is hypothesized to be caused by a disturbed fatty acid (FFA) metabolism. Evidence of a defective 
postprandial and postabsorptive FFA metabolism in FCH has been demonstrated in vivo 93, 
94. An increased ﬂow of FFA may lead to hepatic overproduction of VLDL 95. In patients with 
FCH, this increased ﬂux of FFA to the liver is possibly caused by inadequate FFA trapping in the 
adipose tissue 96, 97. So, it is hypothesized that a disturbed adipose tissue metabolism is involved in 
the pathophysiology of FCH. Presented in ﬁgure 2, is a schematic overview of the hypothesized 
mechanisms by which the adipose tissue contributes to insulin resistance, dyslipidemia and 
atherosclerosis, all characteristics features of FCH.
Disturbed adipose tissue metabolism
The adipose tissue is the major site for storage and mobilization of free fatty acids (FFAs) 
97, 98. FFAs are transported in the blood bound to albumin to the adipose tissue, where the 
FFAs are taken up by the adipocytes to be esteriﬁed to TG. Furthermore, the lipoprotein lipase 
(LPL) catalyzed hydrolysis of TG in chylomicrons and VLDL particles, results in the liberation 
of FFAs, which are also taken up by the adipocyte to be esteriﬁed into triglycerides 99. This 
process of esteriﬁcation to TG is mediated by the action of acylation stimulatory protein (ASP) 
and modulated by insulin 100. The TG can also be de-esteriﬁed again into FFAs. This process 
of reesteriﬁcation of FFAs into TG in the adipose tissue is stimulated by hormone-sensitive 
lipase (HSL) 101. These FFAs leave the adipose tissue and enter the bloodstream, where they bind 
to albumin, which transports it to other organs for utilization. FCH patients are suggested to 
have a defective estiﬁcation and mobilization of FFA in the adipose tissue, leading to reduced 
FFA uptake into adipocytes. This results in an increased delivery of FFA to the liver, which 
in turn leads to enhanced synthesis of VLDL conversion to sdLDL, characteristic for FCH
(Figure 2, A) 102. 
 
Adipokines 
Adipose tissue was for a long time regarded as a relatively passive site of energy storage. 
Presently, it is clear that adipose tissue is not only involved in energy storage, but also acts as an 
endocrinological active tissue which releases numerous proteins involved in inﬂammation, lipid 
and glucose metabolism and atherogenesis 103. Two major adipokines produced by the adipose 
tissue are leptin and adiponectin.
Leptin is involved in the regulation of the energy expenditure and appetite via 
hypothalamic receptors, including the leptin receptor (LEPR) 104. An increase in leptin 
concentration will lead to more energy expenditure and less appetite in normal persons 
via the hypothalamus. In obese individuals, however, increased leptin levels appear to fail 
to inﬂuence energy intake or expenditure to restore fat mass to normal. Obesity is therefore 
believed to be a state of leptin resistance. Since leptin has direct eﬀects on insulin secretion, 
elevated leptin levels are not only associated with obesity, but also with insulin resistance 105. 
18
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Furthermore, leptin levels are associated with CVD (Figure 2, B).
Another major adipokine derived from the adipose tissue is adiponectin, which is abundantly 
present in human plasma 106. In contrast to leptin, adiponectin production is inversely correlated 
with adipose tissue mass 107. Adiponectin stimulates the oxidation of fatty acids in muscle, 
enhances insulin sensitivity in muscle and liver and inhibits the inﬂammatory process and 
thereby, possibly atherosclerosis 107-110. In addition, adiponectin had been reported to directly and 
indirectly modulate plasma lipid levels 111, 112. Based on these properties, adiponectin is suggested 
to be the missing link between obesity, insulin resistance and atherosclerosis (Figure 2, B). 
Visfatin is a very recently discovered visceral fat-speciﬁc protein that may be related to the 
development of obesity-related diseases such as diabetes mellitus and cardiovascular disease 113. 
Other proteins released by the adipose tissue include adipsin, resistin, tumor necrosis factor 
alpha, interleukine 6 and plasminogen activator inhibitor 1 114, 115. These proteins released by the 
adipose tissue are also potentially involved in dyslipidemia, insulin resistance and atherosclerosis, 
and may thus contribute to FCH (Figure 2, C).
Figure 2
Presented is a schematic overview of the potential central role of adipose tissue in dyslipidemia, insulin 
resistance and atherosclerosis. Defective FFA trapping in the adipose tissue, leads to an increased delivery of 
FFA to the liver, which in turn leads to enhanced synthesis of VLDL (A). Furthermore, adipose tissue releases 
adipocytokines including leptin and adiponectin (B) and numerous other proteins (C), which are involved 
in  insulin resistance, dyslipidemia and atherosclerosis. ApoB, apolipoprotein B; ASP, acylation stimulating 
protein; FFA, free fatty acids; HSL, hormone-sensitive lipase; LPL, lipoprotein lipase; TG, triglycerides; 
VLDL, very low-density lipoprotein.
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Objectives and outline of this thesis
The central aim of the present thesis was to further explore the genetic origin of FCH by 
performing both genome-wide linkage analyses in our well-deﬁned FCH families and using the 
candidate gene approach for TXNIP, USF1 and APOA5, three genes reported to be potentially 
involved in FCH (Part 1).
The second aim was to further evaluate the role of adipose tissue in the etiology of FCH. First 
we reviewed several metabolic disturbances that may contribute to the pathogenesis of FCH, 
including the presence of a possible defect in the adipose tissue metabolism in relation to the lipid 
levels, parameters of obesity and insulin resistance and the presence of atherosclerosis (Figure 3). 
We have evaluated the plasma levels of two major adipokines, adiponectin and leptin. Finally, 
variations in two genes, the gene encoding for adiponectin (ApM1), and the gene, encoding for 
the leptin receptor (LEPR), were determined in relation to FCH (Part 2).
FCH study population
To investigate the genetic and metabolic origin of FCH, we used the Nijmegen FCH study 
population ascertained in 1994 and followed-up and expanded in 1999. In 2004, all FCH 
patients and normolipidemic relatives from both 1994 and 1999 were invited for the 10-years 
follow-up study.
In 1994, 40 FCH families, including both FCH patients, normolipidemic relatives and spouses, 
were recruited. These multigenerational families varied in size from 12 to 114 members and 
spanned multiple (between 3 and 5) generations. In total, 201 FCH patients, 357 normolipidemic 
relatives and 102 spouses were recruited.
Thirty-two of the 40 FCH families, recruited in 1994, participated in the 5-years follow-
up study in 1999. These families were further extended by the recruitment of 127 new family 
members, including 19 FCH patients. Furthermore, 5 new FCH families were recruited, 
including 121 individuals. So, in 1999 the Nijmegen FCH study population comprised 37 FCH 
families, including 644 individuals. 
In 2004 the 10-years follow-up study was started. In total 31 families from 1994 and 30 
families from 1999, including in total 312 subjects, participated in this follow-up study. From 28 
families, including 63 patients with FCH and 125 normolipidemic relatives, data were available 
from 1994, 1999 and 2004. In total 341 individuals of 33 families, including 103 FCH patients, 
participated in this 10-years follow-up study. Non-invasive measurements of atherosclerosis, 
including intima-media thickness (IMT) measurements, were performed in all participating 
individuals.
Part 1: The genetic origin of familial combined hyperlipidemia
A genome-wide linkage scan was performed in the thirteen most informative families of our 
FCH study population in 1994, consisting of 414 individuals with phenotypic data. In total 377 
autosomal markers with an average density of 10 cM and an average heterozygosity of 0.75 were 
genotyped in the 275 most informative individuals. Linkage analyses were performed for two 
diﬀerent diagnostic criteria of FCH, the traditional diagnostic criteria and the nomogram, and 
for related quantitative traits, including TC, TG, apoB, HDLc and sdLDL levels (Chapter 1). 
To evaluate the potential role of TXNIP in the FCH phenotype in humans, we analyzed 
20
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the coding region, 5’UTR and introns of the TXNIP gene by direct sequencing in 10 well-
deﬁned patients with FCH and 5 healthy controls (Chapter 2). The 3’UTR of the TXNIP gene, 
inﬂuencing the expression levels of TXNIP, has not been sequenced in FCH patients. We have 
quantiﬁed TXNIP mRNA expression levels in peripheral blood mononuclear cells (PBMCs) of 
30 patients with FCH and 30 healthy controls (Chapter 3).
In chapter 4, powerfull family-based analyses were used to analyze the role of USF1 in FCH. 
Two SNPs of the USF1 gene were measured and the association of the individual SNPs and 
their combination into haplotypes with FCH and its associated phenotypes was investigated. 
Furthermore, USF1 mRNA expression levels were quantiﬁed in PBMCs of 30 FCH patients and 
30 healthy controls. 
Finally we investigated the potential role of the APOA5 gene in the etiology of FCH. Two SNPs 
in this gene, -1131T>C and S19W, were determined and analyzed by family-based association 
analyses of the individual SNPs and haplotypes (Chapter 5).
Part 2: The metabolic origin of familial combined hyperlipidemia
In chapter 6 we review the characteristic phenotypes of FCH, the central role of FFA in 
the pathogenesis of FCH and the possibility of a disturbed adipose tissue metabolism in the 
pathophysiology of FCH. Furthermore, the role of remnant-like particles cholesterol (RLPc), as 
a characteristic phenotype of FCH, and its contribution to the increased risk of CVD in FCH 
patients are explored (Chapter 7).
To investigate the role of adipose tissue in FCH, we measured plasma leptin levels in 37 FCH 
families, and analyzed the relation of leptin levels with FCH, obesity and CVD. (Chapter 8). In 
addition, we determined the eﬀect of the Gln223Arg polymorphism in the leptin receptor in our 
FCH study population (Chapter 9). 
Plasma adiponectin levels were measured, to evaluate a possible association of adiponectin 
levels with FCH (Chapter 10). To investigate the role of genetic variations in the ApM1 gene, 
encoding for adiponectin, in determining the adiponectin levels in patients with FCH, we 
measured two variations in this gene. Furthermore, we studied the association of these variants 
in the ApM1 gene with FCH and its associated atherogenic lipid proﬁle, using a family-based 
single-nucleotide polymorphism (SNP) and haplotype approach (Chapter 11). 
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Figure 3
Presented is a schematic overview of the hypothesized role of a disturbed adipose tissue metabolism in the 
pathophysiology of FCH. A: Defective FFA trapping in the adipose tissue, leads to reduced FFA uptake into 
adipocytes. Resulting in an increased delivery of FFA to the liver, which in turn leads to enhanced synthesis 
of VLDL and sdLDL, characteristic for FCH. B: The release of leptin is hypothesized to be increased in 
patients with FCH, whereas the release of adiponectin is hypothesized to be decreased in patients with 
FCH. These disturbed adipocytokine levels may contribute to obesity, dyslipidemia, insulin resistance and 
atherosclerosis in patients with FCH. C: The release of other proteins by the adipose tissue, which are involved 
in atherogenesis, may also be disturbed and are therefore also potentially involved in FCH.
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Genome-wide linkage analysis in familial 
combined hyperlipidemia: eﬀect of diagnostic 
criteria and quantitative traits
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Gerly M. van der Vleuten, Sita H.H.M. Vermeulen, 
Lodewijk A. Sandkuijl †, Rune R. Frants, 
Martin den Heijer, Jacqueline de Graaf, 
Anton F.H. Stalenhoef. 
Abstract
Background Several linkage analyses for familial combined hyperlipidemia (FCH) have been 
performed, all using diﬀerent diagnostic criteria, leading to the identiﬁcation of multiple loci for 
FCH. Diﬀerent diagnostic criteria were, however, used for these linkage analyses. The aim of the 
present study was to investigate whether diﬀerent diagnostic criteria for FCH aﬀect the results 
of linkage analyses. Methods For the genome-wide scan we used thirteen informative Dutch 
FCH families. Multipoint linkage analyses were performed using SOLAR. Results The linkage 
analyses using the traditional diagnostic criteria for FCH did not result in the identiﬁcation of 
a region of interest. Linkage analyses using the nomogram did result in the identiﬁcation of two 
regions of interest (lod score > 1), on chromosome 6q25-27  (lod score = 1.30) and 12q23-24 
(lod score = 1.02). Linkage analysis of two characteristic quantitative traits of FCH, including 
small, dense LDL (sdLDL) and plasma triglyceride (TG) levels, supported chromosome 6q as 
potential locus for FCH (sdLDL: lodscore = 1.13; TG: lodscore = 1.92).  Linkage analysis of 
the other quantitative traits of FCH showed four regions with suggestive evidence of linkage, 
including TG levels (10p14-q21 (lod score = 2.24)), total cholesterol levels (1p32-12 (lod score 
= 1.98) and 8p22-21 (lod score = 2.11)) and HDL-cholesterol levels (19q13 (lod score = 1.73)). 
Conclusion The use of diﬀerent diagnostic criteria for FCH aﬀects the results of linkage analyses; 
only when using the nomogram, a region of interest on chromosome 6q was identiﬁed, which 
was supported by suggestive evidence of linkage for TG levels and a region of interest for sdLDL, 
two characteristic traits of FCH. 
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Introduction
Familial combined hyperlipidemia (FCH) is a multifactorial disease, characterized by 
the presence of multiple lipid and lipoprotein phenotypes, including hypercholesterolemia, 
hypertriglyceridemia and hyperapobetalipoproteinemia. Decreased levels of high-density 
lipoprotein cholesterol (HDLc) and the presence of small dense low-density lipoprotein (sdLDL) 
are also characteristic for FCH 13, 116. In addition to a disturbed lipid proﬁle, FCH patients are 
obese and insulin resistant 9.
The diagnosis of FCH, ﬁrst described in 1973, is traditionally based on elevated plasma total 
cholesterol (TC) and/or triglyceride (TG) levels above the 90th percentile adjusted for age and 
gender, within a family with multiple types of hyperlipidemia and the presence of premature 
CVD 14. Other groups studying FCH, however, use diﬀerent cut-oﬀ points for elevated TC 
and/or TG levels, i.e. the 95th percentile or absolute values of TC (> 6.5mmol/l) and/or TG (> 
2.3 mmol/l) levels 26-28, 30, 32, 34. Since 1983, hyperapobetalipoproteinemia has been identiﬁed as 
a characteristic phenotype of FCH 117. Also for apolipoprotein B (apoB) levels, diﬀerent cut-oﬀ 
points are used (i.e. the 75th or 90th percentile) as diagnostic criterion for FCH 27, 34. Recently, we 
showed that the traditional diagnostic criteria for FCH were not consistent within a person over 
time, thereby making these criteria less suitable as diagnostic tool 16. Therefore, we developed a 
nomogram, based on 5 years follow-up data of 32 FCH families, to establish the diagnosis FCH 
more consistent over time 17. This nomogram is based on plasma TG and TC levels, adjusted for 
age and gender, and absolute apoB levels.
Despite more than 30 years of research, the complex genetics of FCH is still not fully understood. 
Back in 1973, FCH was reported as a monogenetic disorder with dominant inheritance 14; 
however, subsequent studies have proven that the inheritance of FCH is multifactorial. Evidence 
for a major gene eﬀect on various FCH related traits, including apoB levels 20, 22, 23, TG levels 21, 
the presence of sdLDL 18, 23, and insulin resistance 19 has been provided by segregation analyses.
Several linkage analyses have been performed in various ethnic groups, leading to the 
identiﬁcation of multiple suggestive or signiﬁcant loci for FCH and its related phenotypes. 
Using the traditional diagnostic criteria, loci on chromosome 1q, 10q and 21p were identiﬁed 
in Finnish FCH families 28, 29 and additional loci on chromosome 2p and 11p were identiﬁed 
when combined analyses of these Finnish FCH families with a separate Dutch FCH population 
were performed 35. Separate linkage analyses in this set of Dutch FCH families, using traditional 
diagnostic criteria in combination with apoB levels above the 75th percentile, provided evidence 
of linkage on chromosome 11p, 16q and 19q 34. Within British FCH families, using more strict 
criteria with TC or TG plasma levels above the 95th percentile, genome-wide linkage analyses led 
to the identiﬁcation of loci on chromosome 6q, 8p and 11p 32, 36. FCH diagnosis based on TC 
levels above 250 mg/dL and/or TG levels above 200 mg/dL and/or apoB levels above the 75th 
percentile, as diagnostic criteria in Dutch FCH families, resulted in the identiﬁcation of loci 
on chromosome 6q, 11q and 16q 31. The linkage analyses in Chinese, German, American and 
Mexican FCH families, where supportive results for linkage of FCH with chromosome 1q21-23 
have been reported, were performed again with other diagnostic criteria 26, 27, 30. The discrepancy 
between the linkage analyses in the identiﬁed loci may be caused by the use of diﬀerent diagnostic 
criteria, in addition to its complex etiology.
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The aim of the present study was to evaluate whether the use of diﬀerent diagnostic criteria 
aﬀect the results of linkage analyses, thereby contributing to the diversity in identiﬁed loci in the 
diﬀerent FCH study populations. Therefore we performed linkage analyses for two diagnostic 
criteria of FCH, using the traditional diagnostic criteria and the nomogram. Here we present the 
results of never before published genome-wide linkage analyses performed in our group of very 
well documented Dutch FCH families from Nijmegen with 10-years follow-up data. 
Methods
Ascertainment of FCH families
The study population consisted of 40 large FCH families 16, 18, 20. The families were ascertained 
through probands, recruited from the outpatient lipid clinic of the Radboud University 
Nijmegen Medical Centre 18, 20. Back in 1994, families were included if the proband exhibited a 
combined hyperlipidemia with both plasma TC and TG levels above the age- and gender-related 
90th percentile during several periods in which they were not treated with lipid-lowering drugs 
and despite dietary advice 18, 20. In addition, a ﬁrst-degree relative had to present elevated levels of 
TC and/or TG above the 90th percentile and the proband or a ﬁrst-degree relative had to present 
premature cardiovascular disease (CVD) before the age of 60 years. Families were excluded when 
probands had underlying diseases causing hyperlipidemia (i.e., diabetes mellitus type 1 and 2, 
hypothyroidism, and hepatic or renal impairment), a ﬁrst-degree relative had tendon xanthomata 
or probands were homozygous for the APOE2 allele. All included subjects were Caucasian and 
above the age of 10 years 18, 20.
Diagnostic criteria for FCH
In the present study we have used two diagnostic criteria for FCH, namely the traditional 
diagnostic criteria and the nomogram, which is based on our 5-years follow-up data and more 
consistent over time 17. The traditional diagnostic criteria for FCH are based on TC and/or TG 
above the age- and sex-related 90th percentile and was used for the ascertainment of the families. 
The nomogram was used to calculate the probability of being aﬀected with FCH and is based on 
plasma TC and TG levels, adjusted for age and gender, and absolute apoB levels 17. In short, in 
the nomogram for each of the three variables the corresponding number of points was read from 
a scale and then summed to give a total point score, which was translated into a probability of 
being aﬀected by FCH. When having a probability of more than 60% the subject was deﬁned as 
aﬀected by FCH. For both diagnostic criteria for FCH, the diagnostic lipid phenotype had to be 
present in at least one ﬁrst-degree relative, and premature CVD, before the age of 60 years, had 
to be present in at least one individual in the family. The total study population comprised 40 
multigenerational families including 663 individuals with phenotypic data 18, 20. 
Genome-wide linkage scan
The genome-wide linkage scan was performed in the thirteen most informative families 
consisting of 414 individuals with phenotypic data. Of these subjects, 275 subjects were 
genotyped. In 11 of these 13 families, ascertained through the traditional criteria, the proband 
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also fulﬁlled the criterion of the nomogram for the FCH diagnosis; for the other 2 probands, the 
nomogram could not be applied because of missing apoB data. The families varied in size from 
12 to 114 members and spanned multiple (between 3 and 5) generations. The selection of the 
families and individuals, based on their position in the pedigree and informativity, was based on 
simulation analyses performed with the SLINK software 118. As in the literature, linkage analyses 
of a separate independent Dutch FCH population has been published, we will refer to our FCH 
families as the Nijmegen FCH families.
The ethical committee of the Radboud University Nijmegen Medical Centre approved the 
study protocol and the procedures were in accordance with institutional guidelines. All subjects 
gave informed consent.
Biochemical analyses
Plasma TC and TG were determined by enzymatic, commercially available reagents 
(Boehringer-Mannheim, Germany, catalog No. 237574 and Sera Pak, Miles, Belgium, catalog 
No. 6639, respectively). TC and TG levels were available for all 414 individuals. Plasma apoB 
concentrations were successfully determined by immunonephelometry  in 395 individuals 119. 
HDLc was successfully determined by the polyethylene glycol 6000 method in all individuals. 
LDL subfractions were separated by single spin density gradient ultracentrifugation 120. A 
continuous variable K represents the LDL subfraction proﬁle of each individual. A negative K-
value (K ≤ -0.1) reﬂects a more dense LDL subfraction proﬁle, and a positive K-value (K>-0.1) 
reﬂects a more buoyant proﬁle. A K-value was available for 386 individuals.
Genotyping
DNA was obtained from peripheral blood lymphocytes using a standard technique 121. The 
genotyping was performed by the Mammalian Genotyping Service at the Marshﬁeld Medical 
Research Foundation (Marshﬁeld, Wisconsin, USA). The 377 autosomal markers had an average 
density of 10 cM and an average heterozygosity of 0.75. The markers primarily originated from 
screening set 9 and in part from screening set 10. Sex-averaged marker maps were obtained from 
the Marshﬁeld Center of Medical Genetics. To ensure the quality of genotyping data, Mendelian 
inconsistencies were checked with the PedCheck program and inconsistent marker genotypes 
were eliminated (0.5%) 122. 
Statistical analysis
Descriptive statistics, presented separately for FCH patients, normolipidemic relatives 
and spouses, are expressed as mean with standard deviation (SD). Heritability estimates and 
multipoint linkage analysis were performed using the pedigree-based variance components 
method as implemented in the Sequential Oligogenic Linkage Analysis Routines (SOLAR) 
package (version 2.1.3 and prerelease version 4.0.0) 123. Since FCH has a complex pattern of 
inheritance, nonparametric linkage methods, not requiring assumptions regarding the mode of 
inheritance, were used. Multipoint linkage analysis increases the power to detect true linkage, 
decreases the false positive rate and gives a more precise localisation of the linkage regions 123. 
Multipoint linkage analyses were performed for FCH using the traditional diagnostic criteria and 
the nomogram to diagnose FCH, both having a dichotomous distribution. Multipoint linkage 
analyses were also performed for the traits associated with FCH, including TC, TG, apoB, HDLc 
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levels and the K-value, as quantitative parameters. These traits were adjusted for age and gender 
by using the regression modeling option of SOLAR. The variance components method assumes 
multivariate normality of the trait and is vulnerable to a high kurtosis 124. In order to obtain 
normally distributed values, TG was logarithmically transformed and z-scores were calculated for 
all quantitative parameters. Allele frequencies of the markers were estimated through maximum 
likelihood techniques and were used to impute missing genotype data and to create identical by 
descent (IBD) ﬁles. The program HOMO, implemented in the SOLAR package, was used to 
assess genetic heterogeneity. Simulation techniques were applied to calculate empirical pointwise 
p-values of observed lod scores. 
The heritability estimates were calculated for the quantitative traits using SOLAR 123. We 
obtained heritability estimates of 0.59 for TC, 0.49 for TG, 0.63 for apoB, 0.40 for HDLc and 
0.54 for the K-value. The power to obtain a lod score above 1, representing a region of interest, 
for a locus that explains at least 20% of the trait heritability was approximately 80%. According 
to Lander and Kruglyak 125, a lod score above 1.9 provides suggestive evidence of linkage and 
a lod score above 3.3 provides signiﬁcant evidence of linkage. As we have only included the 
autosomal chromosomes of the genome-wide linkage scan in the linkage analyses, the threshold 
of 1.9 for suggestive and 3.3 for signiﬁcant evidence of linkage may be to conservative. Therefore, 
we have applied the statistical methods as described by Lander and Kruglyak 125 for the traits with 
a lod score above 1.5 to determine if a lower lod score was already suggestive for linkage in our 
population. Based on these methods, a lod score of 1.7, as discovered in our linkage analyses, 
provided suggestive evidence of linkage for HDLc, for all other traits a lod score above 1.9 
was suggestive for linkage. Regions with suggestive and/or signiﬁcant evidence of linkage were 
screened for biologically plausible candidate genes that could explain the observed linkage peaks 
with the NCBI map viewer, the UCSC genome browser and the ENSEMBL genome browser.
Results
Subject characteristics
According to both the traditional criteria and the nomogram, 106 subjects were aﬀected 
with FCH. In addition, 24 patients were aﬀected with FCH according to either the traditional 
diagnostic criteria (n = 12) or the nomogram (n = 12) as diagnostic criterion. So, in total 
118 subjects were diagnosed with FCH according to the nomogram. Descriptive statistics of 
anthropometric and metabolic characteristics of the study population, presented below and in 
table 1, were based on the nomogram as diagnostic criterion for FCH. 
Besides the 118 FCH patients, another 209 normolipidemic relatives and 72 spouses, with 
available phenotypic data, were included. The percentages of males and females were comparable 
between the FCH patients, normolipidemic relatives and spouses (Table 1). With a mean age 
of 46 years, FCH patients were older than the normolipidemic relatives and younger than the 
spouses. Compared to normolipidemic relatives and spouses, FCH patients had signiﬁcantly 
higher levels of plasma TC, TG and apoB and signiﬁcantly lower levels of HDLc. Furthermore, 
FCH patients were characterized by the presence of sdLDL, as reﬂected by a signiﬁcantly lower 
K-value. Normolipidemic relatives had lower levels of TC, TG and apoB, compared to the 
spouses (Table 1).
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Linkage analyses for two diagnostic criteria of FCH
When using the traditional criteria for the diagnosis of FCH, we were unable to identify a 
region of interest with a lod score > 1 (Figure 1). A region on chromosome 1, where previously a 
locus for FCH was identiﬁed in Finnish FCH families 28, did not show evidence of linkage in our 
Nijmegen FCH families. A modest peak with a lod score of 0.98 (nominal p-value = 0.021) was 
observed close to this region, however, with a wide range of approximately 100 cM, overlapping 
the previously identiﬁed locus for FCH in Finnish FCH families. So, no regions of interest with a 
lod score > 1 were found when using the traditional diagnostic criteria for FCH. However, when 
using the nomogram as diagnostic criterion for FCH, in our population two regions of interest 
with lod scores above 1 were observed (Figure 1). A lod score of 1.30 (nominal p-value = 0.008) 
was located on chromosome 6q25-27 between markers D6s305 and D6s1277. For this locus, a 
lod score above 1 was present in a moderate interval of 19 cM. On chromosome 12q23-24, a lod 
score of 1.02 (nominal p-value = 0.017) was observed between the markers D12s2070 and PAH. 
No genetic heterogeneity was observed for the two identiﬁed loci. So, two regions of interest for 
FCH were observed when using the nomogram as diagnostic criterion for FCH. However, both 
loci did not reach the level of suggestive (lod score > 1.9) or signiﬁcant (lod score > 3.3) evidence 
of linkage.
Linkage analyses for the quantitative traits related to FCH
For the quantitative traits, related to FCH, we identiﬁed several loci with suggestive evidence 
of linkage (Figure 2 and 3). Interestingly, for both TG levels and sdLDL, we identiﬁed a locus on 
chromosome 6q, which co-localized with the peak for FCH, when using the nomogram. For the 
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The diagnosis of familial combined hyperlipidemia is based on the nomogram; The results are presented as 
mean (SD); * Results are presented as number (%); FCH, familial combined hyperlipidemia; NL relatives, 
normolipidemic relatives; TC, total cholesterol; TG, triglycerides; ApoB, apolipoprotein B; HDL-c, HDL 
cholesterol; K-value, a value ≤ -0.1 represents the presence of small dense LDL; †, p < 0.05, FCH patients 
compared to NL relatives; ‡, p <0.05, FCH patients compared to spouses; §, p < 0.05, NL relatives compared 
to spouses.
Table 1     Characteristics of patients with familial combined hyperlipidemia, normolipidemic 
                 relatives and spouses
FCH patients
(n = 118)
NL relatives
(n = 209)
Spouses
(n = 72)
Gender (males) * 46 (39.0%) 104 (49.8%) 30 (41.7%)
Age (years) 44.6 (16.4) † ‡ 35.9 (15.7) § 51.8 (12.0)
Lipids
- TC (mmol/L) 6.9 (1.2) † ‡ 5.2 (1.1) § 6.0 (1.3)
- TG (mmol/L) 2.9 (1.7) † ‡ 1.1 (0.5) § 1.4 (0.8)
- ApoB (mg/L) 1413 (253) † ‡ 970 (243) § 1133 (277)
- HDL-c (mmol/L) 1.06 (0.29) † ‡ 1.30 (0.34) 1.28 (0.38)
- K-value -0.48 (0.23) † ‡ -0.11 (0.26) -0.16 (0.28)
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Figure 1
Multipoint lod score for each chromosome in the genome scan for FCH according to the nomogram and the 
traditional diagnostic criteria. The blue line represents the multipoint lod scores for FCH according to the 
nomogram; the green line represents the multipoint lod scores for FCh according to the traditional diagnostic 
criteria based on total cholesterol and/or triglyceride levels above the 90th percentile; A shows the lod scores for 
each chromosome in the genome scan; B shows in detail the region with a lod score above 1 on chromosome 6; 
C shows in detail the region with a lod score above 1 on chromosome 12; lod scores > 1.0 represent a region 
of interest; lod scores > 1.9 represent loci with suggestive evidence of linkage; lod score > 3.3 represent loci 
with signiﬁcant evidence of linkage.
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Figure 2
Multipoint lod score for each chromosome in the genome scan for the quantitative lipid and lipoprotein 
parameters. Represented are the multipoint lod scores for the related phenotypes; the blue line represents the 
lod score obtained for total cholesterol levels; the green line represents the lod score obtained for triglyceride 
levels; the red line represents the lod score obtained for apolipoprotein B levels; the orange line represents the 
lod score obtained for high-density lipoprotein cholesterol; the grey line represents the lod score obtained for 
the K-value, a marker for the presence of small dense LDL; lod scores > 1 represent a region of interesg; lod 
scores > 1.9 represent loci with suggestive evidence of linkage; lod scores > 3.3 represent loci with signiﬁcant 
evidence of linkage.
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quantitative trait TG (green line) suggestive evidence of linkage for chromosome 6q was found 
with a lod score of 1.92 (nominal p-value = 0.001). This linkage peak on chromosome 6q for 
TG, had a moderate range of 58 cM, with nearby, another peak with a lod score of 1.28, with a 
diﬀerent underlying locus, as their maxima were > 40 cM apart 126. For the K-value, representing 
sdLDL (grey line) we report a region of interest on chromosome 6q with a lod score of 1.13.  
For TG levels (green line), we identiﬁed another locus on chromosome 10p with a lod score 
of 2.24 (nominal p-value = 0.0002). For the quantitative trait TC (blue line), two loci on 
chromosome 1p and 8p were found, with lod scores of 1.98 (nominal p-value = 0.002) and 2.11 
(nominal p-value = 0.002), respectively (Figure 2). For apoB (red line) no suggestive evidence 
of linkage was found, although a locus with a lod score of 1.25 was located on chromosome 8p, 
which co-localized with the peak of TC. Finally, for HDLc (orange line) we identiﬁed one locus 
with suggestive evidence, when applying the statistical methods of Lander and Kruglyak, on 
chromosome 19q13 with a lod score of 1.73 (nominal p-value = 0.004). No genetic heterogeneity 
was observed for the identiﬁed loci. The exact lod score and position of the peaks with a lod score 
above 1 are shown for all quantitative traits in ﬁgures 2 and 3.
Discussion
In the present study, consisting of 13 Nijmegen FCH families, we performed linkage analyses 
of two diagnostic criteria for FCH. The linkage analyses using the traditional diagnostic criteria 
to diagnose FCH did not result in the identiﬁcation of a region of interest (all lod scores < 1). 
Linkage analyses using the nomogram did, however, result in two regions of interest with a 
lodscore above 1, on chromosome 6q25-27 (lod score = 1.30) and 12q23-24 (lod score = 1.02). 
Most interestingly, this locus on chromosome 6q was supported by suggestive evidence of linkage 
for plasma TG levels (lod score = 1.92) and a region of interest for sdLDL (LOD score = 1.13), 
two major characteristics of FCH.  
Suggestive evidence of linkage for FCH on chromosome 6q25-27 was previously reported 
in another Dutch FCH population 31. In that separate, independent Dutch FCH population, 
the obtained linkage was supported by suggestive evidence of linkage for LDL particle size, TC, 
apoB, apoCIII levels and diastolic blood pressure 31, 37, 127. In another population consisting of 
families enriched in coronary artery disease, signiﬁcant evidence of linkage with this region on 
chromosome 6q was found for LDL particle size 128. One of the genes located in this region on 
chromosome 6q is the manganese superoxide dismutase (MnSOD; SOD2) gene, the primary 
defense of cells against free radical mediated damage, suggested as a candidate gene for FCH 31. 
The mechanism, however, by which MnSOD may inﬂuence the lipid metabolism is yet unclear. 
Within the supportive region on chromosome 6 in our Nijmegen FCH population, several other 
candidate genes could also be identiﬁed, including the nearby located Lp(a) gene (6q26-27). 
Lp(a) is considered as an independent risk factor for cardiovascular disease 129. The role of Lp(a) 
in FCH, however, remains controversial 129, 130. 
Previous linkage analyses for FCH have also identiﬁed other suggestive loci, located on 
chromosomes 1q, 2p, 8p, 10q, 11p, 11q, 16q, 19q and 21q 26-32, 34-36. Only the loci for FCH 
identiﬁed on chromosome 1q  and 11q have been identiﬁed in more than one FCH study 
population. A candidate gene, USF1, has been proposed to underlie the linkage signal on 
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chromosome 1q 46. In our Nijmegen FCH families, USF1 was identiﬁed as a modiﬁer gene 
131. In the present study we show that there is no evidence of linkage for our Nijmegen FCH 
population in this region. This absence of evidence of linkage for chromosome 1q is supported 
by linkage analyses performed in the other separate, independent Dutch FCH population, where 
also no linkage for FCH was found in this region 31, 34, 35. The apolipoprotein A1-C3-A4-A5 gene 
cluster is located on chromosome 11q23-24, a multigene locus repeatedly found to be involved 
in modulating the expression of FCH 33, 51, 59. In our FCH families, however, no evidence of 
linkage for FCH is present in this region. 
The discrepancy in identiﬁed loci for FCH between diﬀerent studies, may be caused by the use 
of diﬀerent diagnostic criteria. In the present study of Nijmegen FCH families we have used two 
diagnostic criteria for FCH. Two loci with lod scores above 1, revealing regions of interest, were 
identiﬁed for FCH when using the nomogram as diagnostic criterion, while no loci with a lod 
score above 1 were identiﬁed for FCH based on the traditional criteria. We have already shown 
that the traditional diagnostic criteria for FCH are not consistent over time and therefore may 
be less suitable for performing genetic analysis 16. The nomogram, as previously published, is 
more consistent over time and therefore clinically a better diagnostic criterion to diagnose FCH 
17. As it is important for genetic studies that the diagnosis of FCH is consistent over time, it was 
expected that, based on a decrease in misclassiﬁcation, the nomogram had more power to reveal 
linkage. Although the lod scores using the nomogram were higher than 1, whereas when using 
the traditional diagnostic criteria for FCH all lod scores were < 1, linkage analysis of FCH using 
either diagnostic criteria did not reach the level of suggestive or signiﬁcant evidence of linkage 
according to Lander and Kruglyak 125. Nevertheless, lod scores above 1, revealing regions of 
interest, are presented in line with previously reported linkage analysis of FCH 26-28, 30, 32, 34.
Also within another separate, independent Dutch FCH population, there was support that the 
diﬀerence in obtained loci by linkage analysis for FCH can be explained by the use of diﬀerent 
diagnostic criteria for FCH. Two genome-wide linkage analyses, using diﬀerent diagnostic 
criteria for FCH within one population, have been reported 31, 35. These two studies, performed 
in the same study population, have identiﬁed in total 10 suggestive loci for FCH; however, only 
3 comparable loci were obtained in both studies 31, 35. In the same population, a third linkage 
analysis of 14 candidate genes was performed, with again other diagnostic criteria for FCH and 
only 1 of these 3 regions of interest showed supportive evidence of linkage 34. So, the diﬀerence 
in reported loci obtained within one study population could be explained by the use of diﬀerent 
diagnostic criteria for FCH. 
Other possible explanations for the diversity of loci reported for FCH by diﬀerent study 
populations include ethnic admixture and population stratiﬁcation. Since FCH is a complex 
multifactorial lipid disorder and genetic heterogeneity is potentially present in diﬀerent FCH 
populations, which may aﬀect the outcome of linkage analyses and contribute to the fact that 
most studies are underpowered to resolve minor loci of interest.
Our FCH study population for the genome-wide linkage analyses consisted of 13 informative 
FCH families including 275 individuals with genotypic and phenotypic data. We performed 
simulation analysis to determine the power of our population to detect linkage. This power 
calculation revealed that, even when assuming a 50% heterogeneity, our population provided a 
61% chance of ﬁnding a lod score > 2. So, although our sample size appears relatively small, the 
power calculations indicated a fair chance of ﬁnding a locus for FCH, when present. 
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Figure 3
The regions with suggestive evidence of linkage obtained for the quantitative lipid and lipoprotein parameters 
in detail. Presented are in detail the regions with suggestive evidence of linkage for the related phenotypes; 
the blue line represents the lod score obtained for total cholesterol levels; the green line represents the lod score 
obtained for triglyceride levels; the red line represents the lod score obtained for apolipoprotein B levels; the 
orange line represents the lod score obtained for high-density lipoprotein cholesterol; the grey line represents 
the lod score obtained for the K-value, a marker for the presentce of small dense LDl; lod scores > 1 represent a 
region of interest; lod scores > 1.9 represent loci with suggestive evidence of linkage; lod scores > 3.3 represent 
loci with signiﬁcant evidence of linkage.
Chapter 1
B. Chromosome 6q
C. Chromosome 8p D. Chromosome 10p
E. Chromosome 19q
D1S1596
 
D1S1665
D1S1728
GATA124C08
 
GATA133A08
D1S1653
 
D1S1653
D6S1009
 
GATA184A08
D6S2436
D6S305
D6S1277
 
D6S1027
D8S1469
GATA151F02
D8S1145
D8S136
D8S1048
D8S1110
D8S1113
D10S189
D10S1412
D10S1430
D10S1423
D10S1426
D10S1208
D10S1221
D10S1225
GATA121A08
D10S1432
D19S245
D19S559
D19S246
 
D19S589
 
D19S254
1.98
1.92
1.13
2.11
1.25
2.24
1.73
A. Chromosome 1p
FCH is a multifactorial disease, in which the interplay of multiple genes and environmental 
factors are involved in the complicated phenotype to be expressed. Therefore, the binary 
classiﬁcation of family members into aﬀected and unaﬀected may not be the best approach 
for ﬁnding disease-predisposing genes. In addition to this, no consensus has been reached on 
the diagnostic criteria for FCH, making it hard to compare the results of the diﬀerent linkage 
analyses. So, to enhance power to detect comparable susceptibility genes for FCH, quantitative 
trait linkage analyses could be performed for the related lipid proﬁles. The wide variance of 
quantitative traits could provide more statistical power to detect linkage than the binary 
categorization of the FCH diagnosis.
In the present study we performed quantitative trait linkage analyses (QTL) for the following 
traits; TC, TG, apoB, HDLc and the K-value, resulting in the identiﬁcation of ﬁve loci with 
suggestive evidence of linkage. On chromosome 1p32-12 we have identiﬁed a locus with a lod 
score of 1.98 for TC, where a lod score above 1 was present within an interval of 50 cM. This 
same region was also found to be associated with apoB levels in the other Dutch FCH families 38, 
40. The leptin receptor (LEPR) gene was previously suggested as a candidate gene for this region. 
We have shown in a previous study, that the Gln223Arg polymorphism in the LEPR gene was 
associated with an increased risk on FCH and decreased HDLc levels in our Nijmegen FCH 
families 132. No increased TC levels were, however, found to be associated with the LEPR gene 
132. Also located in this region is the 5'-AMP-activated protein kinase alpha 2 (AMPK) gene 133-
135. The AMPK cascade is a sensor of cellular energy status and plays a key role in the regulation 
of fatty acid and cholesterol metabolism. The AMPK cascade is, furthermore, involved in the 
regulation of energy expenditure and appetite at the whole body level by mediating, among other 
things, leptin, adiponectin and ghrelin 135.
In our FCH population, suggestive evidence of linkage was found for TC on  chromosome 
8p22-21. Within other study populations, this region has previously been identiﬁed as a candidate 
region for FCH, TC, TG, diastolic blood pressure and waist-hip ratio 36, 37. The lipoprotein lipase 
(LPL) gene is located in this region and it is suggested in the literature that FCH patients have 
reduced LPL activity 136. In a previous study in our Nijmegen FCH families, we showed that LPL 
is a susceptibility gene for several types of dyslipidemia, including TC levels 82. 
The highest lod score of 2.24 was identiﬁed for TG levels on chromosome 10p14-q21. In the 
Finnish FCH families, suggestive evidence of linkage for FCH and elevated TG levels was found 
for this region 29. Suggestive evidence of linkage for TG was also found in the Mexican FCH 
families; however, in the multipoint analysis no additional support for this region was found 42. 
No biologically plausible candidate gene was found in this region.
On chromosome 19q13 a locus for HDLc has been identiﬁed. In other FCH study 
populations, this region has never been reported as an interesting region for FCH or any of 
the related phenotypes. In the Quebec family study signiﬁcant evidence of linkage for LDLc 
has been reported for this region 137. In the HERITAGE family study, suggestive evidence for a 
pleiotropic QTL at 19q12-q13 for the covariation of TG levels and adiposity was reported 138 and 
a meta-analysis of 4 genome scans provided suggestive evidence of linkage for LDLc and apoB 
139. Several candidate genes that inﬂuence lipid metabolism are located in this region, including 
the apolipoprotein E and hormone-sensitive lipase genes 140-142.
In conclusion, we show that the use of diﬀerent diagnostic criteria for FCH aﬀects the results 
of the linkage analyses. Only when using the nomogram, we report a region of interest for FCH 
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on chromosome 6q which is supported by the results of the linkage analysis for TG levels and 
sdLDL, two characteristic features of FCH. Future research concerning linkage analyses in FCH 
should focus on unequivocal diagnostic criteria for FCH in addition to underlying quantitative 
traits that show a high genetic correlation with FCH in multivariate linkage analyses.
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Abstract
Background Familial combined hyperlipidemia (FCH), characterized by multiple lipoprotein 
phenotypes, is the most common hereditary lipid disorder in humans. A mutant mouse strain, 
HcB-19, with similar biochemical features as FCH patients, has recently been identiﬁed. The 
mutation causing the FCH phenotype in these mice is located in the thioredoxin interacting 
protein (TXNIP) gene. The TXNIP gene in mice is located on chromosome 3F2.2, which is 
syntenic to chromosome 1q21 in humans, a region where several groups have positioned a locus 
for FCH. Methods To evaluate the potential role of TXNIP in the FCH phenotype in humans, 
we analyzed the coding region, 5’ UTR and introns of the TXNIP gene by direct sequencing in 
10 well-deﬁned patients with FCH and 5 healthy controls. Results We did not ﬁnd any sequence 
variants in these regions of the TXNIP gene in patients with FCH. Conclusion Our results 
suggest that diﬀerent genes are involved in the FCH phenotype in humans compared to mice. 
We conclude that in our Dutch FCH patients, the TXNIP gene, based on its intronic, exonic and 
5’ UTR sequences, is not involved as a major contributor to the FCH phenotype.
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Introduction
Familial combined hyperlipidemia (FCH) is the most common genetic hyperlipidemia 
in humans of unknown etiology, aﬀecting 1-2% of the general population. FCH is strongly 
associated with premature cardiovascular disease and among survivors of a premature myocardial 
infarction, up to 20% are aﬀected with FCH 4. FCH is characterized by hypercholesterolemia 
and/or hypertriglyceridemia. Other phenotypes of FCH include elevated levels of apolipoprotein 
B (apoB), elevated levels of very low-density lipoprotein (VLDL) remnants, the presence of small 
dense LDL (sdLDL) 13, 18, 23, 97, obesity and insulin resistance 9, 93.
Recently a mutant mouse strain, HcB-19/Dem (HcB-19), which shows several phenotypic 
similarities with FCH patients, i.e., increased levels of total cholesterol (TC), triglycerides (TG), 
apoB and triglyceride-rich lipoproteins, has been identiﬁed 143. Castellani et al. identiﬁed a locus 
(Hyplip1) which strongly linked to the FCH features in these mice 143. A few years later it was 
shown that these mice had a decreased expression of the thioredoxin interacting protein (TXNIP). 
By sequencing, a spontaneous nonsense mutation (T97Z) in the TXNIP gene was identiﬁed. This 
mutation changes a tyrosine codon (TAT) into a stop codon (TAA), which leads to a truncated 
protein of only 97 amino acids 44. The TXNIP gene in mice is located on chromosome 3F2.2, 
which is syntenic to chromosome 1q21 in humans 144, a region to which a major contributor 
of the FCH phenotype has been mapped in a Finnish, German and Chinese population 26, 28, 
30. Chen and DeLuca were the ﬁrst to identify the human homologue of TXNIP on 1q21, by 
diﬀerential screening of HL-60 cell lines 145. The coding region of the human gene spans 2.3 Kb, 
consists of 8 exons and encodes a polypeptide of 391 amino acids. Exon sizes ranged from 36 bp 
(exon 8) to 471 bp (exon 1) and intron sizes ranged from 106 bp (intron 5) to 539 bp (intron 1). 
The 5’UTR region is 212 bp compared with a 1,306 bp long 3’UTR. 
TXNIP is a major regulator of the cellular redox state in mice and humans by binding and 
inhibiting thioredoxin and thereby also inhibiting the insulin reducing activity of thioredoxin 45. 
The mutant mice had decreased CO2 production, but increased ketone body synthesis, suggesting 
that the altered redox status down-regulates the citric acid cycle and so sparing fatty acids for TG 
and ketone body production. This revealed a new pathway of potentially clinical signiﬁcance, 
which quantitatively contributes to plasma lipid metabolism and the FCH phenotype in mice 
and possibly in humans 143. In the present study, we evaluated the putative role of the TXNIP 
gene in humans by sequencing the coding region, the 5’ UTR and all introns of the TXNIP gene 
in 10 well deﬁned patients with FCH, selected from 32 unrelated FCH families and 5 healthy 
controls 16. 
Methods
In 1994, we recruited 32 large families with FCH (n = 660). In 1999 we completed the ﬁrst 5 
years follow-up study for these families, to investigate the metabolic and genetic aspects of FCH. 
For sequencing the TXNIP gene, we selected 10 well-deﬁned patients with FCH from these 
32 unrelated FCH families 16. The FCH patients were selected based on the presence of FCH, 
in both 1994 and 1999, according to the standard lipid criteria, i.e., TC and TG levels above 
Thioredoxin interacting protein gene variants in patients with FCH
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the 90th percentile adjusted for age and gender, according to the PROCAM study 146. Recently, 
we showed that elevated apoB levels and the presence of sdLDL are more consistent diagnostic 
criteria for FCH 16. So in addition to the traditional lipid diagnostic criteria, all selected patients 
with FCH required elevated apoB levels (apoB > 1,200 mg/L) and the presence of sdLDL
(K-value ≤ -0.1) in both 1994 and 1999 147. From the cohort of 1999, ﬁve healthy control subjects 
were randomly selected from the spouses of the families. The ethical committee of the UMC 
Nijmegen approved the study protocol. Table 1 summarizes the data in patients and controls.
Plasma TC and TG were determined enzymatically, using commercially available reagents 
(Boehringer-Mannheim, Germany and Sera Pak, Miles, Belgium, respectively). LDL subfractions 
were separated by single-spin density gradient ultracentrifugation 120. A continuous variable K 
was deﬁned to characterize the LDL subfraction proﬁle of each individual.  A K-value below –0.1 
reﬂects a sdLDL subfraction proﬁle 147. Total plasma apoB concentrations were determined by 
immuno-nephelometry as described in detail elsewhere 119.
Genomic DNA was extracted from peripheral blood leukocytes, using the Puregene DNA 
isolation kit (Biozym, Landgraaf, The Netherlands). The TXNIP gene was ampliﬁed in six 
Table 1     Anthropometric and biochemical parameters in patients with familial combined 
                hyperlipidemia and controls both in 1994 and 1999.
Cohort 1994 Cohort 1999
Sex CVD Age * BMI TC TG apoB K BMI TC TG apoB K
FCH M No 54 27 8.6 1.6 1586 -0.5 27 7.9 3.7 1739 -0.4
F No 63 24 7.9 2.0 1695 -0.4 24 6.7 2.8 1473 -0.1
F No 61 30 8.0 3.4 1717 -0.7 30 7.2 3.1 1608 -0.3
M Yes 48 24 7.4 3.5 1418 -0.6 25 7.7 6.8 1469 -0.6
F Yes 71 - 8.9 3.1 2020 -0.7 29 8.6 3.3 2035 -0.6
F No 76 22 8.0 3.0 1750 -0.6 22 7.7 2.5 1710 -0.4
F No 49 27 8.6 1.6 1808 - 29 8.3 6.7 2000 -0.4
F No 51 26 7.6 3.1 1553 -0.6 28 7.9 5.2 1792 -0.7
M No 56 33 7.7 2.7 1531 -0.3 36 7.4 4.2 1546 -0.2
M No 70 30 7.2 3.6 1604 -0.5 31 7.2 4.4 1531 -0.7
Control M No 58 24 3.8 0.5 710 0.1
F No 60 37 2.8 0.5 549 0.1
F No 36 22 3.7 0.4 638 0.2
F No 40 28 4.3 0.8 742 0.3
M No 63 18 3.9 0.5 678 0.2
Chapter 2
Sex: F, female; Sex: M, male; CVD, cardiovascular disease; age (years); BMI, body mass index (kg/m2); 
TC, total cholesterol (mmol/L); TG, triglycerides (mmol/L); apoB, apolipoprotein B (mg/L); K, a K-value 
≤ -0.1 represents the presence of small dense LDL (sdLDL); FCH, familial combined hyperlipidemia; *, 
age in 1999
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overlapping fragments (2,573 bp in total) by polymerase chain reaction (PCR) using the following 
conditions: 20 mM Tris-HCl (pH = 8.4), 50 mM KCl, 1.75 mmol/l MgCl2 (for fragment 5 the 
MgCl2 was 2.25 mM), 200 µmol of each dNTP, 0.01% gelatin, 100 ng forward and reverse 
primers, 1.25 U Taq polymerase (Invitrogen, Breda, The Netherlands) and 400 ng DNA in a 
50 µl reaction volume. The primer sequences, annealing temperatures, locations, and product 
sizes of the six fragments are listed in table 2. PCR ampliﬁcations were performed, with an 
initial denaturation (94°C, 3 min) then 40 cycles of 94°C for 1 min, annealing at a temperature 
speciﬁc for each fragment for 1 min (Table 2), extension at 72°C for 30 sec followed by a ﬁnal 
extension (72°C, 7 min). The PCR products were column-puriﬁed using Roche High Pure PCR 
puriﬁcation kits (Roche Applied Science, Mannheim, Germany), and bi-directional sequencing 
analysis was performed on an ABI Prism 3100 Genetic analyzer using the ABI Prism BigDye 
Terminator version 3 chemical sequencing kit according to the instructions of the manufacturer 
(PE Applied Biosystems, Nieuwerkerk a/d Yssel, The Netherlands). The sequences were aligned 
with the reference sequence to detect sequence variants.
Results and discussion
The anthropometric and biochemical characteristics of the participants in the present study are 
presented in table 1. The patients with FCH and controls did not signiﬁcantly diﬀer in age and 
gender. Cardiovascular diseases were more prevalent in the FCH patients. FCH patients had a 
higher BMI compared to controls. By deﬁnition the FCH patients had higher plasma TC and 
TG concentrations compared to the controls. In addition, patients with FCH were characterized 
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Table 2     Primer sets used for sequencing.
Primer sequence (5'  > 3') Position primer * 
(bp)
Tm 
(°C)
Products 
(bp)
1F GCTTAGTGTAACCAGCGGCGT 3,004–3,024 53 514
1R CTCTAATCAGCTTTCACCCTCCAAC 3,518–3,494
2F CTTCTGGAAGACCAGCCAACAG 3,554–3,475 53 538
2R TAGCCATTAGGCTTGCTGTTACAC 3,991–3,969
3F CTTCAATACCTTGCATGCCACC 3,915–3,936 62 599
3R CCATCAGGAATGAACATGCAGG 4,514–4,493
4F TCAGACGTCTTGGGCATTAGATTG 4,397–4,420 53 614
4R GAAACAAGACAGCTGTGGTAACAGATG 5,011–4,985
5F GGGTAGATGCAGGGTGGCTTC 4,949–4,969 62 513
5R CGGTGGTGGCATGAACTTGAAC 5,462–5,441
6F GGATGTCATTCCTGAAGATCACCG 5,339–5,362 53 403
6R CACACTCCATTGCAGAGACTGTTG 5,742–5,719
a According to GenBank Accession number AB051901
46
by higher apoB concentrations and a more sdLDL subfraction proﬁle, as reﬂected by a more 
negative value of the parameter K.
When sequencing the 5’UTR, the introns and exons of the TXNIP gene in 10 unrelated 
patients with FCH and in 5 healthy controls, we did not detect any sequence variants by direct 
sequencing. 
We therefore conclude that it is unlikely that single nucleotide polymorphisms in the TXNIP 
gene are causally related to the pathophysiology of FCH in our patients. To the best of our 
knowledge this is the ﬁrst report to explore the potential role of TXNIP in the FCH phenotype 
in humans. The interest in the TXNIP gene as potential contributor to the FCH phenotype 
in humans is based on the intriguing ﬁnding of a mutation in the TXNIP gene causing FCH 
phenotype in HcB-19 mice. Several explanations may be oﬀered for our apparent negative 
ﬁnding that excludes the role of the TXNIP gene in the FCH phenotype in humans. First of 
all, the phenotype of the HcB-19 mice is not completely comparable to FCH in humans. These 
mutant mice do share common features with patients with FCH, including hypertriglyceridemia, 
hypercholesterolemia, elevated plasma apoB levels, increased secretion of triglyceride-rich 
lipoproteins and hyperlipidemia, which is progressive with age. However, in mice TG levels 
were 10- to 30-fold higher and apoB levels were 2- to 4.5-fold increased compared with the 
parental strains and other recombinant congenic mice strains derived from the parental strains 
143. Such highly increased TG and apoB levels are not observed in FCH patients and are therefore 
not representative for FCH in humans. Furthermore, the HcB-19 mice strain is not obese and 
does not show elevated insulin levels nor decreased levels of HDLc, characteristics of FCH in 
humans, which suggest another pathophysiology of FCH in these mice. In addition to this, these 
HcB-19 mice have decreased production of CO2, possibly caused by a decreased oxidation of 
free fatty acids (FFA) 143. Therefore more FFA are available for the synthesis of TG and keton 
bodies. Increased levels of plasma lactate and decreased levels of pyruvate are also present in these 
mice 143. These features have not been described in humans with FCH.
Secondly, inconsistencies between research groups in diagnostic criteria for FCH may also 
be a reason why we did not ﬁnd a relationship between the TXNIP gene and FCH in humans. 
Linkage of the FCH phenotype to the 1q21-q23 region is based on the standard diagnostic 
criteria for FCH, i.e., TC and TG levels above the 90th percentile, adjusted for age and gender 
26, 28, 30. We also included apoB levels and the presence of sdLDL as diagnostic criteria for FCH, 
because our 5-years follow-up study on FCH showed that these parameters are less variable over 
time and are more consistent in diagnosing FCH than the standard lipid diagnostic criteria 16. 
This lack of unequivocal diagnostic criteria of FCH contributes to the heterogeneity between 
FCH populations, and may result in a lack of consistency between linkage analyses in diﬀerent 
FCH populations. 
The human TXNIP gene has been mapped to 1q21.1, which is approximately 5-10 Mb 
proximal to the peak marker for linkage of FCH in this region 148. Therefore, other genes within 
this linkage region may as well contribute to the FCH phenotype. Other candidate genes for 
FCH that have been mapped to this region include the apolipoprotein A2 (APOA2) gene and 
the genes encoding L-, P- and S-selectinm 148. 
FCH is a genetic heterogeneous disease, which means that diﬀerent genes can be involved in 
diﬀerent populations. This heterogeneity may account for excluding TXNIP as a candidate gene 
in our patients, but does not necessarily exclude TXNIP as a candidate gene in other populations, 
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in which linkage has been found for this region.
Finally, we cannot completely exclude the TXNIP gene as a quantitative contributor of the 
FCH phenotype, because 3’ UTR of the TXNIP gene, existing out of 1,307 base pairs, was not 
completely analyzed for sequence variants. 
In conclusion, we did not ﬁnd sequence variants in the coding regions, nor in the introns and 
the 5’UTR of the TXNIP gene, which argues against an involvement of TXNIP in FCH patients. 
Therefore, we conclude that in our Dutch FCH patients, the TXNIP gene is not involved as a 
major contributor to the FCH phenotype, but further analyses on expression level are warranted 
to completely exclude the TXNIP gene as a candidate gene for FCH.
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To the editor 
Familial combined hyperlipidemia (FCH) is the most common genetic hyperlipidemia in 
humans and is characterized by elevated levels of plasma total cholesterol (TC), triglycerides (TG) 
and/or apolipoprotein B (apoB) 116. A mutant mouse strain, HcB-19/Dem (HcB-19), which 
shows several phenotypic similarities with FCH patients, has been reported 143. Within these 
mice, a spontaneous nonsense mutation (T97Z) in the thioredoxin interacting protein (TXNIP) 
gene has been identiﬁed, which resulted in a truncated protein of only 97 of the 391 amino acids 
44. In humans the TXNIP gene is located on chromosome 1q21 144, a region where linkage for 
FCH has been found 26, 28, 30. Recently, we have published the sequence data of the TXNIP gene 
in humans and reported no sequence variants for this gene in humans 149. We concluded that, 
based on the sequence data, the TXNIP gene is not involved as a major contributor to FCH. 
Other groups have also sequenced the TXNIP gene and although they did ﬁnd rare sequence 
variants, these variants were not associated with FCH nor with the associated phenotypes 46, 150. 
However, as none of these studies sequenced the 3’UTR region of the TXNIP gene in patients 
with FCH, the TXNIP gene cannot be excluded completely. The 3’UTR is known to inﬂuence 
RNA stability and thereby the expression levels of genes. So, by measuring the expression levels 
of TXNIP, information on a functional mutation in the 3’ UTR can be obtained. Apart from 
the 3’UTR, however, also other factors are known to inﬂuence regulation of the TXNIP gene 
expression, such as transcription factors, methylation and cellular stresses, including oxidative 
stress, ultraviolet irradiation and heat shock 151 and these inﬂuences on the expression levels of 
the TXNIP gene are also taken into account when measuring expression levels. Expression levels 
of TXNIP are substantially decreased within the HcB-19 mice 44. The expression levels of TXNIP 
in human patients with FCH have not been studied before. In the present study, we quantiﬁed 
TXNIP mRNA expression levels in peripheral blood mononuclear cells (PBMCs) of 30 FCH 
patients and 30 healthy controls, selected from our study population 16, 69. 
The selection of the FCH patients was based on the presence of FCH in both 1994 and 
1999, according to the recently published nomogram, i.e., TC and TG levels above the 90th 
percentile adjusted for age and gender and elevated apoB levels 17. The healthy controls were 
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Table 1     Characteristics of patients with familial combined hyperlipidemia and controls.
FCH patients (n = 30) Controls (n = 30)
Total cholesterol (mmol/L) 6.6 (0.9) † 5.3 (0.9)
Triglycerides (mmol/L) * 2.89 (1.50) † 1.13 (1.44)
Apolipoprotein B (mg/L) 1369 (245) † 940 (216) 
HDL cholesterol (mmol/L) 1.11 (0.20) † 1.32 (0.29)
BMI (kg/m2) 29.1 (4.3) † 25.3 (3.4)
HOMA-index a 2.5 (1.6) † 1.7 (1.5)
Results are presented as mean (SD); a Presented are geometric mean (mean SD); FCH, familial combined 
hyperlipidemia; HDL cholesterol, high-density lipoprotein cholesterol; BMI, body mass index; HOMA-
index, homeostasis model assessment-index; † p-value < 0.05.
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randomly selected from the normolipidemic relatives, being unaﬀected in both 1994 and 1999. 
After withdrawal of lipid-lowering medication for 4 weeks and an overnight fast, these 60 
subjects re-visited the hospital and blood was drawn by venipuncture. The ethical committee 
of the Radboud University Nijmegen Medical Centre approved the study protocol. RNA was 
isolated from PBMCs, including both lymphocytes and monocytes, and reversed transcribed 
to cDNA. Real-time quantitative PCR (Q-PCR) was applied to determine the threshold cycle 
(Ct). These Ct values were normalized to a housekeeping gene, beta-2-microglobulin (B2M) 
(∆Ct = Ct,TXNIP – Ct,B2M) and the diﬀerence in expression between patients and controls was 
calculated (∆∆Ct = ∆Ct,Patient – ∆Ct,Control). Finally, the relative expression was calculated as
2-∆∆Ct  152. 
Table 1 summarizes the descriptives of the patients and controls. FCH patients had signiﬁcantly 
elevated levels of plasma TC, TG and apoB levels, and decreased high-density lipoprotein 
cholesterol (HDLc) levels. Furthermore, FCH patients were more obese and more insulin 
resistant compared to their normolipidemic relatives (Table 1).
FCH patients demonstrated a relative expression of 0.97 [0.5 – 2.2] for the TXNIP gene, this 
was compared to controls (1.00 [0.2 – 4.3]) not signiﬁcantly diﬀerent. From this we concluded 
that the expression levels of the TXNIP gene in PBMCs did not diﬀer between FCH patients and 
controls (Table 2). In addition, we analyzed the data split up by gender; no diﬀerences between 
males and females were found (data not shown). The correlation between expression levels of the 
TXNIP gene and levels of TC (r = 0.02), TG (r = -0.02), apoB (r = 0.02), HDLc (r = -0.05) or 
insulin resistance, as represented by the homeostasis model assessment-index (HOMA-index) 
(r = -0.09), were also investigated. No signiﬁcant correlation existed between expression levels of 
the TXNIP gene and any of the phenotypes of FCH.
Previously, it has already been shown by others and us that none of the sequence variants found 
in the TXNIP gene in humans were associated either with FCH or with any of the phenotypes 
of FCH. In the present study, we show that, unlike in mice, there is no diﬀerential expression 
of the TXNIP gene in human patients with FCH. Taken together we conclude that the TXNIP 
gene does not contribute to FCH nor to its associated phenotypes, in our population of Dutch 
patients with FCH. 
In the present study we measured the TXNIP expression in PBMCs; in the HcB-19 mice the 
diﬀerence in expression of TXNIP was found in several tissues including liver, spleen, kidney, 
brain, lung, skeletal muscle, testis and heart tissue 44; however, expression levels in PBMCs have 
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Table 2     Relative quantiﬁcation of TXNIP mRNA levels in FCH patients and controls.
∆Ct ∆∆Ct 2 -∆∆Ct P-value *
FCH (n = 30) 1.98 ± 1.07 0.05 ± 1.07 0.97 (0.5 - 2.2) 0.73
Controls (n = 30) 1.93 ± 2.11 0.00 ± 2.11 1.00 (0.2 - 4.3)
∆Ct = Ct, target - Ct, B2M, Ct of TXNIP normalized to the housekeeping gene, B2M; ∆∆Ct = ∆Ct, Patient - ∆Ct, 
Control, the diﬀerence in expression between the FCH patients and controls; 2 -∆∆Ct, the relative expression; 
FCH, familial combined hyperlipidemia; *, p-value, signiﬁcance of diﬀerence between FCH patients and 
controls.
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not been reported in mice. Obviously, these tissue are not readily available in FCH patients, in 
contrast to PBMCs. Morello et al. investigated whether the FCH-speciﬁc transcription proﬁle 
was detectable in immortalized cell lines from peripheral blood 153. They conclude that it was 
possible to detect complex disease-speciﬁc transcriptional abnormalities of FCH in peripheral 
blood, which justiﬁes our compelled choice for PBMCs.
The lack of a diﬀerence in expression levels of TXNIP in human FCH patients compared to 
mice could be suggestive for another etiology of the FCH phenotype in mice. These mice are not 
obese nor insulin resistant 143, in contrast to FCH in humans. Furthermore, TG levels were 10- to 
30-fold and apoB levels 2- to 4.5-fold increased in mice, whereas such extreme increased levels 
are not observed in human FCH patients. So, the phenotype of the HcB-19 mice is diﬀerent 
from FCH in humans.  
Recently, Pajukanta et al. has identiﬁed a new candidate gene for FCH, located in the same 
region as the TXNIP gene 46. This gene, upstream stimulatory factor 1 (USF1), is thought to be 
responsible for the linkage found in this region and not the TXNIP gene. So, all data available 
point to the same direction that the TXNIP gene is unlikely to be involved in the pathogenesis 
of FCH in humans. We conclude that the TXNIP gene is not a causal gene for FCH in humans, 
based on both expression levels and sequence data.
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Abstract
Background Familial combined hyperlipidemia (FCH) is the most common hereditary lipid 
disorder in humans; however, the genetic origin is still unknown. Recently, the upstream 
stimulatory factor 1 (USF1) gene was proposed as a candidate gene. Two polymorphisms 
in this gene were associated with FCH and its related phenotypes. In the present study, we 
examined these two SNPs with respect to FCH, and its related phenotypes, in Dutch FCH 
families. Methods The study population consisted of 36 Dutch FCH families, including 157 
FCH patients. The diagnosis of FCH was based on both the traditional diagnostic criteria and a 
nomogram. The polymorphisms, USF1s1 and USF1s2, were genotyped with PCR-RFLP. USF1 
expression levels in PBMCs were measured using a SYBR Green-based quantitative real-time 
PCR. The family-based association test (FBAT) software was used for statistical analyses. Results 
The two polymorphisms were in complete linkage disequilibrium. No association was found 
for the individual SNPs with FCH deﬁned by the nomogram (USF1s1: p = 0.53 and USF1s2: 
p = 0.53) whereas suggestive associations were found when using the traditional diagnostic 
criteria for FCH (USF1s1: p = 0.08 and USF1s2: p = 0.07). USF1 was associated with total 
cholesterol (USF1s1: p = 0.05 and USF1s2: p = 0.04) and apolipoprotein B (USF1s1: p = 0.06 
and USF1s2: p = 0.04). Small dense LDL showed suggestive association (USF1s1: p = 0.10 
and USF1s2: p = 0.09). The results from the haplotype analyses supported the results obtained 
for the individual SNPs. Quantitative RT-PCR experiments did not show haplotype-dependent 
diﬀerences in USF1 expression levels in PBMCs. Conclusion The previously identiﬁed risk 
haplotype of USF1 showed a suggestive association with FCH and contribute to the related lipid 
traits in our Dutch FCH families. 
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Introduction
Familial combined hyperlipidemia (FCH, OMIM-144250) is the most common genetic 
lipid disorder of unknown etiology in humans, aﬀecting up to 5% of the general population 10. 
Major characteristics of FCH include elevated levels of apolipoprotein B (apoB), triglycerides 
(TG) and/or plasma total cholesterol (TC). Other FCH phenotypes are decreased levels of high-
density lipoprotein cholesterol (HDLc) and the presence of small, dense low-density lipoprotein 
(sdLDL). In addition, patients with FCH have a two-fold increased risk of cardiovascular disease 
(CVD) and are often obese and insulin resistant 97.
Over the past few years, several groups performed linkage analyses in an attempt to determine 
the genetic defects causing FCH 26, 28, 30, 34, 36, 42. By doing this, a locus on chromosome 
1q21-23 was identiﬁed 26-28, 30. The ﬁrst candidate gene proposed in this region was the thioredoxin 
interacting protein (TXNIP) 44. It was demonstrated, however, that the TXNIP gene was not a 
major contributor to the FCH phenotype 46, 149, 150. More recently, a second candidate gene, 
the upstream stimulatory factor 1 (USF1) gene, was suggested as the prime candidate gene 
for FCH in this linkage region, in 60 Finnish FCH families 46. Twenty-three single nucleotide 
polymorphisms (SNPs) were reported in the USF1 gene. Two of these SNPs, USF1s1 (3’ UTR, 
rs3737787) and USF1s2 (intron 7, rs2073658), individually, and combined into a haplotype, 
showed linkage and association with FCH and multiple phenotypes of FCH, including TG, 
apoB, TC and sdLDL, implying that USF1 contributes to the complex pathophysiology of FCH 
in these Finnish FCH families 46. The association of USF1 with FCH was, however, strongest in 
males with elevated levels of triglycerides 46. 
Huertas-Vazquez et al. 42 reported that USF1 was associated with FCH and elevated TG levels 
in 24 Mexican FCH families, whereas other phenotypes were not investigated. No sex-speciﬁc 
eﬀect of USF1 was found in these families. The study by Coon et al. 47 investigated the association 
of USF1 with FCH in Utah pedigrees ascertained for early death due to coronary heart disease 
(CHD), early strokes, or early onset hypertension. They reported suggestive associations for 
FCH, TG and low-density lipoprotein cholesterol (LDLc) levels, in the pedigrees ascertained 
for early strokes and early onset of hypertension. However, in the families ascertained for early 
death due to CHD, in which 60% of the FCH patients were present, no assocation of USF1 
with FCH was found 47. 
The USF1 protein regulates the transcriptional activation of a variety of genes involved in 
glucose and lipid metabolism and in the development of atherosclerosis 154, 155. USF1 plays a 
pivotal role in adipose tissue where it inﬂuences de novo lipogenesis by mediating the glucose-
regulated expression of hormone-sensitive lipase (HSL), a key enzyme in the regulation of lipid 
storage in adipose tissue 156. An interaction between SNPs in the HSL and USF1 genes on 
postprandial TG levels has been previously reported 157. Despite this, HSL activity in adipose 
tissue was unchanged in Finnish patients with FCH 158. USF1 also inﬂuences the transcription of 
fatty acid synthase (FAS), which is involved in the synthesis of fatty acids 154, 159. FAS might play 
a role in FCH, as patients with FCH have decreased circulating levels of FAS ligand 160. USF1 
also plays a role in the transcription of several apolipoproteins (APOCIII, APOAII and APOE) 
155, 161, glucokinase 162, hepatic lipase 163, angiotensinogen 164 and ATP-binding cassette sub-family 
A member 1 (ABCA1) 165. Genetic variation in APOCIII, APOAII and hepatic lipase have been 
associated with FCH 61, 73, 166, 167, however, the role of glucokinase, angiotensinogen and ABCA1 
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in FCH has not been explored yet.
In the present study, we evaluated the putative role of the USF1 gene in Dutch patients with 
FCH. We investigated the eﬀect of two individual SNPs, and the haplotypes formed by these 
two SNPs, on FCH and its associated phenotypes, including not only lipids and lipoproteins, 
but also parameters of obesity and insulin resistance. 
Methods
Study population
The FCH population was ascertained in 1994 and followed-up and expanded in 1999. The 
families were ascertained through probands, recruited from the outpatient lipid clinic of the 
Radboud University Nijmegen Medical Centre. In 1994 and 1999, we ascertained families in 
which the proband exhibited a combined hyperlipidemia with both plasma TC and TG levels 
above the age- and gender-related 90th percentile 146, during several periods in which they were not 
treated with lipid-lowering drugs, and despite dietary advice. Additionally, a ﬁrst-degree relative 
had elevated levels of TC and/or TG above the 90th percentile and the proband, or a ﬁrst-degree 
relative, suﬀered from premature (before the age of 60 years) cardiovascular disease. Families 
were excluded when probands were diagnosed with underlying diseases causing hyperlipidemia 
(i.e., diabetes mellitus type 1 and 2, hypothyroidism, and hepatic or renal impairment), a ﬁrst-
degree relative had tendon xanthomata or probands were homozygous for the APOE2 allele.
In the present study we used the data of all participating subjects in 1999, including the 
spouses. The total population consists of 36 families from multiple (between 2 and 4) generations 
and comprised of 611 subjects with known genealogic and phenotypic data. The diagnosis of 
FCH was based on (1) the traditional diagnostic criteria including TC and/or TG levels above the 
90th percentile 168 and (2) on the nomogram, as recently published by our group 17. Plasma TG 
and TC levels, adjusted for age and gender, and absolute apolipoprotein B levels, were applied to 
the nomogram to calculate the probability of being aﬀected with FCH. When this probability 
is greater than 60%, the diagnostic phenotype is present in at least one ﬁrst-degree relative, 
and premature CVD (before the age of 60 years) is present in at least one individual in the 
family, the individual is deﬁned as aﬀected by FCH. In 26 of the 36 FCH families, ascertained 
through the traditional criteria 169, the proband also fulﬁlled the criterion of the nomogram for 
the FCH diagnosis; for the other 10 probands, the nomogram could not be applied because of 
missing apoB data. The normolipidemic relatives (n = 390), unaﬀected spouses of both the FCH 
patients and the normolipidemic relatives (n = 64) and subjects without known phenotypic and/
or genotypic data (n = 230) were included in the family-based analyses. After withdrawal of lipid-
lowering medication for four weeks and an overnight fast, blood was drawn by venipuncture. The 
maximum waist circumference (cm) at the umbilical level were measured in the late exhalation 
phase while standing. All included subjects were Caucasian and above the age of 10 years. The 
ethical committee of the Radboud University Nijmegen Medical Centre approved the study 
protocol and the procedures followed were in accordance with institutional guidelines. All 
subjects gave informed consent. 
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Biochemical analyses
Plasma TC and TG were determined by enzymatic, commercially available reagents (Boehringer-
Mannheim, Germany, catalog No. 237574 and Sera Pak, Miles, Belgium, catalog No. 6639, 
respectively). Total plasma apoB concentrations were measured by immunonephelometry 119. 
LDL subfractions were separated by single spin density gradient ultracentrifugation, according 
to a previously described method 120. A continuous variable, K, represents the LDL subfraction 
proﬁle of each individual. A negative K-value (K ≤ -0.1) reﬂects a more dense LDL subfraction 
proﬁle, and a positive K-value (K > -0.1) reﬂects a more buoyant proﬁle. Glucose concentrations 
were analyzed in duplicate using the oxidation technique (Beckman®, Glucose Analyser2, 
Beckman Instruments Inc., USA). Plasma insulin concentrations were ascertained using a 
double antibody method 170. Insulin resistance was assessed by the homeostasis model assessment 
(HOMA) method 171. 
DNA was obtained from peripheral blood lymphocytes using a standard technique. 
Microsatellite markers, D1s104 and D1s1677, were ampliﬁed by polymerase chain reaction 
(PCR) and analyzed on polyacrylamide gels, as described by Hughes 172. D1s104 and D1s1677 
were succesfully genotyped in 611 and 545 individuals, respectively. The genotyping of D1s1677 
failed in 38 FCH patients. For the USF1 variants, PCRs were performed in a ﬁnal volume of 50 
µl at an annealing temperature of 53.7°C for both polymorphisms. Primer sequences for USF1s1 
were 5’-GGTGTGTCCTTGAACTGAG-3’ (forward) and 5’-CAAGCCAGAGCATCACC 
TG-3’ (reverse) and for USF1s2 5’-CTTTAGTAGAGACAGGGTTTCAC-3’ (forward) and 
5’-GATTTAGCAGGTATTAGGAGCA-3’ (reverse). The mismatch (underlined) for USF1s2 
was introduced to create a restriction site for BsiHKA I. The PCR products were digested by 
either 10 U BstF5 I (USF1s1) or 10 U BsiHKA I (USF1s2) at 65°C (New England Biolabs, USA) 
and, subsequently, the resulting fragments (242, 172 and 70 bp in heterozygotes for USF1s1 or 
154, 136 and 18 bp in heterozygotes for USF1s2) were separated on agarose gels. USF1s1 and 
USF1s2 were genotyped in all 611 individuals, including 157 FCH patients. The genotyping of 
USF1s2, however, failed for 6 individuals, including 3 FCH patients.
Quantitative real-time PCR analysis of USF1 expression in PBMCs
USF1 mRNA expression levels were quantiﬁed in peripheral blood mononuclear cells (PBMCs) 
of 30 FCH patients and 30 sex-matched normolipidemic relatives randomly selected from our 
study population, as previously described 173. RNA was isolated from PBMCs, including both 
lymphocytes and monocytes, and reversed transcribed to cDNA. A quantitative real-time PCR 
was carried out in a total 25 µL containing 2 µL cDNA, 0.25xSYBR® green solution (Invitrogen, 
The Netherlands), 1xﬂuorescein (Biorad, The Netherlands), 2 mM MgCl2, 50 ng of forward 
(5’ATGACCCAGGCGGTGATCCA3’) and reverse (5’GACGCTCCACTTCATTATGC3’) 
primers, 100 µM dNTPs, 1x AmpliTaq Gold ampliﬁcation buﬀer and 1.5 unit of AmpliTaq 
Gold DNA polymerase (Applied Biosystems, The Netherlands). PCR conditions were; a hot-
start by 95°C for 10 minutes, followed by 40 cycles of 95°C for 30 s, 60°C for 30 s and 72°C for 
30 s. Samples were run in duplicate on the Icycler iQ real-time PCR detection system (Biorad, 
The Netherlands) to determine the threshold cycle (Ct) 174. Expression levels were normalized to 
B2M by comparative quantiﬁcation using the ∆∆Ct method 175.
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Statistical analyses
The characteristics of the study population are expressed as mean ± standard deviation 
(SD). Prior to further statistical analyses, extended Mendelian error-checking was performed 
for 36 families, including 219 nuclear families (n = 611), with Pedcheck 122. Data was only 
available for 25 of the 36 probands, as these 11 probands were already recruited in 1994 and 
did not participate in 1999. For families with Mendelian inconsistencies, which can be due to 
paternity problems and/or misgenotyping, problematic genotypes were set to missing for the 
complete nuclear families or the isolated problematic individuals (n = 10 (1.6%)). The parental 
data for each polymorphism were tested for Hardy-Weinberg equilibrium by use of an exact-
test. Variables with a skewed distribution, including triglycerides and the HOMA-index, were 
logarithmically transformed. Multipoint parametric linkage analysis of the two microsatelite 
markers on chromosome 1 and the two USF1 polymorphisms were performed for three traits, 
the FCH trait, deﬁned by both the traditional diagnostic criteria and the nomogram and the TG 
trait, deﬁned by TG levels above the 90th percentile 146, using SIMWALK2 176. Data was prepared 
using MEGA2 177. We assumed a disease allele frequency of 0.01 and 0.10 under the dominant 
and recessive mode of inheritance, respectively. The assumed penetrance in the dominant model 
was 0.99. In the recessive model, the assumed penetrances with risk and non-risk genotypes 
were 0.99 and 0.50, respectively. A phenocopy rate of 0.01 was assumed. These conditions are 
comparable to those used by Pajukanta et al. 28. Two-point nonparametric linkage analysis of 
the two microsatelite markers and the USF1 polymorphisms were carried out using the SOLAR 
2.1.4 software 123. The presence of nonparametric linkage was tested for FCH and the related 
quantitative traits, including apoB, TC and TG levels and the presence of sdLDL, represented 
by the K-value. The haploview program 178 was used to calculate allele and haplotype frequencies 
and to calculate the linkage disequilibrium between the two SNPs. Haploview was also used 
to calculate transmission disequilibrium association tests (TDT) with permutation analysis to 
correct for multiple testing.
Associations between the individual polymorphisms or haplotypes and FCH and its related 
phenotypes in our extended families were determined using two programs, namely, the family-
based association test (FBAT) 179 and the pedigree-based association test (PBAT) software 180. An 
additive model of inheritance was used, as the mode of inheritance of FCH is unknown and this 
model is particularly robust 179. FBAT handles pedigrees by breaking the pedigrees into all possible 
nuclear families, and evaluating their contribution to the test statistics. According to FBAT, our 
36 FCH families included 219 nuclear families. The –e option of FBAT, which computes the 
test statistic using an empirical variance estimator 181, was implemented as the nuclear families 
were not independent. The –p option, which performs the Monte-Carlo permutation procedure, 
was used to correct for multiple testing. As Pajukanta et al. 46 reported a sex-speciﬁc eﬀect for 
USF1, adjustments were made for age and gender by calculating the unstandardized residuals. 
No adjustment for age and gender was made for FCH, as the FCH diagnosis is already corrected 
for age and gender. For the haplotype analysis, the haplotype-based association test (HBAT) 
command of the FBAT program was used, utilizing the –e and –p options.
PBAT is capable of handling extended pedigrees without breaking them into nuclear families. 
Despite this, our extended pedigrees had to be divided into smaller units, due to computational 
limitations. This resulted in a total of 92 pedigrees, with a maximum of 14 non-founders per 
pedigree. Age and gender were used as covariates in the models. All tested variables, except for 
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the dichotomous variables, were transformed to a Z-score, as recommended by PBAT 180. The 
proportion of trait variation for TC, apoB and sdLDL explicable by USF1 polymorphisms were 
tested by means of generalized estimating equations (GEE) because of possibly correlated values 
within families.
Diﬀerences were considered statistically signiﬁcant at P ≤ 0.05. These analyses were conducted 
using SPSS 12.0.1, PedCheck 1.1, MEGA2, SIMWALK2, SOLAR 2.1.4, HAPLOVIEW 3.2, 
FBAT 3.2 and PBAT 3.0. 
Results
Subject characteristics
According to both the traditional diagnostic criteria and the nomogram, 135 subjects were 
aﬀected with FCH. In addition, 38 patients were aﬀected with FCH according to either the 
traditional diagnostic criteria (n = 16) or the nomogram (n = 22) as diagnostic criterion. So, in 
total 157 subjects were diagnosed with FCH according to the nomogram. Descriptive statistics 
of anthropometric and metabolic characteristics of the study population, presented below and in 
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Table 1     Characteristics of patients with familial combined hyperlipidemia, normolipidemic 
                 relatives and spouses
FCH patients
(n = 157)
NL relatives
(n = 390)
Spouses
(n = 64)
Allele frequency (Wt) 
(USF1s1/USF1s2)
0.75 / 0.75 0.69 / 0.69 0.72 / 0.72
Gender (males) 75 (47.8%) 177 (45.4%) 31 (48.4%)
Age (years) 47.0 (15.6) * † 37.9 (15.7) ‡ 56.0 (10.5)
CVD 32 (20.4%) * † 20 (5.1%) 4 (6.3%)
Waist (cm) 87.2 (12.2) * 77.7 (10.9) ‡ 84.3 (12.5)
TC (mmol/L) 6.5 (1.1) * † 4.9 (0.9) ‡ 5.2 (0.8)
TG (mmol/L) 3.1 (1.5) * † 1.2 (0.5) 1.3 (0.6)
TG >90th percentile 113 (71.6%) * † 11 (2.9%) 2 (3.1%)
ApoB (mg/L) 1370 (264) * † 960 (220) 996 (175)
LDLc (mmol/L) 4.1 (1.2) * † 3.2 (0.9) ‡ 3.4 (0.7)
K-value -0.26 (0.26) * † 0.05 (0.19) 0.05 (0.25)
HOMA-index 3.4 (1.8) * † 2.3 (1.3) ‡ 2.7 (1.3)
FCH diagnosis based on the nomogram. Bivariate variables are presented as number (%); Continuous 
variables are presented as mean (SD); FCH, familial combined hyperlipidemia; NL relatives, normolipidemic 
relatives; Wt allele (USF1s1/2), allele frequencies for the wildtype alleles of USF1s1 and USF1s2; 
CVD, cardiovascular disease; waist, waist circumference; TC, total cholesterol; TG, triglycerides; Apo B, 
apolipoprotein B; K-value, a value < -0.1 represents the presence of small dense LDL; HOMA, homeostasis 
model assessment-index; *, p-value < 0.05, compared to NL relatives; †, p-value <0.05, compared to spouses; 
‡, p-value < 0.05, compared to spouses.
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table 1, were based on the nomogram as diagnostic criterion for FCH.
FCH patients were older than normolipidemic relatives, but younger than spouses. The 
higher prevalence of CVD in patients with FCH was evident, compared to normolipidemic 
relatives and spouses. The mean waist circumference of patients with FCH was signiﬁcantly 
higher, compared to normolipidemic relatives. By deﬁnition, FCH patients were characterized 
by increased plasma TC, TG and apoB levels. Furthermore, FCH patients exhibited higher levels 
of sdLDL, as reﬂected by a lower K-value. Finally, FCH patients were more insulin resistant, as 
reﬂected by a higher HOMA-index. In the total population 126 subjects showed the TG trait, as 
deﬁned by TG levels > 90th percentile, including 52 men. In table 1, the distribution of the TG 
trait among FCH family members is presented.
For both USF1s1 and USF1s2, the wildtype allele (C or A, respectively) had a frequency 
of 0.81 in probands. The wildtype allele frequency of 0.72 in spouses was comparable to 
the frequency found in probands (p = 0.30). The distributions of the parental alleles and 
genotypes for both polymorphisms were in Hardy-Weinberg proportions. Analysis performed 
with haploview showed that the two polymorphisms were in complete linkage disequilibrium 
(D’ = 1.0; R2 = 1.0), resulting in the presence of only two haplotypes in our study population. 
The C–A haplotype had an overall frequency of 71% (n = 853) and the T–G haplotype of 29% 
(n = 357). 
In total 302 subjects (85 FCH patients, 184 normolipidemic relatives and 33 spouses) carried 
two common alleles for both SNPs. Two hundred and ﬁfty subjects (59 FCH patients, 165 
normolipidemic relatives and 26 spouses) were heterozygous fot both SNPs and 53 subjects 
(9 FCH patients, 39 normolipidemic relatives and 5 spouses) carried two rare alleles for both 
SNPs. 
With a TDT association test, we observed no overtransmission of one of the alleles (USF1s1: 
p = 0.62 and USF1s2: p = 0.62) or haplotypes (p = 0.32) to the FCH patients. Correction for 
multiple testing by permutation analysis did not alter these results.
Linkage analyses
Parametric and nonparametric linkage analyses for the 1q21-23 region were performed utilizing 
the two SNPs in the USF1 gene and two microsatellite markers on chromosome 1, D1s104 and 
D1s1677, previously identiﬁed as the markers underlying the linkage signal on 1q21-23 in the 
Finnish population. Two-point nonparametric linkage analyses of these two markers and the two 
SNPs in the USF1 gene did not show evidence of linkage with FCH trait (lod score = 0.0 for the 
nomogram and lod scores = 0.0 – 0.3 for the traditional diagnostic criteria), the TG trait (lod 
score = 0.0 – 0.2) or any of the related quantitative traits, including apoB, TC, LDL-c levels and 
the presence of sdLDL (all two-point lod scores < 0.5). As parametric linkage analyses can be 
more powerful than nonparametric linkage analyses in our extended families, we also performed 
parametric linkage analyses which also did not show any evidence of linkage with the FCH trait 
(lod score = 0.0 for the nomogram and lod score = 0.6 for the traditional diagnostic criteria) and 
the TG trait, deﬁned by TG levels above the 90th percentile (lod score = 0.5).
Association and haplotype analyses
In table 2, the associations of the polymorphisms of the USF1 gene, individually and 
combined into haplotypes, with FCH and its related phenotypes in the total population are 
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presented. No statistical association of the USF1 gene with FCH, deﬁned by the nomogram, 
was found. Applying the traditional diagnostic criteria of FCH revealed a suggestive association 
of the USF1 gene with FCH. No association of the USF1 gene with the TG trait was found. 
However, after correction for age and gender, suggestive associations for the wildtype haplotype, 
previously identiﬁed as the risk haplotype by Pajukanta et al., were obtained for TC, apoB and 
sdLDL, when the structure of the pedigrees were taken into account (Table 2). Correcting for 
multiple testing, with the –p option, resulted in an association of USF1s1 and USF1s2 with TC 
(p = 0.05 and p = 0.04, respectively) and apoB (p = 0.06 and p = 0.04, respectively). sdLDL 
showed suggestive association with USF1s1 (p = 0.10) and USF1s2 (p = 0.09). The USF1 
gene could, however, only explain a small proportion of the variation in plasma TC (1.7%), 
apoB (1.5%) and sdLDL (0.5%) levels. LDL-c and the obesity- and insulin resistance-related 
phenotypes of FCH were not associated with USF1 (Table 2).
PBAT was also used to analyze the association between the haplotypes of the USF1 gene 
and FCH and its associated phenotypes. PBAT does not implement an overall haplotype test, 
but generates a p-value for each haplotype. As shown in table 2, the risk haplotype was not 
associated with FCH when the nomogram was used as diagnostic criterion, but a suggestive 
association was found when using the traditional diagnostic criteria for FCH. The analyses of 
the association between USF1 with other characteristics of FCH did not reveal any statistically 
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Table 2     Association of the individual polymorphisms and haplotypes of the USF1 gene with 
                 familial combined hyperlipidemia and its related phenotypes after correction for age 
                 and gender in the total population.
FBAT -e FBAT -p HBAT -e HBAT -p PBAT -e
USF1s1 USF1s2 USF1s1 USF1s2 Overall 
Haplotype
Overall 
Haplotype
Risk 
Haplotype
FCH - NG 0.45 0.52 0.53 0.53 0.52 0.55 0.95
FCH - Trad 0.07 0.06 0.08 0.07 0.06 0.06 0.05
TG * 0.31 0.27 0.39 0.33 0.27 0.38 0.61
TG > 90th 0.66 0.66 0.67 0.69 0.66 0.69 0.96
TC 0.08 0.06 0.05 0.04 0.06 0.05 0.11
ApoB 0.05 0.05 0.06 0.04 0.04 0.05 0.12
LDLc 0.31 0.24 0.24 0.20 0.27 0.22 0.27
K-value 0.09 0.09 0.10 0.09 0.09 0.11 0.46
Waist 0.66 0.71 0.68 0.69 0.65 0.67 0.55
HOMA * 0.43 0.57 0.53 0.69 0.60 0.73 0.43
Presented are the obtained p-values for the individual SNPs and haplotypes in the total population; *, ln-
transformed variable; FCH – NG, FCH diagnosis based on the nomogram; FCH –Trad, FCH diagnosis 
based on the traditional lipid criteria; TC, total cholesterol; TG, triglycerides; Apo B, apolipoprotein B; 
LDL-c, LDL-cholesterol; K-value, a value < -0.1 represents the presence of small dense LDL; waist, waist 
circumference; HOMA, homeostasis model assessment-index; -e, correction for the non-independence of the 
nuclear families; -p, correction for multiple testing by permutation tests.
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signiﬁcant association. The associations found for TC and apoB, however, pointed in the same 
direction as the associations found with the FBAT and HBAT statistics (Table 2). 
In view of the fact that Pajukanta et al. 46 demonstrated a gender-speciﬁc eﬀect of the USF1 
gene on FCH and TG levels in males, the analyses of both the individual SNPs and the haplotypes 
of USF1 were also performed in males only (Table 3). The male population (n = 283), included 
65 FCH patients based on the traditional diagnostic criteria and 75 FCH patients based on the 
nomogram. In total, 52 (18.5%) men had TG levels > 90th percentile. No signiﬁcant association 
of the USF1 gene with the FCH or the TG trait was found, only suggestive evidence for an 
association in males was present for apoB levels and sdLDL, in concordance with the analysis 
in the complete families. So, no apparent gender-speciﬁc eﬀect was present for these parameters 
(Table 3). For the obesity parameters, waist circumference, we found suggestive evidence for an 
association with USF1 in males only (Table 3).
Expression analyses of USF1 in PBMC’s
To further explore the role of USF1 in FCH, expression levels of USF1 in PBMCs were 
measured in 30 FCH patients (deﬁned by the nomogram) and 30 controls. Anthropometric 
and metabolic characteristics of these subjects are presented in table 4. The FCH patients 
demonstrated a relative expression of 0.9 [0.5 – 2.2] for the USF1 gene, this was compared to 
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Table 3     Association of the individual polymorphisms and haplotypes of the USF1 gene with 
                 familial combined hyperlipidemia and its related phenotypes after correction for age 
                 and gender in males.
FBAT -e FBAT -p HBAT -e HBAT -p PBAT -e
USF1s1 USF1s2 USF1s1 USF1s2 Overall 
Haplotype
Overall 
Haplotype
Risk 
Haplotype
FCH - NG 0.45 0.52 0.48 0.56 0.52 0.55 0.70
FCH - Trad 0.41 0.31 0.47 0.29 0.31 0.31 0.83
TG * 0.53 0.44 0.59 0.54 0.44 0.52 0.75
TG > 90th 0.98 0.98 0.94 0.94 0.98 0.94 1.00
TC 0.33 0.30 0.32 0.29 0.30 0.34 0.11
ApoB 0.12 0.10 0.13 0.12 0.10 0.13 0.05
LDLc 0.63 0.64 0.57 0.62 0.64 0.61 0.65
K-value 0.15 0.12 0.23 0.19 0.12 0.22 0.26
Waist 0.11 0.10 0.06 0.06 0.10 0.06 0.15
HOMA * 0.49 0.47 0.64 0.58 0.47 0.59 0.59
Presented are the obtained p-values for the individual SNPs and haplotypes in males only; *, ln-transformed 
variable; FCH – NG, FCH diagnosis based on the nomogram; FCH –Trad, FCH diagnosis based on the 
traditional lipid criteria; TC, total cholesterol; TG, triglycerides; Apo B, apolipoprotein B; LDL-c, LDL-
cholesterol; K-value, a value < -0.1 represents the presence of small dense LDL; waist, waist circumference; 
HOMA, homeostasis model assessment-index; -e, correction for the non-independence of the nuclear families; 
-p, correction for multiple testing by permutation tests.
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controls (1.0 [0.3 – 4.0]) not signiﬁcantly diﬀerent (p-value = 0.27). Of the 30 FCH patients, 14 
carried the risk haplotype, 12 were heterozygous for the USF1 variants and 4 were homozygous 
for the rare haplotype. In the control group, 12 subjects carried the risk haplotype, 15 were 
heterozygous and 3 were homozygous for the rare haplotype. As the FCH patients carrying 
the USF1 risk haplotype had a relative expression of 1.3 [0.5 – 1.9] and the FCH patients 
carrying the rare haplotype had a relative expression of 1.0 [0.6 – 1.6], no diﬀerence based on the 
haplotype were observed within the FCH patients. The results in the controls were comparable.
Discussion 
In the present study, we investigated the putative role of USF1 in Dutch FCH families. We 
show that the wildtype haplotype of USF1, previously identiﬁed by Pajukanta et al. as a risk 
haplotype 46, is not associated with FCH when using the nomogram to diagnose FCH, which is 
based on plasma levels of total cholesterol, triglyceride and apolipoprotein B; however, a suggestive 
association of USF1 with FCH in our Dutch FCH families was found when using the traditional 
lipid criteria to diagnose FCH. Furthermore, we report no association of USF1 with the TG 
trait. The risk haplotye of USF1 was, however, associated with other important phenotypes 
of FCH, including plasma total cholesterol levels, apolipoprotein B levels and the presence of 
small dense LDL, accounting for approximately 1% of the variation in these phenotypes. We 
conclude that USF1 shows suggestive association with FCH and can be considered a modiﬁer 
gene, contributing to related lipid traits in our Dutch FCH families.
Several groups tried to replicate the results with regard to USF1 found in the Finnish FCH 
families 46 (Table 5).  Huertas-Vazquez et al. 42 reported an association of USF1 with FCH and TG 
levels in a Mexican population, although their results were less conclusive and no gender-speciﬁc 
eﬀect was found (Table 5). Coon et al. 47 also reported an association of USF1 with FCH in Utah 
pedigrees ascertained for early death due to CHD, early strokes, or early onset hypertension. 
When restricting the analyses to the families ascertained for early death due to CHD, in which 
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Table 4     Characteristics of the subgroup of subjects with familial combined hyperlipidemia and
                 controls, in whom USF1 expression levels were determined.
FCH patients (n = 30) Controls (n = 30)
Gender (males) 11 (36.7%) 11 (36.7%)
Age (years) 52.0 (14.0) 46.5 (14.5)
Waist (cm) 88.8 (10.2) * 99.2 (10.3)
Total cholesterol (mmol/L) 6.6 (0.9) * 5.3 (0.9)
Triglycerides (mmol/L) 3.17 (1.63) * 1.21 (0.46)
Apolipoprotein B (mg/L) 1369 (245) * 940 (216)
HOMA-index 2.9 (1.8) * 2.3 (1.5)
Results are presented as mean (SD); FCH patients, familial combined hyperlipidemia; waist, waist 
circumference; HOMA-index, homeostasis model assessment-index; * p < 0.05. 
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60% of the FCH patients were present, no evidence for the involvement of USF1 in FCH, TG 
or LDLc levels was found, although the strongest association would be expected in these families 
(Table 5). This lack of association in the families ascertained for early death due to CHD could 
be due to limited power, as only a few families were ascertained for CHD (n = 17). Another 
explanation could be the use of diﬀerent diagnostic criteria for FCH in the diﬀerent populations. 
To diagnose FCH, Pajukanta et al. and Huertas-Vazquez et al. used the traditional diagnostic 
criteria, based on elevated plasma TC and/or TG levels above the 90th percentile, adjusted for 
age and gender, while Coon et al. deﬁned FCH based on LDLc and/or TG levels above the 90th 
percentile, adjusted for age and gender. In the present study, we applied two diagnostic criteria 
for FCH, i.e. the recently published nomogram 17 and the traditional diagnostic criteria 14. We 
show that diﬀerent diagnostic criteria aﬀect the result of the association analyses. As shown 
in table 2, a suggestive p-value for association of USF1 with FCH was found when using the 
traditional FCH criteria, whereas no association was found when using the nomogram.
In sharp contrast to the results obtained by Pajukanta et al., who reported the strongest 
association of USF1 in males with high TG levels, we report, in the present study, no gender-
speciﬁc eﬀect and no association of USF1 with high TG levels. The absence of this association in 
our population might be explained by the relatively mildly elevated levels of TG in our population 
in comparison to the Finnish population (2.8 versus approximately 3.3 mmol/L, respectively) 
182, 183. FCH remains a multifactorial disease, with extensive genetic heterogeneity, in which the 
combination of many genes and the environment determine the expression of the phenotype, 
contributing to the apparently conﬂicting results in diﬀerent FCH populations. Our results are, 
however, supported by a study in Mexican FCH families 42, which also found not gender-speciﬁc 
eﬀect. 
Although we did not ﬁnd an association between USF1 and TG levels in the present study, we 
were able to replicate some associations for other important phenotypes of FCH, including TC, 
apoB and sdLDL. A study performed in obese Scandinavian women 184 and diabetes mellitus 
type 2 185, however, failed to demonstrate an association between USF1 and lipid/lipoprotein 
levels. This suggests that the inﬂuence of USF1, as a modiﬁer gene, on these lipid levels is speciﬁc 
for patients with FCH.
Recently, a close relationship between USF1 and catecholamine-stimulated lipolysis in human 
fat cells was found 184 and, based on this, it was suggested that the adipocyte lipolysis-related 
eﬀects of genetic variation in USF1 can have clinical consequences against a certain background 
such as FCH. In healthy young males it was demonstrated that USF1 is associated with glucose 
levels and has a modulating eﬀect on the correlation between BMI and TC levels 157. In the 
present study, however, we did not ﬁnd an association between USF1 and glucose, insulin levels, 
or obesity parameters. In males, however, a suggestive association was found between USF1 and 
the obesity parameter, waist circumference.
In the search for candidate genes underlying complex genetic disorders, haplotype analyses have 
become a valuable tool. The most convincing results for the association of USF1 with FCH from 
pajukanta et al. 46 and Huertas-Vazquez et al. 42 were obtained when analyzing the USF1 SNPs 
as haplotypes (Table 5). In our study, however, the two SNPs resulted in only two haplotypes, so 
no increased power was obtained from haplotype analyses. The complete linkage disequilibrium 
between these two SNPs has been reported previously in 196 healthy obese women 184. In the 
present study, we used two programs, FBAT and PBAT. In FBAT the presence of linkage is not 
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mandatory for analyzing haplotypes. FBAT, however, splits up the pedigrees into nuclear families 
and, thereby, important information about the family structure is lost. The second program, 
PBAT, does not require the presence of linkage and is said to be capable of handling extended 
pedigrees. PBAT, however, could not handle our extended pedigrees, necessitating their division 
into smaller units. Haplotype analyses in extended pedigrees, therefore, remain a challenge.
For the association analyses of USF1 with FCH, Pajukanta et al. 46 and Huertas-Vazquez et 
al. 42 used several programs (Table 5). In the HHRR and the genotype pedigree disequilibrium 
test programs, linkage is assumed to be present in the region under investigation, making these 
programs unsuitable in our situation of no linkage. The association of USF1 with FCH in 
Mexican families was found using the gamete competition test program, which analyzes the 
presence of both linkage and association, so the signiﬁcant result can represent the presence 
of linkage only, as reported for this region in this population 42. Pajukanta et al. resolved this 
problem in the Finnish FCH families by gene dropping 46.
In the present study we genotyped two of the SNPs present in the USF1 gene. In the present 
study we genotyped two of the SNPs present in the USF1 gene. By genotyping these two SNPs 
we did not capture the complete genetic variation in this region. It is possible, therefore, that in 
our FCH Dutch population, another haplotype is the major risk haplotype. We assume, however, 
that this is unlikely, as not only in the Finnish families, but also in the Mexican and USA families 
this particular haplotype was identiﬁed as the risk haplotype. Furthermore, associations of this 
haplotype with underlying phenotypes of FCH were present in these Dutch FCH families. The 
identiﬁcation of USF1 as a modiﬁer gene in our population may, however, be of great importance 
as genome wide linkage analyses in our population revealed no loci with lod scores reaching the 
level of suggestive linkage (data not shown), making it unlikely to ﬁnd major genes for FCH.
Although USF1 was thought to be a good candidate gene for FCH, our results do not support 
the role of USF1 as a major gene in our population. This is reinforced by the lack of functionality 
of the genetic variations in USF1, as the two polymorphisms do not result in amino acid changes. 
The identiﬁcation of a site for DNA binding proteins in the region of USF1s2 has been reported; 
however, no evidence was found for the presence of the suggested internal promoter causing the 
transcription of truncated mRNA 48. Pajukanta et al. reported diﬀerential expression of three of 
the USF1 regulated genes in adipose tissue based on the USF1s2 allele 48. The expression of USF1 
itself, however, was not diﬀerent in adipose tissue. In the present study, we have measured the 
expression of USF1 in PBMCs and, consistent with the results of Pajukanta et al., we did not 
ﬁnd any haplotype-dependent diﬀerences. Our decision to use PBMCs, in the absence of adipose 
tissue samples from our study population, was justiﬁed by a study by Morello et al., showing that 
the FCH-speciﬁc transcription proﬁle was detectable in peripheral blood cells 153.
In conclusion, in our Dutch FCH patients, USF1 shows a suggestive association with FCH 
and can be considered a modiﬁer gene, contributing to related lipid traits in our Dutch FCH 
families.
Upstream stimulatory factor 1 gene in patients with FCH
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Abstract
Background Familial combined hyperlipidemia (FCH) is the most common genetic lipid 
disorder with an undeﬁned genetic etiology. Apolipoprotein A5 gene (APOA5) variants were 
previously shown to contribute to FCH. The aim of the present study was to evaluate the 
association of APOA5 variants with FCH and its related phenotypes in Dutch FCH patients. 
Furthermore, the eﬀects of variants in the APOA5 gene on carotid intima-media thickness (IMT) 
and cardiovascular disease (CVD) were examined. Materials and methods The study population 
consisted of 36 Dutch families, including 157 FCH patients. Two polymorphisms in the APOA5 
gene (-1131T>C and S19W) were genotyped. Results Haplotype analysis of APOA5 showed 
an association with FCH (p = 0.029), total cholesterol (p = 0.031), triglycerides (p < 0.001), 
apolipoprotein B (p = 0.011), HDL-cholesterol (p = 0.013), small dense LDL (p = 0.010) and 
remnant-like particle cholesterol (p = 0.001). Compared to S19 homozygotes, 19W carriers 
had an increased risk of FCH (OR = 1.6 [1.0 - 2.6]; p = 0.026) and a more atherogenic lipid 
proﬁle, reﬂected by higher triglyceride (+22%) and apolipoprotein B levels (+5%), decreased 
HDL-cholesterol levels (-7%) and an increased prevalence of small dense LDL (16% vs 26%). In 
carriers of the –1131C allele, small dense LDL was more prevalent than in –1131T homozygotes 
(29% vs 16%). No association of the APOA5 gene with IMT and CVD was evident. Conclusion 
In Dutch FCH families, variants in the APOA5 gene are associated with FCH and an atherogenic 
lipid proﬁle.
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Introduction
Familial combined hyperlipidemia (FCH) is the most common lipid disorder of unknown 
genetic etiology, aﬀecting 2-5% of the general population 10, 14. Major characteristics of FCH 
include elevated plasma levels of apolipoprotein B (apoB), triglycerides (TG) and/or total 
cholesterol (TC). Other phenotypes include decreased levels of high-density lipoprotein 
cholesterol (HDLc) and the presence of small, dense low-density lipoproteins (sdLDL). In 
addition, FCH patients have an increased risk of cardiovascular disease (CVD) and are often 
obese and insulin resistant 97. 
Despite decades of research, the complex genetics of FCH are still not fully understood. Several 
linkage analyses were performed, leading to the identiﬁcation of multiple loci for FCH 26, 28, 30, 34, 
36, 42. One repeatedly identiﬁed locus is located on chromosome 11q, a site involved in modulating 
the expression of FCH 31-33. This region includes the apolipoprotein A1-C3-A4-A5 gene cluster 
186. The apolipoprotein A5 (APOA5) gene encodes the apolipoprotein AV protein (APOAV), 
which is exclusively expressed in the liver. APOAV is found on very low-density lipoprotein 
(VLDL), HDL and chylomicrons and is, compared to other apolipoproteins, present in very low 
plasma concentrations 187, 188. Variations in the APOA5 gene are related to TG levels, however, the 
underlying mechanism is not yet fully understood 49. One hypothesis, based on mouse studies, 
suggests that APOAV modulates TG levels by guiding VLDL and chylomicrons to proteoglycan-
bound lipoprotein lipase for lipolysis and by increasing VLDL clearance 52, 53.
In the human APOA5 gene, several single-nucleotide polymorphisms (SNPs) have been 
identiﬁed (-1131T>C, -3A>G, S19W (56C>G), IVS3+476G>A and 1259T>C) 189, 190. The three 
major haplotypes, representing approximately 98% of all haplotypes in these populations, were 
deﬁned by the –1131T>C and the S19W SNPs 189, 190. In Caucasians, the rare alleles of these two 
SNPs were associated with elevated plasma levels of TC, TG, remnant-like particle cholesterol 
(RLPc), low-density lipoprotein cholesterol (LDLc) and apoB, decreased HDLc levels and the 
presence of sdLDL 186, 189, 191. In patients with FCH, APOA5 polymorphisms were associated with 
an increased risk of FCH and related lipid phenotypes, including TG, apoB and HDLc levels and 
LDL particle size 33, 50, 51. The relationship between variants in the APOA5 gene and RLPc levels 
was not previously studied in FCH patients.
Hypertriglyceridemia is an independent risk factor for the development of CVD 192. Despite 
its eﬀect on plasma triglycerides, the role of APOA5 in the development of CVD remains 
controversial 189, 193-197. In 372 Finnish men with CVD, who participated in the LOCAT study, it 
was demonstrated that only the rare allele of the S19W SNP (19W) was associated with increased 
progression of atherogenesis 197. In contrast, in 2,578 subjects from the general population in 
the Framingham Heart Study, an increased risk of CVD was found only for the rare allele of the 
–1131T>C SNP (-1131C) 189, 197. The results for CVD in the Framingham Heart Study, however, 
conﬂicted with the results obtained for intima-media thickness (IMT), a surrogate marker of 
CVD. Diﬀerences in IMT were associated with the 19W allele, but an association of the –1131C 
allele was only present in obese subjects 193. In FCH patients, who have an increased risk of CVD, 
the relationship between variants in the APOA5 gene and CVD was not previously examined.
The aim of the present study was to investigate the association of APOA5 gene variants 
(-1131T>C and S19W) with FCH and its associated phenotypes, including RLPc levels, using a 
family-based SNP and haplotype approach in well-characterized FCH families. Furthermore, the 
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suggested increased risk of CVD associated with variants in the APOA5 gene was investigated in 
our FCH families by taking both intima-media thickness and CVD prevalence into account.
Methods
Study population
Back in 1994, we have recruited FCH families from the outpatient lipid clinic of the Radboud 
University Nijmegen Medical Centre, ascertained through probands, exhibiting a combined 
hyperlipidemia with both plasma TC and TG levels above the age- and gender-related 90th 
percentile 146, during several periods in which they were not treated with lipid-lowering drugs, 
and despite dietary advice 146. Additionally, a ﬁrst-degree relative possesed elevated levels of TC 
and/or TG above the 90th percentile and the proband, or a ﬁrst-degree relative, suﬀered from 
premature (before the age of 60 years) cardiovascular disease. Families were excluded when 
probands were diagnosed with underlying diseases causing hyperlipidemia (i.e., diabetes mellitus 
type 1 and 2, hypothyroidism, and hepatic or renal impairment), a ﬁrst-degree relative had 
tendon xanthomata or probands were homozygous for the APOE2 allele. All included subjects 
were Caucasian and above the age of 10 years. The ascertained families had a mean size of 24 
members from multiple (between 2 and 4) generations. The present FCH study population 
include the 5-year follow-up data of our original FCH families, consisting of 36 Dutch families, 
comprised of 611 subjects with known genealogic, phenotypic, and genotypic data, of whom 
157 individuals were diagnosed as FCH patients 17. In 1999, the diagnosis of FCH was based 
on the nomogram 17. Plasma TG and TC levels, adjusted for age and gender, and absolute apoB 
levels, were applied to the nomogram to calculate a probability of being aﬀected with FCH. 
When this probability of being aﬀected with FCH is greater than 60%, the diagnostic phenotype 
is present in at least one ﬁrst degree relative, and premature CVD (before the age of 60 years) is 
present in at least one individual in the family, the individual is deﬁned as aﬀected by FCH. Also 
included in the family-based analyses were the normolipidemic relatives (n = 390), the unaﬀected 
spouses of both FCH patients and normolipidemic relatives (n = 64), and subjects without 
known phenotypic and/or genotypic data (n = 230) to complete the pedigree structure. After the 
withdrawal of lipid-lowering medication for four weeks and an overnight fast, blood was drawn 
by venipuncture. Body mass index (BMI) was calculated as body weight (kilograms) divided by 
the square of height (meters).
Information concerning CVD was gathered through personal interviews and physical 
examinations performed by the clinical investigator. When the clinical investigator suspected 
the presence of CVD, further details and conﬁrmation of the diagnosis were sought from the 
participant’s general practitioner and hospital records. CVD was deﬁned by angina pectoris (AP), 
myocardial infarction (MI), stroke, peripheral vascular disease or vascular surgery. In our study 
population (n = 611), 56 subjects were identiﬁed with CVD, including 26 subjects with AP, 25 
with previous MI, 10 with peripheral vascular disease, seven with stroke and 23 who underwent 
vascular surgery. In total, 45% (n = 25) of these individuals were diagnosed with CVD based 
on the presence of two or more manifestations of CVD. The ethical committee of the Radboud 
University Nijmegen Medical Centre approved the study protocol and all procedures were in 
accordance with institutional guidelines. All subjects provided written informed consent.
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 Biochemical analyses
Biochemical analyses were performed as previously described for this population 17. In short, 
plasma TC and TG were determined by enzymatic, commercially available reagents (Boehringer-
Mannheim, Germany, catalog No. 237574 and Sera Pak, Miles, Belgium, catalog No. 6639, 
respectively). Total plasma apoB concentrations were measured by immunonephelometry. HDLc 
was quantiﬁed by the polyethylene glycol 6000 method. LDL subfractions were separated by 
single spin density gradient ultracentrifugation. A continuous variable, K, represented the LDL 
subfraction proﬁle of each individual. A negative K-value (K ≤ -0.1) reﬂected the presence of 
small dense LDL 17. RLPc levels were measured using an immuno-separation technique as 
described elsewhere 198. Glucose concentrations were analyzed using the oxidation technique 
(Beckman®, Glucose Analyser2, Beckman Instruments Inc., Fullerton, CA 92634, USA). Plasma 
insulin concentrations were ascertained by a double antibody method. Insulin resistance was 
assessed by the homeostasis model assessment (HOMA) method.  
DNA was extracted from peripheral blood lymphocytes using a standard technique 121. 
Genotyping for the S19W and the –1131T>C SNPs was carried out by PCR and restriction 
enzyme digestion, as previously described 199. Genotyping of the S19W and –1131T>C SNPs 
failed in 5% and 3% of the subjects, respectively.
Table 1     Characteristics of patients with familial combined hyperlipidemia, normolipidemic 
                 relatives and spouses
FCH patients 
(n = 157)
NL relatives 
(n = 390)
Spouses 
(n = 64)
Male gender (n (%)) 75 (47.8 %) 177 (45.4 %) 31 (48.4 %)
Age (years) 47.0 (15.6) * † 37.9 (15.7) ‡ 56.0 (10.5)
CVD (n (%)) 32 (20.4 %) * † 20 (5.1 %) 4 (6.3 %)
IMT (mm) 0.80 (0.12) * 0.72 (0.12) -
BMI (kg/m2) 27.3 (4.1) * 24.1 (3.8) ‡ 26.8 (3.6)
Total cholesterol (mmol/L) 6.5 (1.1) * † 4.9 (0.9) ‡ 5.2 (0.8)
Triglycerides (mmol/L) 3.1 (1.5) * † 1.2 (0.5) 1.3 (0.6)
Apolipoprotein B (mg/L) 1370 (264) * † 960 (220) 996 (175)
LDLc (mmol/L) 4.1 (1.2) * † 3.2 (0.9) ‡ 3.4 (0.7)
HDLc (mmol/L) 0.98 (0.26) * † 1.22 (0.30) 1.28 (0.40)
K-value -0.26 (0.26) * † 0.05 (0.19) 0.05 (0.25)
RLPc (mmol/L) 0.57 (0.40) * † 0.26 (0.09) ‡ 0.29 (1.3)
HOMA-index 3.4 (1.8) * † 2.3 (1.3) ‡ 2.7 (1.3)
Continuous variables are presented as mean (SD); FCH, familial combined hyperlipidemia; NL relatives, 
normolipidemic relatives; CVD, cardiovascular disease; IMT, mean common artery intima-media thickness 
was measured in 61 FCH patients and 155 normolipidemic relatives; BMI, body mass index; LDLc, low-
density lipoprotein cholesterol; HDLc, high-density lipoprotein cholesterol; K-value, a value ≤ -0.1 represents 
the presence of small dense LDL; RLPc, remnant-like particle cholesterol; HOMA-index, homeostasis model 
assessment-index; *, p-value < 0.05, compared to normolipidemic relatives; †, p-value < 0.05, compared to 
spouses; ‡, p-value < 0.05, compared to spouses.
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Carotid IMT measurements
All our FCH families were invited to participate in an on-going follow-up program. As part 
of the follow-up screening, non-invasive measurements of atherosclerosis were performed, 
including carotid intima-media thickness (IMT), in all family members, including both patients 
and normolipidemic relatives 200. An AU5 Ultrasound machine (Esaote Biomedica) with a 7.5 
MHz linear-array transducer was used to measure the IMT of both common carotid arteries. 
Longitudinal images of the most distal 10 mm of both the far and the near wall of the common 
carotid artery were obtained with the optimal projection (anterolateral, lateral or posterolateral). 
The actual measurement of IMT was performed oﬄine by the sonographer using semi-
automatic edge-detection software (M’Ath®Std version 2.0, Metris, Argenteuil, France) 201. All 
measurements were carried out in end-diastole using the R-wave of a simultaneously recorded 
ECG as a reference frame. From each frame the mean IMT was calculated over at least 7.5 mm of 
the aforementioned 10 mm segment (yielding a minimum quality index of 75%). The outcome 
variable was deﬁned as the mean IMT of the near and far wall of both common carotid arteries.
Statistical analyses
Descriptive statistics were compared using ANOVA for continuous traits and Pearson’s chi-
square test for discrete traits. Prior to further statistical analyses, extended Mendelian error-
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Continuous variables are presented as mean (SD); FCH, familial combined hyperlipidemia; NL relatives, 
normolipidemic relatives; CVD, cardiovascular disease; IMT, mean common artery intima-media thickness; 
BMI, body mass index; LDLc, low-density lipoprotein choleterol; HDLc, high-density lipoprotein cholesterol; 
K-value, a value ≤ -0.1 represents the presence of small dense LDL; RLPc, remnant-like particle cholesterol; 
HOMA-index, homeostasis model assessment-index; *, p-value < 0.05.
Table 2     Characteristics of the subjects with data on intima media tickness.
FCH patients 
(n = 61)
NL relatives 
(n = 155)
Male gender (n (%)) 28 (45.9 %) 70 (45.2 %)
Age (years) 47.4 (14.2) * 37.9(14.7)
CVD (n (%)) 9 (14.8 %) * 9 (5.8 %)
IMT (mm) 0.80 (0.12) * 0.72 (0.12)
BMI (kg/m2) 28.3 (4.05) * 24.1 (3.6)
Total cholesterol (mmol/L) 6.6 (1.3) * 5.4 (1.0)
Triglycerides (mmol/L) 2.9 (1.8) * 1.5 (1.1)
Apolipoprotein B (mg/L) 1327 (297) * 973 (233)
LDLc (mmol/L) 4.2 (1.2) * 3.2 (0.9)
HDLc (mmol/L) 1.14 (0.26) * 1.33 (0.33)
K-value -0.28 (0.25) * 0.05 (0.21)
RLPc (mmol/L) 0.62 (0.45) * 0.25 (0.09)
HOMA-index 2.4 (1.3 )* 1.8 (1.0)
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checking was performed with Pedcheck 122. For families with Mendelian inconsistencies, 
problematic genotypes were set to missing for the complete nuclear family or the isolated 
problematic individual (1%). The parental data for both SNPs were tested for Hardy-Weinberg 
equilibrium by use of Fisher’s exact-test. Variables with a skewed distribution, including TG 
levels, RLPc levels and the HOMA-index, were logarithmically transformed. The HAPLOVIEW 
program 178 was used to estimate allele and haplotype frequencies in founders, representing 
the unrelated individuals of the study population, including probands and spouses. Linkage 
disequilibrium (LD) and allelic association (R2) between the two SNPs were calculated with 
HAPLOVIEW using the conﬁdence interval method of Gabriel et al.  202.
To study the relation of APOA5 in FCH, we used both linkage and association analysis. The 
SOLAR 2.1.4 software was used to implement two-point linkage analysis 123. The presence of 
linkage was tested for FCH and its related phenotypes. As linkage analysis may have limited 
power to identify common variants with moderate eﬀects for more complex diseases, such as 
FCH,  we also performed association analysis 203. 
Associations between the individual polymorphisms (1131T>C and S19W), or haplotypes 
and FCH, or the related phenotypes, were analyzed using a family based approach, with the 
family based association test (FBAT) software 179. FBAT is attractive because it can test for 
linkage and/or association while avoiding biases due to population admixture or stratiﬁcation, 
misspeciﬁcation of the trait distribution, and/or selection based on the trait. The FBAT test 
statistics utilizes a general approach to family-based association tests, as proposed by Rabinowitz 
and Laird (2000), and is based on the distribution of the oﬀspring genotypes conditional on any 
trait information and on the parental genotypes 179. An additive model of inheritance was used, as 
the mode of inheritance of FCH is unknown and this model is particularly robust. FBAT broke 
down the extended pedigrees into nuclear families (n = 219) and evaluated their contribution to 
the test statistics. The –e option of FBAT, which computes the test statistic using an empirical 
variance estimator, was implemented to correct for the non-independence of the nuclear families 
and for the presence of linkage. The –p option, which performs a Monte-Carlo permutation 
procedure, was used to estimate empirical p-values. Adjustments for age, gender and BMI were 
done by calculation of the residuals. For the haplotype analysis, the haplotype-based association 
test (HBAT) command of FBAT was used, utilizing the –e and –p options. Diﬀerences were 
considered statistically signiﬁcant at p-value < 0.05. 
The explained variance in FCH by the APOA5 variants was explored using the measured 
genotype method in the SOLAR Program 123. The measured genotype analyses uses variance 
component methodology to estimate the proportion of variance due to environmental and 
additive genetic eﬀects. By comparing models with and without the APOA5 genotypes, estimations 
are calculated of what proportion of the FCH trait variance is attributable to the genotype by 
examining the changes to the estimates of environmental and additive genetic variance. P-values 
and the explicable proportion of variance are presented. 
To test diﬀerences between the diﬀerent genotypes, generalized estimating equation (GEE) 
analyses were performed in the STATA 8.0 software. The GEE analyse is especially designed 
to take into account possible correlated values within families. In the models used for the GEE 
analyses the link function ‘canonical’ was used and an equal-correlation population-averaged 
model was used as the working correlation matrix.
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The analyses were conducted using SPSS 12.0.1, PEDCHECK 1.00, HAPLOVIEW 3.2, 
SOLAR 2.1.4, FBAT 3.2 and STATA 8.0 software. 
Results
Characteristics of study population
Anthropometric and metabolic characteristics of FCH patients, normolipidemic relatives 
and spouses are presented in table 1. FCH patients were older than normolipidemic relatives, 
but younger than spouses. Compared to normolipidemic relatives and spouses, FCH patients 
had a higher prevalence of CVD and higher IMT values. When correcting the IMT values for 
the age diﬀerence between FCH patients  and normolipidemic relatives, the diﬀerence in IMT 
remained signiﬁcant (0.78 mm (SD 0.08) in FCH versus 0.73 mm (SD 0.08) in normolipidemic 
relatives, p = 0.000). FCH patients were characterized by increased lipid levels, including TC, 
TG, apoB, LDLc and RLPc concentrations, decreased HDLc and an increased prevalence 
of sdLDL, as reﬂected by a K-value below -0.1. Finally, FCH patients were more also obese, 
as reﬂected by a higher BMI, and insulin resistant, as reﬂected by a higher HOMA-index 
(Table 1). The anthropometric and metabolic characteristics of the subgroup of subjects with 
IMT data are presented in table 2. Characteristics of the subjects with IMT data did not diﬀer 
signiﬁcantly from the total group as presented in table 1 (all p < 0.05). Anthropometric and 
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Continuous variables are presented as mean (SD); CVD, cardiovascular disease; FCH, familial combined 
hyperlipidemia, IMT, mean common artery intima-media thickness; BMI, body mass index; LDLc, low-
density lipoprotein choleterol; HDLc, high-density lipoprotein cholesterol; K-value, a value ≤ -0.1 represents 
the presence of small dense LDL; RLPc, remnant-like particle cholesterol; HOMA-index, homeostasis model 
assessment-index.
Table 3     Characteristics of subjects with cardiovascular disease
Subjects with CVD (n = 56)
Male gender (n (%)) 35 (62.5 %)
age (years) 62.5 (9.3)
FCH (n (%)) 24 (42.9 %)
IMT (mm) 0.88 (0.13)
BMI (kg/m2) 27.3 (3.4)
Total cholesterol (mmol/L) 6.8 (1.5)
Triglycerides (mmol/L) 2.9 (2.1)
Apolipoprotein B (mg/L) 1339 (302)
LDLc (mmol/L) 4.0 (1.2)
HDLc (mmol/L) 1.19 (0.31)
K-value -0.18 (0.31)
RLPc (mmol/L) 0.46 (0.27)
HOMA-index 2.3 (1.4)
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metabolic characteristics of the subgroup of subjects with CVD are presented in table 3. As 
expected, patients with CVD were relatively old and predominantly men. Furthermore, patients 
with CVD had a relatively high IMT value and a more atherogenic lipid proﬁle reﬂected by 
high TC and TG levels, low HDLc levels and the presence of sdLDL. Forty three percent of the 
subjects with CVD were diagnosed FCH.
Analyses of the APOA5 gene with FCH and related lipid phenotypes
In founders, rare allele frequencies for the –1131T>C and S19W SNPs were 0.08 and 0.11, 
respectively. In the probands, rare allele frequencies for the –1131T>C and S19W SNPs were 
0.10 and 0.16, respectively. The genotypic distributions of –1131T>C and S19W were in Hardy-
Weinberg proportions. The alleles of the –1131T>C and the S19W SNPs were in complete 
linkage disequilibrium (D’ = 1.00), but with very little correlation (R2 = 0.01). A consequence 
of this linkage disequilibrium is that, only three of the possible four diﬀerent haplotypes were 
observed. Haplotype analyses can, therefore, provide additional information compared to the 
single SNP analyses, since it accounts for both sources of variation. The wildtype haplotype 
(APOA5*1) had a frequency of 0.83. The frequencies of the haplotype deﬁned by a rare allele 
for the –1131T>C (APOA5*2) or by a rare allele for the S19W SNP (APOA5*3) were 0.11 
and 0.06, respectively. In total 394 individuals (92 FCH patients, 261 normolipidemic relatives 
and 41 spouses) carried only common alleles for both SNPs, who are referred to as “wildtypes”. 
64 subjects (8 FCH patients, 50 normolipidemic relatives and 6 spouses) carried one or two 
rare for the –1131T>C SNP and wildtype alleles for the S19W SNP and 115 subjects (38 FCH 
patients, 63 normolipidemic relatives and 14 spouses) carried one or two rare alleles for the 
S19W and wildtype alleles for the –1131T>C SNP. A rare allele for both the –1131T>C and 
the S19W SNP were present in 18 subjects (9 FCH patients, 9 normolipidemic relatives and 
0 spouses), referred to as “compound heterozygotes”.
Linkage analysis of the APOA5 region
Two-point linkage analyses performed utilizing the –1131T>C and S19W SNPs in the APOA5 
gene did not provide evidence of linkage for FCH (-1131T>C; lod score = 0.04 and S19W; 
lodscore = 0.38). For TG levels a lod score of 1.6 was obtained for the S19W SNP, whereas a 
lod score of 0.005 was found for the –1131T>C SNP. For all other phenotypes, including apoB, 
TC, RLPc and HDLc levels, and the presence of sdLDL, no linkage was present (all two-point 
lod scores < 0.5). 
 
Association analyses of APOA5 variants with FCH and related phenotypes
The associations of the –1131T>C and the S19W SNPs, individually and as haplotypes, with 
FCH and its related phenotypes are presented in table 4A. These associations are corrected for 
age, gender and multiple testing. The APOA5*2 haplotype was not associated with FCH, while 
the APOA5*3 haplotype was overrepresented in patients with FCH (p=0.014). Haplotype 
analysis showed that the APOA5 haplotypes were associated with FCH (p=0.029). This resulted 
in an increased risk of FCH for subjects (n = 119) with the rare allele for the S19W SNP 
(1.62 [95% C.I.: 1.03 - 2.55]; p = 0.026) and for the compound heterozygotes (n = 19) carrying 
a rare allele for the –1131T>C and the S19W SNPs (3.28 [95% C.I.: 1.38 - 7.82]; p = 0.008). 
The APOA5*3 haplotype was also associated with individual lipid and lipoprotein levels, 
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including TC (p = 0.042), TG (p < 0.001), apoB (p = 0.024), HDLc (p = 0.019), K-value 
(p = 0.024) and RLPc (p = 0.001). No associations were found for the obesity (BMI) and insulin 
resistance parameters (HOMA-index) (Table 4A). The APOA5*2 haplotype was not signiﬁcantly 
associated with any of the characteristics of FCH. Comparable results were found when the non-
independence of the families and the possible presence of linkage (-e option) were taken into 
account (data not shown).
Explained variance in FCH by the APOA5 gene
By measured genotype analyses, it was estimated that 2% of the genetic variance in FCH is 
attributable to the S19W SNP (p < 0.001). The S19W SNP also explained 3% of the variation 
in TG levels (p < 0.001), 1% of the variance in HDLc levels (p = 0.005) and 1% of the variation 
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Table 4     Association of rare alleles of the -1131T>C and the S19W SNPs and haplotypes in the
                APOA5 gene with familial combined hyperlipidemia and its related phenotypes.
SNPs Haplotypes
                                 N   -1131C 19W APOA5*2 APOA5*3
Overall 
Haplotype
A
FCH 611  0.921  0.048  0.931  0.014  0.029
BMI 611  0.519  0.697  0.373  0.799  0.808
TC 611  0.055  0.063  0.272  0.042  0.031
TG * 611  0.041  0.000  0.141  0.000  0.000
ApoB 611  0.097  0.087  0.253  0.024  0.011
LDLc 608  0.403  0.320  0.596  0.630  0.787
HDLc 609  0.445  0.041  0.397  0.019  0.013
K-value 611  0.233  0.045  0.119  0.024  0.010
RLPc * 559  0.031  0.000  0.120  0.001  0.001
HOMA-index * 550  0.534  0.385  0.560  0.273  0.623
B
CVD 611  0.482 0.379  0.066  0.607  0.202
IMT 216  0.437 0.494  0.797  0.656  0.542
P-values for the individual SNPs (FBAT) and haplotypes (HBAT) corrected for age, gender and multiple 
testing are presented; *, ln-transformed variable; N, number of subjects with available data for the relevant 
phenotype; APOA5*2, haplotype represented by the rare allele of -1131T>C SNP; APOA5*3, haplotype 
represented by the rare allele of S19W SNP; Overall haplotype, the p-value obtained for the model including 
all haplotypes; FCH, familial combined hyperlipidemiawas present in 157 subjects; BMI, body mass index; 
TC, total cholesterol; TG, triglycerides; ApoB, apolipoprotein B; LDLc, low-density lipoprotein cholesterol; 
HDLc, high-density lipoprotein cholesterol; K-value, a value ≤ -0.1 represents the presence of small dense 
LDL; RLPc, remnant-like particle cholesterol; HOMA-index, homeostasis model assessment-index; CVD, 
cardiovascular disease was present in 56 subjects; IMT, mean common carotid artery intima-media thickness 
data were present in 61 FCH patients and 155 normolipidemic relatives.
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in K-value (p = 0.005). The -1131T>C SNP did not contribute to the variation in FCH or any 
of the related phenotypes (TC, TG, ApoB, LDLc, HDLc, K-value, RLPc and HOMA-index); 
in fact, the point estimates for the combined eﬀects of both genotypes, S19W and –1131T>C, 
were identical to the point estimate obtained for S19W alone.
Association analyses of the APOA5 gene with IMT and CVD 
The associations of the –1131T>C and the S19W SNPs in APOA5, and their haplotypes, with 
IMT values and CVD prevalence, are presented in table 4B. These associations are corrected 
for age, gender and multiple testing. The APOA5*3 haplotype was not associated with IMT 
or CVD. The APOA5*2 haplotype did show a trend towards signiﬁcant association with CVD 
(p = 0.07), but no association with IMT was present. Overall, no association of the haplotypes 
with IMT values or CVD prevalence was evident. Further adjustment of IMT values for obesity 
did not change these results.
Eﬀect of APOA5 variants on lipid and lipoprotein levels, IMT and prevalence of CVD
To determine the eﬀect of the genetic variation in the APOA5 gene on lipid levels in the 
general population, we combined the normolipidemic relatives and spouses in one control group, 
which was allowed because no diﬀerence in anthropometric and biochemical parameters, based 
Table 5     Diﬀerences in phenotypic parameters in the control group including normolipidemic 
                 relatives and spouses with a rare allele for the -1131T>C of the S19W SNP in the 
                 APOA5 gene compared to wildtype individuals.
Wildtypes 
n = 302 
(68.0 %)
-1131C
n = 56
(12.6 %)
19W
n = 77
(17.4 %)
Compounds
n = 9
(2.0 %)
CVD (n (%)) 10 (3.3 %) 5 (8.9 %) 6 (7.8 %) 1 (11.1 %)
IMT (mm) 0.74 (0.72 - 0.76) -1.4 % -4.0 % +0.0 %
TC (mmol/L) 4.99 (4.86 - 5.11) +3.0 % +2.0 % -3.4 %
TG (mmol/L) * 1.07 (1.01 - 1.14) +8.4 % +22.4 % † +23.4 %
ApoB (mg/L) 975 (949 - 1001) +5.3 % +5.0 % † +4.6 %
HDLc (mmol/L) 1.24 (1.20 - 1.28) -2.4 % -7.3 % † -17.7 % †
K-value ≤ -0.1 (n (%)) 48 (15.9 %) 16 (28.6 %) † 20 (26.0 %) † 4 (44.4 %) †
RLPc (mmol/L) * 0.25 (0.24 - 0.26 +0.0 % +4.0 % +8.0 %
Presented are the data of the combined group of normolipidemic relatives and spouses. For the subjects with 
wildtype alleles for both SNPs, dichotomous variables are presented as number (%) and the continuous 
variables, standardized for age and gender, are presented as mean (95% CI); For the other groups, 
dichotomous variables are presented as number (%) and the continuous variables as percent of diﬀerence 
compared to the wildtype individuals; *, ln-transformed variables; -1131C, subjects carrying either 1 or 2 
rare alleles for the 1131T>C SNP, 19W, subjects carrying either 1 or 2 rare alleles for the S19SW SNP; 
Compounds, subjects carrying 1 rare allele for both SNPs; CVD, vardiovascular disease; IMT, common 
carotid artery intima-media thickness; TC, total cholesterol; TG, triglycerides; ApoB, apolipoprotein B; 
HDLc, high-density lipoprotein cholesterol; K-value, a value ≤ -0.1 represents the presence of small dense 
LDL; RLPc, remnant-like paritcle cholesterol; †, p-value < 0.05 compared to wildtypes.
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on genotypes, were observed between relatives and spouses (data not shown). The results were 
standardized for age and gender and presented in table 5. Compared to the wildtypes, individuals 
carrying a rare allele of the S19W SNP had increased TG levels (+22%) apoB levels (+5%) and 
decreased HDLc levels (-7%). Furthermore, in subjects with a 19W allele, a K-value below –0.1 
was present in 26% of the subjects, which was signiﬁcantly higher than in wildtypes (16%; 
p = 0.046). Additionally, in carriers of the –1131T>C rare allele, sdLDL was present in more 
individuals (29%; p = 0.035) compared to wildtypes. The compounds had approximately 15% 
lower HDLc levels and sdLDL was present in more individuals. Compared to the wildtypes, 
individuals carrying rare alleles for either or both SNPs had no increased IMT or increased 
prevalence of CVD (Table 5).
The eﬀect of APOA5 on lipid levels among FCH patients were comparable (data not shown).
Discussion
The results from this study demonstrate that the S19W variant in the APOA5 gene are 
associated with FCH. We show that the APOA5*3 haplotype is over-represented in patients with 
FCH. Furthermore, we provide evidence for the association of the  APOA5*3 haplotype with a 
more atherogenic lipid proﬁle. However, no association of the –1131T>C and S19W variants 
in the APOA5 gene with higher IMT values or an increased prevalence of CVD in patients with 
FCH was evident.
The 19W allele was previously associated with an increased risk of FCH and elevated levels 
of TG and apoB 33, 50. In the present study, we performed family-based haplotype analyses with 
the FBAT program, corrected either for multiple testing or for the presence of linkage in this 
region. We conﬁrmed the independent association of the 19W allele with FCH and elevated 
TG levels. Additionally, we showed that the 19W allele is associated with an atherogenic lipid 
proﬁle including elevated apoB levels, decreased HDLc levels and the presence of sdLDL. This is 
in agreement with previously documented associations in general populations 33, 186, 189, 191. From 
the literature, it is also suggested that the haplotype containing the 19W is associated with the 
highest TG levels 190, 199. 
In the present study, no independent association for the –1131C allele was found with FCH 
or any of the related lipid phenotypes whereas the –1131C allele was previously associated with 
an increased risk of FCH, and elevated levels of TG and sdLDL 33, 50, 51. In the present study we 
deﬁned FCH based on the nomogram 17. To exclude that the lack of association of the –1131T>C 
SNP with FCH in our population is due to diﬀerent diagnostic criteria of FCH, we repeated 
the analyses, now applying the traditional diagnostic criteria of FCH, based on TC and/or TG 
levels above the 90th percentile. No association of the –1131T>C SNP with FCH, based on the 
traditional diagnostic criteria was found (Table 6). Most likely, the small number of subjects 
carrying one or two C alleles of the –1131T>C SNP contribute to the lack of involvement of 
this SNP to FCH. In contrast, compound heterozygotes did show a signiﬁcant increased risk on 
FCH, despite the low number of subjects. However, as the lipid and lipoprotein levels among 
wubjects who were compound heterozygotes did not diﬀer from wildtype carriers, it may well be 
possible that the observed increased risk of FCH in compound heterozygotes is a false positive 
ﬁnding and therefore additional studies are required for conﬁrmation of our observed increased 
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risk on FCH in compound heterozygotes.
Previously, two studies investigated the association of variants in the APOA5 gene and RLPc 
levels. In the Framing Heart Study population, both the 19W and –1131C alleles were associated 
with RLPc levels, while no association was found in the MONICA study population 189, 204. We 
report no association of the rare alleles of the –1131T>C and the S19W SNPs in the APOA5 
gene with RLPc levels in our FCH study population, which is in agreement with the ﬁndings of 
the MONICA study 204.
Since the variants in the APOA5 are suggested to be associated with plasma lipid levels, it 
is likely that it plays a role in the development of CVD. Several studies investigated possible 
associations between variants in the APOA5 gene and the prevalence of CVD in Caucasians, 
however, these led to contradictory results 189, 193-197, 205. The LOCAT study showed a trend toward 
increased progression of atherogenesis in male carriers of the rare allele of the S19W SNP; in 
contrast, no eﬀect was found for the –1131C allele 197. In the Framingham Heart Study, an almost 
2-fold increased risk of CVD was found in females carrying the rare allele of the –1131T>C SNP, 
but there was no eﬀect in males. For the 19W allele, no eﬀect was found in either gender 189. In 
contrast, in the same Framingham Heart Study, the 19W allele was associated with IMT values 
in both genders. In obese subjects, this relationship with IMT was also found for the rare allele 
of the –1131T>C SNP 193. 
The association of variants in the APOA5 gene with CVD and IMT values was not previously 
studied in FCH patients, which are known to have thicker IMT and an increased risk of CVD 
200. In the present study, we show that, although the rare allele of the S19W variant in the APOA5 
gene was associated with FCH and a disturbed lipid proﬁle, no association with CVD or IMT 
was evident. This could be a result of the limited number of individuals with CVD in our study 
population, and the availability of IMT data in only a sub-set of the study population, resulting 
in limited power for studying these associations. Possible explanations for the contradictory 
results previously found for CVD could be that the association of variants in the APOA5 gene 
with CVD is independent of TG levels, suggesting diﬀerent mechanisms, or that the inﬂuence 
of APOA5 gene variants on TG is relatively small and therefore not translated into diﬀerences in 
CVD 193, 195, 197.
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Table 6     Association of rare allele of the -1131T>C and the S19W SNPs and haplotypes in the 
                 APOA5 gene with familial combined hyperlipidemia based on the traditional 
                 diagnostic criteria.
SNPs Haplotypes
N -1131C 19W APOA5*2 APOA5*3 Overall 
Haplotype
FCH 611 0.615 0.124 0.914 0.105 0.429
P-values for the individual SNPs (FBAT) and haplotypes (HBAT) corrected for age, gender and multiple 
testing are presented; N, number of subjects with available data for the relevant phenotype; APOA5*2, 
haplotype represented by the rare allele of -1131T>C SNP; APOA5*3, haplotype represented by the rare 
allele of S19W SNP; Overall haplotype, the p-value obtained for the model including all haplotypes; FCH, 
familial combined hyperlipidemiawas present in 151 subjects.
In the present study, the measured genotype method and FBAT were used to analyse the 
assocation of variants in the APOA5 gene with FCH and its related phenotypes. The measured 
genotype method is more powerful, uses the whole pedigree and provides an eﬀect estimate for 
the tested variables, but is not robust in the presence of population stratiﬁcation. FBAT, however, 
is robust to stratiﬁcation, but is less powerful and uses incomplete pedigree information. The 
results of both statistical analyses were highly concordant, thereby providing strong evidence for 
the role of the S19W SNP of the APOA5 gene in FCH patients.
In the general population, the inﬂuence of variations in the APOA5 gene on lipid levels is 
still controversial. Some studies show that the association of variations in the APOA5 gene with 
increased TG levels is limited or not present in the general population 33, 50, 51. Based on these 
studies, there is conjecture that APOA5 gene variants modulate TG levels only when there is an 
altered genetic and metabolic background. In the present study, we show that the inﬂuence of the 
rare allele of the S19W SNP on lipid levels was not restricted to FCH patients, but also present 
in normolipidemic relatives and spouses.
In conclusion, in the present study of Dutch FCH families, the rare allele of the S19W SNP in 
the APOA5 gene is associated with FCH and a more atherogenic lipid proﬁle.
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Diagnostic criteria in relation to the pathogenesis 
of familial combined hyperlipidemia
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Abstract
Familial combined hyperlipidemia (FCH) is the most common inherited hyperlipidemia in 
humans, aﬀecting 1 to 3% of the adult population and up to 20% of patients with premature 
myocardial infarction. FCH is traditionally diagnosed by total plasma cholesterol and/or 
triglyceride levels above the 90th percentile adjusted for age and gender; however, the diagnosis 
of FCH based on these diagnostic criteria is inconsistent in 26% of the subjects over a ﬁve-year 
period, emphesizing the need for re-evaluation of the diagnostic criteria for FCH. Recently, 
a nomogram was developed based on absolute apolipoprotein B levels in combination with 
triglyceride and total cholesterol levels adjusted for both age and gender to simply and accurately 
diagnose FCH. When percentiles of triglyceride and total cholesterol adjusted for age and 
gender are not available in a population, the deﬁnition of FCH can be established based on 
hypertriglyceridemia (> 1.5 mmol/L) and hyperapoB (> 1200 mg/L).
Standardized and simple diagnostic criteria are necessary to further delineate the pathogenesis 
of FCH. Several metabolic pathways have been suggested to be important in causing the FCH 
phenotype including hepatic VLDL overproduction either with or without impaired clearance 
of triglyceride-rich lipoproteins from plasma. The presence of insulin resistance and obesity in 
FCH patients further contribute to the expression of the lipid phenotype. A disturbed adipose 
tissue metabolism that results in an increased plasma free fatty acid pool may be the culprit in 
the pathogenesis of FCH.
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Diagnostic criteria in relation to the pathogenesis of FCH
More than three decades ago, familial combined hyperlipidemia (FCH) was identiﬁed 
independently by Goldstein et al., Rose et al., and Nikkila et al. as a new inherited lipid disorder 
characterized by multiple lipoprotein phenotypes deﬁned by the presence of hypertriglyceridemia, 
hypercholesterolemia or both in aﬀected individuals and strongly associated with premature 
cardiovascular disease (CVD) 14, 15, 206. The lipoprotein phenotype can vary in time, both in aﬀected 
individuals and in their ﬁrst-degree relatives, hence the description of this disorder by some as 
multiple type hyperlipidemia. At present, FCH is the most common inherited hyperlipidemia 
in humans, aﬀecting 1 to 3% of the adult population and up to 20% of patients with premature 
myocardial infarction. Despite recent progress, the genetic and metabolic backgrouds of FCH 
have not been elucidated in detail 9, 13, 116, 207-209. This review discusses the evolution of the 
diagnostic criteria of FCH including the complex genetics and diﬀerent metabolic pathways in 
the pathogenesis of this disorder.  
Characteristic features of FCH
Aﬀected individuals are characterized by variable expression of elevated concentrations of total 
cholesterol (TC) and/or triglycerides (TG) above the 90th percentile for age and gender. Within 
a family, multiple type hyperlipidemia in ﬁrst-degree relatives comprising hypertriglyceridemia, 
hypercholesterolemia and/or combined hyperlipidemia is obligatory in addition to the presence 
of atherosclerotic manifestations before the age of 60 years. Usually, FCH becomes manifest only 
at adult age. Because of the absence of a speciﬁc clinical or metabolic marker for the disorder and 
because of characteristic variability in the presenting lipid phenotype, family studies are necessary 
to establish the diagnosis of FCH in a single patient 13, 116. Other major characteristics of FCH 
include elevated apolipoprotein B (apoB) levels 5, 16, 20, 22, 23, the preponderance of small, dense 
low-density lipoprotein (sdLDL) 7, 16, 18, 23, 210 and decreased high-density lipoprotein cholesterol 
(HDLc) levels 6. Furthermore, FCH is associated with obesity and insulin resistance 9, 11, 211-213.
Thus, FCH patients exhibit several risk factors contributing to an increased risk of CVD. 
Indeed, several studies have demonstrated that FCH is associated with a two- to ﬁvefold increased 
risk of  premature CVD 8, 10, 11. 
Therefore, it is of great importance to identify and treat patients with FCH appropriately. 
However, the diagnosis of FCH is diﬃcult because of the complex phenotypic heterogeneity and 
the highly variable nature of FCH as genetic, metabolic and environmental factors inﬂuence its 
expression. 
Diagnostic criteria of FCH 
There is a lack of consensus on diagnostic criteria for FCH. Traditionally, the diagnosis 
FCH in a patient is based on the presence of plasma TC and/or TG levels  above the 90th 
percentile adjusted for age and gender in a family with multiple type hyperlipidemia and the 
presence of premature CVD. Although these internationally accepted diagnostic criteria have 
been formulated for FCH, not all research groups use the same criteria to deﬁne FCH. For 
example in some studies the 95th percentiles or even absolute values for TC (> 6.5 mmol/L) and 
90
TG (> 2.3 mmol/L) levels, not adjusted for age and gender, are used 214-216.
A major chacteristic of FCH is the variability in lipid phenotype expression in time not only 
between individuals but also within a patient. This lipoprotein phenotypic heterogeneity in FCH 
has made the diagnosis of FCH even more diﬃcult.
Total serum cholesterol and triglycerides
FCH phenotype variability at the lipoprotein level has been described in detail 117.  It was 
shown that a single individual over a 6-year period without drug therapy can present with all 
three phenotypes at any given time, suggesting that environmental factors strongly inﬂuence the 
variability in the phenotype in a subject with a genetic underlying cause for this disease. 
We evaluated the variability in lipid phenotype expression over a 5-year period in 32 FCH 
families, comprising 299 subjects 16. We demonstrated that the diagnosis FCH, based on plasma 
TC and/or TG levels, is consistent in only 74% of the subjects over a 5-year period, suggesting that 
inaccurate diagnosis of FCH contributes to heterogeneity in FCH populations in the literature 
16. Thus, most important, 26% of the subjects with FCH in 1994 had a sporadic normolipidemic 
pattern in 1999, deﬁned by TC and TG levels below the 90th  percentile, corrected for age and 
gender.
 For the diagnosis FCH the use of only plasma TC and TG levels, age and gender adjusted, is 
insuﬃcient. When the traditional lipid phenotype is variable and insuﬃcient, accurate clinical 
diagnosis in individual subjects is not possible. Equally important genetic characterization 
becomes problematic, and a biologically correct hypothesis may be falsely rejected because of 
inaccurate diagnosis. Furthermore, the phenotype FCH based on TC and/or TG levels alone 
incompletely accounts for what is going on physiologically . 
ApoB and small, dense LDL
In a previous study we showed that characterization of our FCH cohort was substantially more 
consistent when using two other major characteristics of FCH, elevated apoB levels and the 
presence of sdLDL 16. Subjects aﬀected with FCH in 1994 and/or 1999 had signiﬁcantly higher 
apoB levels and an increased amount  of sdLDL compared to nonaﬀected subjects, even when they 
presented with a normolipidemic phenotype. Together with less variablity in time, measurements 
of apoB and sdLDL in plasma could potentially lead to more consistent diagnostic criteria for 
FCH with a better discriminant power to separate aﬀected from non-aﬀected relatives, compared 
to the use of serum TC and TG levels alone. Ayyobi et al. also reported that sdLDL and elevated 
apoB are the common characteristics for the three major lipid phenotypes, type  IIA, IIB and IV 
of FCH 5. Also McNeely et al. showed during a 20-year follow-up of FCH subjects that apoB 
levels were highest among individuals who were consistently aﬀected with FCH, intermediate 
among those who switched phenotypes, and lowest among individuals who were consistently 
normolipidemic 167. Therefore, it is hypothesized that all lipoprotein phenotypes in FCH, 
despite great serum TC and TG variability, share fundamental characteristics, that is, sdLDL 
and elevated apoB levels. These data encourage the identiﬁcation of unequivocal standardized 
diagnositic criteria for FCH.   
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ApoB as diagnostic criterion of FCH
The characteristic metabolic abnormality in FCH is increased production of very-low- density 
lipoprotein (VLDL) with or without impaired clearance of TG-rich lipoproteins in the majority 
of patients, resulting in hypertriglyceridemia and elevated plasma apoB (Figure 1, route 1) 91, 217. 
Figure 1
Metabolic pathogenesis of familial combined hyperlipidemia. The characteristic metabolic abnormality in 
FCH is increased production of apolipoprotein B (apoB) with or without impaired clearance of triglycerides 
by diminished lipoprotein lipase (LPL) activity, resulting in elevated levels of apoB and hypertriglyceridemia 
(i.e., elevated VLDL) (route 1). By the action of cholesterol ester transfer protein (CETP) and subsequent 
action of lipoprotein lipase (LPL) and hepatic lipase (HL), VLDL particles are converted into small, dense 
LDL (sdLDL) (route 2). As for the metabolic origin of apoB overproduction, emerging evidence points to 
disturbed trapping of peripheral fatty acids in adipose tissue (route 3), resulting in enhanced ﬂux of free fatty 
acids (FFAs) to the liver and contributing to increased apoB production (routes 4 and 5). Furthermore, fatty 
acids activate hepatic gluconeogenesis. Increased production of glucose is a trigger to the pancreas to secrete 
insulin to maintain nomoglycemia and can thus result in an increased fasting plasma insulin concentration, 
which is associated with the syndrome of insulin resistance (IR) (route 6). A defect in insulin action at the 
level of the adipocyte reduces FFA trapping, resulting directly in elevated plasma FFAs (route 4). Finally, 
increase of FFA in plasma and insulin resistance inhibit LPL and promote the release of LPL from the 
endothelial cells, resulting in increased uptake of LPL by the liver, which cuold result in slower clearance 
of triglyceride-rich particles from plasma (route 7). Thus, abnormal metabolism of fatty acids provides a 
pathophysiological link to the hepatic apoB overproduction, partial LPL deﬁciency, and insulin resistance 
syndrome, all characteristics of FCH. The defect in fatty acid metabolism could be in the acylation stimulatory 
protein (ASP) or hormone-sensitive lipase (HSL) pathway, due to resistance to lipolytic hormones, or due 
to disturbed adipokine metabolism (e.g. increased leptin concentration, activation of the TNF-TNFR axis 
(route 8).
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Although apoB overproduction is a well-established feature of FCH, the underlying molecular 
basis is not known. ApoB gene defects have been ruled out by linkage analysis 65, 218. A locus for 
elevated apoB levels on chromosome 1p31 in Dutch families with FCH was reported 38. As for 
the metabolic origin of apoB overproduction, emerging evidence points to a disturbed trapping 
of peripheral fatty acids in adipose tissue, resulting in enhanced ﬂux of free fatty acids (FFA) 
to the liver, contributing to increased apoB production (see later). Several studies have shown 
that apoB is an important phenotypic measure of FCH. In a previous study we showed that 
characterization of our FCH cohort was substantially more consistant when using apoB levels 16. 
Also, in the follow-up study of McNeely et al., elevated apoB was more persistent than elevated TC 
or TG levels 167. Another practical advantage of including apoB levels as new diagnostic criterion 
is to diagnose FCH at a younger age. Several studies have shown that in teenage children, apoB 
may be elevated, whereas lipids are not 219-222. The standardization of the plasma apoB assay has 
been performed by a committee of the World Health Organisation;  apoB can be measured with 
the same precision and accuracy as the lipoprotein lipids 223. All these data encourage to involve 
apoB in the phenotypic deﬁnition of FCH and establish a cutoﬀ level for apoB. 
We showed in our large FCH cohort with 5-year follow-up that the optimal cutoﬀ 
point for apoB to predict FCH is an apoB level above 1200 mg/L 17. Subjects with an 
apoB level over 1200 mg/L have an increased probability of being aﬀected with FCH 
(OR = 12.3 [95% CI: 6.99 to 21.69]) compared with subjects with an apoB level below 
1200 mg/L 17. This has also been suggested in other studies. This value corresponds 
roughly to the 75th percentile in men (results of the Framingham Oﬀspring study) 224  and 
subjects with apoB concentrations greater than 1200 mg/L were signiﬁcantly more 
likely to have CVD than subjects with apoB levels less than 1200 mg/L 225, 226. In our 
opinion, measurement of the apoB concentration is imperative for the diagnosis of FCH.
Small dense LDL as diagnostic criterion of FCH
Small, dense LDL is another important feature in FCH 13, 18, 183, 210,  The intravascular formation 
of LDL subfractions involves the conversion of VLDL precursors 227. Possibly there is also a 
direct hepatic secretion of diﬀerent intermediate-density lipoprotein or LDL subspecies into 
the circulation. In the formation of LDL subfractions, the cholesteryl ester transfer protein 
(CETP) facilitates the distribution of cholesterol esters among diﬀerent  lipoprotein classes in 
exchange for TG 228. The subsequent action of  lipoprotein lipase (LPL) or hepatic lipase (HL) 
on these particles results in the hydrolysis of a signiﬁcant amount of  TG in LDL and thereby in 
a decrease in LDL particle size (Figure 1, route 2) 229, 230. In general, this hypothesis can explain 
the predominance of these sdLDL particles in any form of hypertriglyceridemia. However, 
in FCH, we and several groups have provided evidence that sdLDL is characteristic of FCH, 
independent of plasma TG concentration 13, 119, 231. Genetic inﬂuences on the LDL subfractions 
distribution have been proposed by Bredie et al. and others as well, allthough they are still 
unclariﬁed 13, 23, 183. 
We previously showed that subjects with FCH had signiﬁcantly more atherogenic sdLDL, 
compared with nonaﬀected relatives, even when they had a sporadic normolipidemic phenotype 
16. Similarly, sdLDL has been demonstrated to be the most prominent characteristic shared among 
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the three FCH phenotypes, independent of the classical plasma lipoprotein levels 5. However, 
this was not shown in the follow-up study of McNeely et al., which could be due to diﬀerent 
methods used to determine sdLDL 167.  Although sdLDL is an important feature of FCH, it is of 
interest that in multivariate analysis, LDL heterogeneity did not provide additional information 
in predicting FCH after including TG; TG levels appeared to be  the most important predictor 
of FCH, most likely because of the strong correlation between LDL heterogeneity and TG levels 
(r = -0.68) 17. Serum TG concentration has been suggested to be the most important predictor 
of LDL size in FCH patients 7.  Several studies have shown that plasma TG levels over 1.5 
mmol/L distinguish optimally between atherogenic sdLDL and a large buoyant LDL subfraction 
proﬁle 119, 232.  
Hyper-TG hyper-apoB as diagnostic feature of FCH
During an international forum on FCH in Barcelona in 2001, there was a proposal to redeﬁne 
FCH based on hypertriglyceridemia and elevated plasma apoB (hyperTG hyperapoB) 216. The 
cutoﬀ point proposed for apoB was 1200 mg/L and for plasma TG 1.5 mmol/L. The choice of 
these cutoﬀ points was tentative until recently. We  showed for the ﬁrst time that these cutoﬀ 
point were justiﬁed on the basis of our large FCH cohort with 5-year follow-up 17. 
 A nomogram to diagnose FCH
Based on the pathophysiology of lipid metabolism in FCH, four major lipid phenotypes of 
FCH can be distinguished to be used as diagnostic criteria for FCH. Recently, we evaluated which 
(combination of ) diagnostic features most adequately predicts FCH, including serum TC, TG, 
apoB and sdLDL 17. The TG level, adjusted for age and gender, was the strongest independent 
predictor of FCH. The absolute apoB level was the second most important predictor of FCH. 
Finally, TC levels contributed to the prediction of FCH. Small, dense LDL did not add any 
signiﬁcance in the prediction of FCH because of the strong association with TG levels. Thus, 
absolute apoB levels in combination with TG and TC levels, both age and gender adjusted, are 
most predictive for diagnosing FCH. To develop a clinical tool, a nomogram was constructed to 
calculate simply and reliably the probability of FCH in clinical practice in an individual subject 
on the basis of quantitative serum apoB, TG, and TC values. In case the percentiles of serum 
TC and TG are not available, we showed that it is acceptable to deﬁne FCH by TG levels over 
1.5 mmol/L and apoB values over 1200 mg/L 17. 
The use of the proposed new diagnostic criteria, included in a nomogram, will make it easier to 
identify patients and their relatives with FCH. Still, the diagnostic phenotype has to be present 
in more than one family member and at least one individual in the family must have premature 
CVD to diagnose FCH. Conﬁrmation of the clinical relevance of this new deﬁnition of FCH in 
other large FCH cohorts is warranted to conﬁrm unequivocal diagnostic criteria for FCH. 
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Associated nonlipid features of FCH
Patients with familial combined hyperlipidemiat are characterized by the presence of obesity 
and insulin resistance 9, 11, 211-213. It is well known that insulin resistance and visceral obesity are 
both associated with several metabolic abnormalities, including increased TG levels, lower HDLc 
levels, more sdLDL particles, and increased apoB production rates, all also characteristics of FCH. 
Insulin resistance or visceral obesity or both may therefore be  important factors modulating 
FCH phenotypes. 
Insulin resistance
Impaired insulin action in FCH patients, with respect to the suppression of serum FFA and 
the stimulation of glucose disposal, has been demonstrated directly by means of the euglycemic 
hyperinsulinemic clamp technique by several groups 211, 233, 234. The reported defect in insulin 
ability to suppress the FFA release results in elevated serum FFA concentration; in peripheral 
tissues, particular skeletal muscle, high FFA levels block glucose oxidation, thereby causing 
insulin resistance (Figure 1, route 6) 235. In the liver, a high ﬂux of FAA most likely drives hepatic 
overproduction of TG and apoB, contributing to an elevated concentration of VLDL in the 
plasma (Figure 1, route 5) 95. Thus, insulin resistance is associated with a combined VLDL + LDL 
or hypertriglyceridemic lipid phenotype, but it does not explain (isolated) high LDL-cholesterol 
in FCH.  Indeed, most studies on insulin resistance in FCH have been performed in patients 
who exhibit a combined hyperlipidemia (elevation of both VLDL and LDL) 236, 237.
Therefore, the question arises what the role of insulin resistance is in FCH patients with 
high LDLc in the absence of hypertriglyceridemia. Several reports have shown that insulin 
resistance was found in all three FCH lipoprotein phenotypes, being more severe in subjects 
with hypertriglyceridemia 236, 237. A major concern in all these studies is that changes in lipid 
phenotype, which is traditionally considered an important characteristic of FCH, are not taken 
into account. We reported that 43% of the FCH patients showed a change in lipid phenotype 
expression after 5 years 16. The eﬀect of these intra-individual changes in lipid phenotype 
expression in time on insulin resistance has not been addressed in the literature. It is of great 
interest to study the interdependence of  insulin resistance and change in lipid phenotype 
expression in time to reveal further the role of insulin resistance in FCH. The data on insulin 
resistance in FCH imply that FCH deﬁned by the traditional diagnostic criteria, TC and/or 
TG, includes a heterogenous population in which several metabolic pathways may contribute to 
the lipid phenotype expression. It will be of great interest to demonstrate an association of the 
proposed new FCH diagnostic criteria using the nomogram and insulin resistance to reveal the 
role of insulin resistance in lipid phenotype expression in FCH 17.
Several pathophysiological mechanisms may contribute to insulin resistance in FCH, that is, 
decreased insulin-induced vasodilation in skeletal muscle or impaired post-prandial fatty acid 
metabolism, as discussed subsequently, and, last but not least, visceral obesity.
Visceral obesity
A tempting hypothesis that potentially explains the presence of insulin resistance only in 
patients with hypertriglyceridemia with or without hypercholesterolemia is the frequent presence 
of visceral obesity in hypertriglyceridemic subjects 238. The FCH phenotype can be inﬂuenced by 
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various environmental  factors such as diet and exercise, which can also alter plasma TG levels. 
Accordingly, the body mass index (BMI) of hypertriglyceridemic patients was signiﬁcantly higher 
than that of  the healthy subjects 16. The FCH subjects aﬀected, on the basis of hypertriglyceridemia 
or combined hyperlipidemia, had a signiﬁcantly higher BMI than controls 9, 16. Furthermore, in 
our 5-year follow-up cohort, an increase in BMI over 5 years was associated with an increase 
in the homeostasis model assessment-index (HOMA-index), indicating insulin resistance 
(correlation between delta BMI and delta HOMA of r = 0.47, p < 0.001, unpublished data). The 
interdependence of insulin resistance and visceral obesity in FCH was studied by Purnell et al. 
212. Insulin action was studied by the intravenous glucose tolerance test in 11 male FCH patients 
with combined hyperlipidemia, and visceral obesity was measured by computed tomography 
(CT) scan. In the FCH group insulin sensitivity was inversely associated with intra-abdominal 
fat and BMI but not with subcutaneous fat. Thus, insulin resistance was present in patients 
with FCH who were viscerally obese. The degree of insulin resistance was proportional with 
their degree of visceral obesity. In our FCH cohort the HOMA-index, as a measure of insulin 
sensitivity, was also related to BMI  (r = 0.43, p < 0.001, unpublished data). However, insulin 
resistance is also present in nonobese FCH patients, as measured by BMI 233. It is suggested 
that in nonobese subjects the amount of intra-abdominal fat, as measured by CT scan, can vary 
up to 10-fold. Which parameter is most sensitive to predict insulin resistance - BMI reﬂecting 
degree of adiposity, waist-hip ratio (WHR) reﬂecting abdominal obesity, or IAF measuring intra-
abdominal fat - remains to be determined. 
Can insulin resistance and/or visceral obesity explain the FCH lipid phenotype?
The main question is whether insulin resistance or visceral obesity, or both, can explain the FCH 
lipid phenotype. Purnell et al. examined the relationship between insulin resistance or visceral 
obesity and increased apoB levels in 11 FCH patients 212. For any level of insulin sensitivity or 
intra-abdominal fat, apoB levels remained higher in patients with FCH than in controls. In our 
FCH cohort, including all subjects with diﬀerent lipid phenotypes, the majority of the FCH 
patients had increased apoB levels and more sdLDL at any level of HOMA or BMI (unpublished 
data). Hence, obesity or insulin resistance or both do not fully account for the elevated levels of 
apoB or high prevalence of sdLDL in FCH. These results support the physiological concept of 
separate, but additive, genetic determinants in the etiology of the FCH lipid phenotype. We have 
reported previously that in our FCH families a major gene inﬂuences apoB levels and sdLDL 
18, 20, 23, but the gene has not been identiﬁed yet.
Central role of free fatty acids in the pathogenesis of FCH
As depicted in ﬁgure 1, a disturbed fatty acid metabolism may play a central role in FCH 93, 239, 
240. First, an increased ﬂow of FFA into the portal system has been postulated as a major contributor 
to dyslipidemia in FCH because it could lead to hepatic overproduction of VLDL particles 
(Figure 1, route 5) 95. Second, in vivo evidence has been provided suggesting a pivotal role of 
increased FFA in insulin resistance (Figure 1, route 6) 95, 211, 235. Thus, in FCH both overproduction 
of VLDLapoB and the presence of the syndrome of insulin resistance may be secondary to 
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impaired postprandial fatty acid metabolism. In vivo evidence of defective postprandial and 
postabsorptive FFA metabolism in FCH has been demonstrated 94. Oral fat loading tests during 
24 hours were performed in seven FCH patients with combined hyperlipidemia compared with 
seven nonrelated controls. Changes in FFA and ketone bodies, which represent hepatic products 
of FFA metabolism, were studied. The postprandial (0 – 8 hour) increase in ketone bodies was 
almost four times higher in FCH patients than in controls, suggesting an increased ﬂux of FFA 
to the liver, possibly because of inadequate FFA trapping in the adipocyte (Figure 1, routes 3 
and 4). In the postabsorptive period (8 – 24 hours), FFA and ketone bodies signiﬁcantly decreased 
in FCH patients in contrast to controls, in whom ketone bodies increased, which may represent 
diminished release of FFA from adipocytes by hormone-sensitive lipase (HSL) (Figure 1, 
route 3).
Why is the metabolism of FFA altered in FCH? It is hypothesized that the defect in fatty acid 
metabolism is likely to be localized in the adipocyte: adipose tissue is the body’s  major site for 
storage and mobilization of FFA. 
Disturbed adipose tissue metabolism in FCH
In ﬁgure 1, a simpliﬁed scheme of adipose tissue metabolism is included (routes 3, 4 and 8): 
The FFA liberated by the continuous hydrolysis of core TG by LPL in VLDL and chylomicrons 
are stored in adipocytes by intracellular reesteriﬁcation to TG, a process that is mediated by the 
action of a basic protein called acylation stimulatory protein (ASP) and modulated by insulin 241. 
In the adipocyte, reesteriﬁcation of FFA results in TG, which can be hydrolyzed again by HSL, 
releasing FFA from the fat cell. The most important lipolytic hormones are cathecholamines; 
insulin inhibits the action of HSL 242.  
Abnormal adipose tissue FFA metabolism has been identiﬁed  as a major contributor to the 
increased plasma FFA in FCH. FCH subjects have insulin-resistant adipose tissue lipid metabolism 
213. Potential defects in adipose metabolism include altered activity of ASP and/or HSL.
Acylation stimulatory protein
 The ASP pathway modulates the rate at which fatty acids are trapped by adipocytes and 
converted to TG. ASP also inﬂuences the rate at which fatty acids are released by adipocytes 
(Figure 1, routes 3 and 4) 241, 242. Resistance of adipocytes to the eﬀects of ASP and/or impaired 
ASP activity may contribute to reduced FFA uptake into adipocytes, which may result in an 
increased ﬂux of FFA to the liver and consequently in an increased hepatic VLDL synthesis, 
characteristic of FCH (Figure 1, route 5). For example, impaired ASP activity has been reported 
in hyperapobetalipoproteinemia, a condition apparently related to FCH 243, 244. However, no 
diﬀerence in plasma ASP levels has been found in FCH patients 245. It has been suggested that 
ASP  is only locally generated in adipose tissue and cannot be detected in peripheral plasma. 
Hormone-sensitive lipase 
The release of FFA from visceral adipocytes is mediated by the action of the enzyme HSL 
(Figure 1, route 3). This lipolytic eﬀect of HSL is inhibited by postprandial hyperinsulinemia, 
whereas cathecholamines are the most important lipolytic hormones by activating HSL.
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In FCH patients from Sweden, a marked resistance to the lipolytic eﬀect of cathecholamines 
in fat cells has been demonstrated, predominantly related to a defect in HSL 246. The maximum 
enzymatic activity of HSL was decreased by 40%.  However, in FCH patients from Finland, 
no diﬀerence in adipose tissue HSL activity was found 158. In addition, in the genetically 
homogenenous Finnish population the HSL gene was not a major locus responsible for the 
expression of the FCH phenotype 84, 182. The  discrepancy in HSL activity results between 
Swedish and Finnish FCH population is most likely explained by the  heterogeneity and genetic 
background of FCH, which may be diﬀerent in  the two populations. In addition, genetic defects 
may contribute to increased FFA concentrations in FCH.
Leptin
Leptin is a hormone primarily secreted by adipocytes. Serum leptin levels have been associated 
with obesity, insulin resistance and CVD, all features of FCH. Therefore, it is of great interest to 
determine whether increased leptin levels, as a marker of disturbed adipose tissue metabolism, 
contribute to the FCH phenotype and its associated increased risk for CVD. So far, two small 
studies have studied the relationship between leptin concentrations and FCH, with contrasting 
results. Jacobson et al. found a signiﬁcant diﬀerence of leptin concentration in a group of young 
females, and Haluzik et al. found no signiﬁcant diﬀerences in his group of males 247, 248. 
Furthermore, adipocytes release a great amount of other hormones/adipokines, including 
tumor necrosis factor 249 and adiponectin 250, which have been implicated in the pathogenesis of 
insulin resistance and visceral obesity. The role of these adipokines in the pathogenesis of FCH 
needs further investigation.   
The putative role of adipose tissue in the pathogenesis of FCH has been reviewed 96. Although 
more evidence-based arguments are needed, the current hypothesis suggests that a combined 
defect in lipid storage by reduced ASP and insulin action and in lipolysis by decreased HSL 
activity results in adipose tissue that is metabolically inactive. As a result, FFA are directly 
shunted to the liver which drives apoB synthesis and increases the  secretion of VLDL by the liver 
(Figure 1, routes 3, 4 and 5). Several studies have demonstrated diﬀerential expressed genes in 
adipose tissue from patients with FCH, supporting the potential role of adipose tissue in the 
pathogenesis of FCH 251, 252. 
  
Genetics of FCH
The genetics of FCH and risk of coronary heart disease have been extensively reviewed by 
Shoulders et al. 209. At present, the complex genetics in FCH are not fully understood. FCH was 
orginally described as a monogenic trait, but the inheritance of the FCH-associated phenotypes 
has been shown to be more complex. Segregation analyses have provided evidence for a major 
gene eﬀect on apoB levels 20, 22, 23, TG levels 21, the presence of  sdLDL 13, 18, 23 and insuline 
resistance 19.
Genome-wide linkage studies have indicated that several chromosomal regions harbor genes that 
contribute  to the lipid proﬁle of FCH.  In Finnish families with FCH, ﬁve loci on chromosome 
1q21, 2q31, 10p11.2, 10q11.2-10qter, and 21q21 were identiﬁed, whereas in Dutch families 
with FCH four loci, on chromosome 2p, 11p, 16q and 19q were found 28, 29, 31, 34. Two potential 
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new loci on 6q and 8p for FCH were identiﬁed in two large cohorts of  families with FCH from 
the United Kingdom 36. The locus on 1q21 has been conﬁrmed in German and Chinese FCH 
families and in families from the National Heart, Lung, and Blood Institute Family Heart Study 
26, 30.  A combined data analysis of Dutch and Finnish genome-wide scans for FCH identiﬁed 
three regions, on chromosomes 16q24.1, 2p25.1 and 9p23 with maximum lod scores of 3.6, 
2.2, and 2.1, respectively, which most likely harbor allelic variants for FCH. The 2p25.1 region 
was detected for the FCH trait wheres the other two regions were detected for the low HDL-
cholesterol trait 35. In addition, regions on 2p, 8q, 16q, and 20q have been detected for low 
HDL-cholesterol in the Finnish families with FCH and a region on 1p has been linked to apoB 
in Dutch families with FCH 38. The current genetic model suggests that FCH might result from 
the combination of a dominant major gene or genes in combination with several modiﬁer genes 
inﬂuencing plasma lipid levels. The identiﬁcation of such modiﬁer genes might help in reducing 
the problem of genetic heterogeneity of FCH. Several candidate genes have been evaluated in 
their contribution to the FCH phenotype. These include genes involved in lipid metabolism, 
such as lipoprotein lipase (LPL), hepatic lipase (HL), APOA1/C3/A4 and APOA5 32, 33, 55, 60, 62, 66, 67, 
73, 77, 79, 82, 253; in adipose tissue metabolism, such as TNF and HSL 84, 88, 182; and in insulin resistance 
and FFA metabolism (fatty acid binding protein (FABP), insulin receptor substrate gene and 
beta3-adrenergic receptor, PPAR-γ 83, 86, 87, 89. To summarize the results of these studies, LPL and 
APOA1/C3/A4 have  been most consistently associated as modiﬁer genes in FCH.
To unravel further the genetics of FCH, animal models have been developed. A locus (Hyplip1) 
in mutant mouse strain HcB-19 has been identiﬁed that was strongly linked to the FCH features 
in these mice 143. A few years later it was shown that these mice had decreased expression of 
the thioredoxin interacting protein (TXNIP). By sequencing, a spontaneous nonsense mutation 
(T97Z) in the TXNIP gene was identiﬁed 148. The TXNIP gene in mice is located on chromosome 
3F2.2, which is syntenic to chromosome 1q21 in humans, a region in which a major contributor 
of the FCH phenotype has been mapped in the Finnish, German and Chinese populations 
28, 30. However, in humans, we and others did not ﬁnd any sequence variants in the TXNIP 
gene in patients with FCH, and therefore the TXNIP gene is unlikely to be involved as a major 
contributor to the FCH phenotype 46, 149.  Pajukanta et al. showed that FCH is strongly linked 
and associated with the gene encoding upstream stimulatory factor 1 (USF1)46. This is a very 
intruiging ﬁnding as USF1 is also located at chromosome 1q21 and regulates the expression of 
several genes involved in glucose and lipid metabolism, making it a potentially good candidate 
for a major gene involved in the pathogenesis of FCH.
Chapter 6
Summary
Studies aimed at resolving the complex metabolic and genetic background of FCH have 
been going on for over 30 years. Several metabolic abnormalities and genetic backgrounds have 
been suggested, but the exact cause of these metabolic disturbances is unknown. To delineate 
further the pathogenesis of FCH, it is essential to simplify and standardize the diagnosis of FCH. 
In this respect, great progress has been made. The introduction of unequivocal standardized 
diagnostic criteria of FCH will improve genetic characterization and elucidation of the metabolic 
pathogenesis of FCH, including both the etiology of the increased pool of apoB100 containing 
TG-rich lipoproteins and that of the preponderance of small dense LDL particles.
Diagnostic criteria in relation to the pathogenesis of FCH
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Abstract
Background The traditional lipid and lipoprotein levels in patients with familial combined 
hyperlipidemia (FCH) are relatively mildly elevated and do not fully explain the increased 
risk of CVD. In other populations, high remnant-like particle cholesterol (RLPc) levels are an 
independent risk factor for CVD. In the present study, we investigated whether plasma RLPc 
concentrations are elevated in patients with FCH, and whether these RLPc levels contribute to 
the increased prevalence of CVD. Methods In this cross-sectional study, we studied RLPc levels 
in 37 FCH families comprising 582 subjects, of whom 134 subjects were diagnosed as FCH, 
according to the nomogram. Plasma RLPc concentrations were determined using an immune 
separation technique. Results For both men and women, the mean plasma RLPc level (mmol/l) 
was extremely elevated in FCH patients (0.59 (0.54 - 0.66) and 0.40 (0.37 - 0.43), respectively) 
compared to both normolipidemic relatives (0.27 (0.26 - 0.29) in male and 0.22 (0.21 - 0.23) 
in female, all p < 0.000) and spouses (0.27 (0.23 - 0.31) in male and 0.24 (0.21 - 0.27) in 
female, all p < 0.000). Plasma RLPc levels above the 90th  percentile were associated with an 
increased risk for FCH (OR 17.4 [10.8 - 27.8]) and the presence of CVD, independently of 
nonlipid cardiovascular risk factors (OR 2.18 [1.02 - 4.66]). Most importantly, RLPc levels 
predicted prevalent CVD independently of triglyceride levels (OR 2.35 [1.15 - 4.83]). however, 
RLPc did not provide additional information about prevalent CVD over and above non-HDL 
cholesterol levels. Conclusion Patients with FCH have two-fold elevated plasma RLPc levels, 
which contribute to the increased risk for CVD but not independently of non-HDL cholesterol 
levels.
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Introduction
Familial combined hyperlipidemia (FCH) is the most common genetic hyperlipidemia in 
humans and aﬀects up to 5% of the general population. It is characterized by multiple lipoprotein 
phenotypes and is strongly associated with premature cardiovascular disease (CVD). Of the 
survivors of a premature myocardial infarction, up to 20% are aﬀected with FCH 4, 10, 14. FCH is 
characterized by hypercholesterolemia, hypertriglyceridemia and elevated levels of apolipoprotein 
B (apoB). Other phenotypes of FCH are elevated levels of low-density lipoprotein cholesterol 
(LDLc), very low-density lipoprotein (VLDL), the presence of small dense LDL (sdLDL) and 
decreased levels of high-density lipoprotein cholesterol (HDLc) 116. In addition, FCH is associated 
with obesity and insulin resistance 9. 
The classical concept of the pathogenesis of CVD, based on lipid and lipoproteins, has implicated 
elevated cholesterol, particularly LDLc, as the central atherogenic lipoprotein class. However, 
accumulating data suggest that apoB containing lipoproteins other than LDL, particularly in the 
setting of mild to moderate hypertriglyceridemia, confer additional atherogenic risk beyond that 
due to LDLc levels alone. FCH is an example of a lipid disorder with only mildly elevated plasma 
LDLc levels but characteristic high apoB levels due to increased VLDL-cholesterol (VLDLc) and 
VLDL-triglyceride (VLDLtg) levels, insulin resistance and associated abnormalities. Recently, in 
a large observational study, the calculated plasma non-HDL cholesterol concentration (LDLc + 
VLDLc) was a stronger predictor of cardiovascular events than plasma cholesterol alone 254, 255. 
Improvement of CVD predictability upon inclusion of VLDLc emphasizes the proatherogenic role 
of triglyceride rich lipoproteins (TRL). Smaller, partially lipolyzed TRL remnants i.e. remnant-
like particles cholesterol (RLPc) are considered to be more atherogenic than larger newly secreted 
TRL since they can more readily penetrate the endothelial lining of the arterial wall 256. Several 
lines of evidence have implicated RLPc as playing an etiologic role in atherogenesis, as recently 
reviewed 257, 258. In fact, RLPc have been found to be present in atherosclerotic lesions 259.
Recently, an immuno-aﬃnity separation method was introduced for assaying cholesterol in 
RLPs as RLPc 198. Plasma concentration of RLPc have been shown to be higher in patients with 
CVD 260 and diabetes mellitus 261. In elderly patients, RLPc rather than LDLc was strongly 
associated with CVD 262. Increased RLPc levels are a signiﬁcant predictor of myocardial infaction 
in patients with vasospastic angina 263 and CVD 264 and have been shown to be strongly associated 
with angiographically veriﬁed progressions of focal coronary atherosclerosis 262. Recently, high 
plasma level of RLPc in patients with the metabolic syndrome was reported 265. In the metabolic 
syndrome, elevated levels of RLPc were a risk factor for CVD and endothelial dysfunction, a 
predictor of coronary events 266. 
The aim of the present study was to determine whether increased plasma RLPc levels contribute 
to the FCH phenotype and its increased risk of CVD.
 
Methods
Subjects
The study population existed of 37 families, comprising 644 subjects, of whom 158 subjects 
were diagnosed as FCH patients. The diagnosis of FCH was based on plasma levels of total 
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cholesterol, triglyceride and apoB using the nomogram, as reported recently 17. 
The normolipidemic relatives (n = 390) and spouses (n = 89), also included in this study 
population, served as two independent reference groups, because of the similar genetic 
background of the relatives with the FCH patients. Seven subjects had missing data concerning 
their diagnostic criteria, because of missing data for apoB levels. All subjects ﬁlled out a 
questionnaire about their previous medical history, especially cardiovascular status, medication 
use and smoking habits, as previously reported 16, 17. When the presence of CVD was suspected 
by the clinical investigator, further details and conﬁrmation of the diagnosis were sought from 
the participants general practitioner, plus, if considered necessary from any relevant hospital 
records. In our study population 56 subjects were identiﬁed with CVD, including 26 subjects 
with angina pectoris, 25 subjects with previous MI, 10 subjects with peripheral vascular disease, 
7 subjects with stroke and 23 subjects experienced vascular surgery. In total 45% (n = 25) of these 
subjects were diagnosed CVD based on the presence of 2 or more manifestations of CVD. 
After withdrawal of lipid-lowering medication for four weeks and an overnight fast, venous 
blood was drawn by venipuncture. Body mass index (BMI) was calculated as body weight 
(in kilograms) divided by the square of height (in meters). The maximum hip circumference 
(H) and waist circumference (W) at the umbilical level were measured in the late exhalation 
phase while standing. The waist/hip circumference (W/H) ratio was calculated. Systolic and 
diastolic blood pressure were assessed twice with  an automated blood pressure device (Dinamap; 
Critikon, Tampa, FL, USA) in the right arm in a sitting position after a 5-minute rest period, 
mean blood pressures were used for analysis. The ethical committee of the Radboud University 
Nijmegen Medical Centre approved the study protocol and the procedures followed were in 
accordance with institutional guidelines. All subjects gave informed consent.  
Laboratory measurements
VLDL was isolated from whole plasma by ultracentrifugation at density=1.006 g/ml for 
16 h at 36,000 rpm in a ﬁxed angle rotor (TFT 45.6 rotor, Kontron), in a Beckman L7-55 
ultracentrifuge. HDLc was determined by the polyethylene glycol 6000 method 267. LDLc 
was calculated by subtraction of VLDLc and HDLc from plasma total cholesterol. Cholesterol 
and triglycerides were determined by enzymatic, commercially available reagents (Boehringer-
Mannheim, Germany, catalog No. 237574 and Sera Pak, Miles, Belgium, catalog No. 6639, 
respectively).
Total plasma apoB concentrations were determined by immunonephelometry as recently 
described in detail elsewhere 119. LDL subfractions were separated by single spin density gradient 
ultracentrifugation 120. A continuous variable K represents the LDL subfraction proﬁle of each 
individual. A negative K value (K ≤ -0.1) reﬂected a more dense LDL subfraction proﬁle, and a 
positive K value (K > -0.1) reﬂected a more buoyant proﬁle 268.
Glucose concentrations were measured in duplicate using the oxidation method (Beckman®, 
Glucose Analyser2, Beckman Instruments Inc., Fullerton, CA 92634, USA). Plasma insulin 
concentrations were determined using a double antibody method with an interassay variability of 
10.3% 170. Insulin resistance was assessed by the Homeostasis model assessment (HOMA-index). 
The HOMA-index was calculated from the fasting concentrations of insulin and glucose using 
the following formula: HOMA-index = fasting serum insulin (µU/ml) x fasting plasma glucose 
(mmol/liter)/22.5 171.
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RLPc assay
The RLPc fraction was prepared using an immune separation technique described by Nakajima 
et al. 198. Plasma RLPc was measured by an  enzymatic assay included in the assay kit, using a 
Cobas Mira S auto-analyzer (ABX  Diagnostis, Montpellier, France). The interassay variability 
was 6%. Due to technical errors, plasma RLPc levels could be determined in 582 subjects, 
including 134 FCH patients, 387 normolipidemic relatives and 61 spouses.
Statistical analysis
Table 1     Characteristics of patients with familial combined hyperlipidemia, normolipidemic 
                 relatives and spouses.
FCH patients 
(n = 134)
NL relatives 
(n = 387)
Spouses 
(n = 61)
Gender (males ) * 68 (50.8%) 175 (45.2%) ¥ 36 (59.0%)
Age (years) 45.5 (16.2) ‡ § 37.7 (17.6) ¥ 53.5 (15.8)
Smoking * 34 (25.4%) 89 (23.0%) 10 (16.4%)
Cardiovascular disease * 24 (17.9%) ‡ § 21 (5.4%) 3 (4.9%)
Body mass index (kg/m2) 27.2 (4.4) § 24.1 (5.3) ¥ 26.4 (4.1)
Waist/hip ratio 0.88 (0.08) § 0.83 (0.09) ¥ 0.86 (0.08)
Systolic blood pressure (mmHg) 134.4 (17.3) § 128.1 (19.3) ¥ 134.8 (16.6)
Diastolic blood pressure (mmHg) 84.7 (10.5) § 80.3 (12.1) ¥ 83.1 (9.9)
Total cholesterol (mmol/L) 6.3 (1.0) ‡ § 4.9 (1.1) ¥ 5.2 (1.0)
Triglycerides (mmol/L) † 2.7 (1.6) ‡ § 1.1 (1.6) 1.1 (1.6)
VLDL-cholesterol (mmol/L) 1.09 (1.89) ‡ § 0.34 (1.95) 0.35 (1.87)
VLDL-triglycerides (mmol/L) 1.91 (1.91) ‡ § 0.62 (2.01) 0.63 (1.88)
HDL-cholesterol (mmol/L) 0.98 (0.33) ‡ § 1.22 (0.36) 1.30 (0.32)
LDL-cholesterol (mmol/L) 4.07 (0.98) ‡ § 3.22 (1.06) 3.41 (0.95)
Apolipoprotein B (mg/L) 1337 (229) ‡ § 960 (237) 1000 (227)
K-value -0.23 (0.23) ‡ § 0.04 (0.25) 0.05 (0.22)
non-HDL-cholesterol (mmol/L) 5.34 (1.02) ‡ § 3.63 (1.08) 3.85 (0.99)
Insulin (mU/L) † 12.8 (1.7) ‡ § 9.0 (1.1) 9.6 (1.7)
Glucose (mmol/L) † 5.2 (1.1) § 5.0 (1.1) ¥ 5.2 (1.1)
HOMA-index † 2.9 (1.8) ‡ § 2.0 (2.0) 2.3 (1.8)
Results are presented as means and SD except as indicated; *, presented are number (%); †, presented are 
geometric mean (geometric SD); FCH, familial combined hyperlipidemia; NL relatives, normolipidemic 
relatives; VLDL-cholesterol, very low-density lipoprotein cholesterol; VLDL-triglycerides, very low-density 
lipoprotein triglycerides; K-value, a value ≤ -0.1 prepresents the presence of small dense LDL; HDL-cholesterol, 
high-density lipoprotein cholesterol; LDL-cholesterol, low-density lipoprotein cholesterol; HOMA-index, 
homeostasis model assessment-index; ‡, p-value < 0.05, compared to normolipidemic relatives; §, p-value < 
0.05, compared to spouses; ¥, p-value < 0.05, compared to spouses. 
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The descriptive statistics expressed as means with standard deviation (SD), are represented 
separately for FCH patients, normolipidemic relatives and spouses. Variables like plasma RLPc 
concentration, triglyceride levels, non-HDL cholesterol levels and the HOMA-index, with a 
skewed distribution were logarithmically transformed for analysis. Diﬀerences in characteristics 
between subjects with FCH, spouses and normolipidemic relatives were tested by generalized 
estimating equations (GEE) because of possible correlated values within families. Also odds 
ratios (OR) with corresponding conﬁdence interval as an estimate of risk for FCH or CVD were 
calculated using GEE. Correlations between plasma RLPc and variables were analyzed using 
Pearson correlation coeﬃcients. Multiple linear regression test was used to select the variables 
that contributed independently to plasma RLPc. Probability values < 0.05 were considered 
statistically signiﬁcant. All analyses were computed using the STATA 8.0 software.
Results
Subject characteristics
Descriptive statistics for anthropometric measurements and biochemical variables in patients 
with FCH, normolipidemic relatives  and spouses are presented in table 1. The mean age of the 
group of subjects with FCH was signiﬁcantly higher compared to the normolipidemic relatives 
and signiﬁcantly lower compared to the spouses. As expected, the group of patients with FCH 
had a higher prevalence of CVD compared to both normolipidemic relatives and spouses. The 
mean BMI and WHR of FCH patients was signiﬁcantly higher compared to the normolipidemic 
relatives. Systolic and diastolic blood pressure were signiﬁcantly higher in patients with FCH 
compared to their normolipidemic relatives but did not diﬀer from the spouses. Patients with 
FCH were more insulin resistant than the normolipidemic relatives and spouses as assessed by 
the elevated HOMA-index. By deﬁnition, FCH patients are characterized by increased plasma 
total cholesterol, triglyceride and apoB levels compared to normolipidemic relatives and spouses. 
Furthermore, FCH patients had a more atherogenic lipid and lipoprotein proﬁle as reﬂected 
by signiﬁcantly lower plasma HDLc levels, higher plasma LDLc and non-HDL cholesterol 
levels and the presence of small, dense LDL (sdLDL), as reﬂected by a signiﬁcantly lower 
K-value. In addition, signiﬁcantly increased levels of VLDLc and VLDLtg were present in FCH 
compared to both normolipidemic relatives and spouses. The diﬀerences between the spouses 
and normolipidemic relatives are indicated in table 1. 
Remnant-Like Lipoprotein Cholesterol concentration and FCH
The mean plasma RLPc concentration in the FCH patients was signiﬁcantly higher compared 
to both the normolipidemic relatives and spouses, indicating a two-fold elevation of RLPc in 
FCH patients (Table 2). The mean RLPc levels in the normolipidemic relatives did not diﬀer 
from the spouses. Plasma RLPc levels diﬀered between males and females, i.e. men had higher 
plasma RLPc levels than women, which did only not reach statistical signiﬁcance in the group of 
spouses. After adjustment for gender and age, the mean diﬀerence in plasma RLPc concentration 
between FCH patients versus spouses and normolipidemic relatives remained signiﬁcant 
(0.46 (SD 0.38) versus 0.25 (SD 0.45) and 0.23 (SD 0.36) respectively)). 
As the plasma RLPc concentration in the normolipidemic relatives and spouses did not diﬀer 
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signiﬁcantly, we analyzed the normolipidemic relatives and spouses together deﬁned as the non-
FCH control group.
Among the patients with FCH, 91 (68%) had fasting plasma RLPc levels above the 90th 
percentile as determined in the non-FCH control group without CVD standardized for gender 
(cut-oﬀ point of 0.36 mmol/l) (Table 2). 
Characteristics of subjects with plasma RLPc levels above the 90th percentile
In the non-FCH control group, plasma RLPc levels above the 90th percentile were associated 
with older age, an increased BMI and WHR and elevated blood pressure (Table 3).  Furthermore, 
control subjects with high plasma RLPc levels above the 90th percentile showed a more atherogenic 
lipid and lipoprotein proﬁle characterized by higher total cholesterol and triglyceride levels, lower 
HDL cholesterol levels, higher apoB levels and non-HDL cholesterol levels and more small 
dense LDL i.e. lower K-values (Table 3). Although glucose levels were signiﬁcantly higher in the 
control subjects with high RLPc levels above the 90th percentile, no diﬀerence in HOMA-index 
was found compared to the group with RLPc levels below 90th percentile. Similar associations 
were found in the FCH group (data not shown). 
Plasma RLPc levels above the 90th percentile were associated with an increased risk for FCH 
(OR 19.4 [10.9 - 35.4]). Even after correction for age, gender, CVD, BMI, WHR, blood pressure 
and HOMA, increased plasma RLPc levels above the 90th percentile remained associated with an 
increased risk for FCH (OR 17.4 [10.8 - 27.8]). 
Plasma RLPc levels in relation to lipid, lipoprotein and insulin resistance parameters 
Plasma RLPc level showed signiﬁcant univariate correlations in the control group with age, 
BMI, WHR, both systolic and diastolic blood pressure, total cholesterol, triglycerides, VLDLc, 
VLDLtg, HDLc, non-HDLc, LDLc, apoB, K-value, insulin, glucose and the HOMA-index 
(Table 4). 
Similar correlation coeﬃcients for plasma RLPc with all variables were found among the FCH 
patients, although not reaching statistical signiﬁcance for systolic blood pressure, apolipoprotein 
B and parameters of insulin resistance including HOMA and insulin levels. In FCH patients, an 
increase in RLPc levels was associated with lower LDLc levels whereas in the control group an 
Table 2     Plasma RLPc concentration in patients with familial combined hyperlipidemia 
                 compared to normolipidemic relatives and spouses.
FCH patients 
(n = 134)
NL relatives 
(n = 387)
Spouses 
(n = 61)
Male 0.59 (0.54 - 0.66) † ‡ 0.27 (0.26 - 0.29) 0.27 (0.23 - 0.31)
Female 0.40 (0.37 - 0.43) † ‡ 0.22 (0.21 - 0.23) 0.24 (0.21 - 0.27)
RLPc > 90th percentile * 91 (67.9%) † ‡ 40 (10.3%) 8 (13.1%)
Values are means with 95% conﬁdence intervals except as indicated. a presented are number (%); FCH, 
familial combined hyperlipidemia; NL relatives, normolipidemic relatives; *, 90th percentile of RLPc (0.36 
mmol/L) is calculated from controls without CVD and standardized for gender; CVD, cardiovascular 
disease; †, p-value < 0.05, compared to normolipidemic relatives; †, p-value < 0.05, compared to spouses.
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increase in RLPc levels was associated with higher LDLc levels.
Multiple linear regression analyses in the non-FCH control group and in the group of FCH 
patients showed that the variation in plasma RLPc concentration could be enlightened for 
approximately 66% and 77%, respectively, by the variables gender and lipid and lipoprotein 
levels including triglycerides, VLDLc, non-HDLc, LDLc and small, dense LDL. 
In both controls and FCH patients, gender, triglyceride levels and non-HDLc levels were the 
main contributors in the explanation of the variation in RLPc levels (62% in the non-FCH 
control group and 54% in the FCH-group). 
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Values are means with 95% conﬁdence intervals except as indicated; *, presented are number (%); FCH, 
familial combined hyperlipidemia; 90th percentile of RLPc (0.36 mmol/L) is calculated from controls without 
CVD and standardized for gender; VLDL-cholesterol, very low-density lipoprotein cholesterol; VLDL-
triglycerides, very low-density lipoprotein triglycerides; K-value, a value ≤ -0.1 prepresents the presence 
of small dense LDL; HDL-cholesterol, high-density lipoprotein cholesterol; LDL-cholesterol, low-density 
lipoprotein cholesterol; HOMA-index, homeostasis model assessment-index; †, p-value < 0.05, compared to 
subjects with RLPc ≥ 90th percentile.
Table 3     Characteristics of non-FCH control subjects stratiﬁed by the 90th percentile of plasma
                 RLPc concentration.
Non-FCH control subjects (n = 448)
RLPc < 90th (n = 400) RLPc ≥ 90th (n = 48)
Mean (95% CI) Mean (95% CI)
Age (years) 38.8 (36.8 - 40.9) † 47.4 (42.6 - 52.1)
Cardiovascular disease * 19 (4.8%) 5 (10.4%)
Body mass index (kg/m2) 24.1 (23.7 - 24.6) † 26.0 (24.9 - 27.1)
Waist/hip ratio 0.82 (0.82 - 0.83) † 0.89 (0.86 - 0.91)
Systolic blood pressure (mmHg) 128.2 (126.2 - 130.2 ) † 134.1 (132.1 - 136.1)
Diastolic blood pressure (mmHg) 80.0 (78.8 - 81.3) † 84.7 (81.9 - 87.5)
Total cholesterol (mmol/L) 4.84 (4.74 - 4.95) † 5.30 (5.03 - 5.56)
Triglycerides (mmol/L) 0.99 (0.94 - 1.03) † 1.94 (1.73 - 2.18)
VLDL-cholesterol (mmol/L) 0.31 (0.29 - 0.34) † 0.77 (0.65 - 0.91)
VLDL-triglycerides (mmol/L) 0.56 (0.52 - 0.60) † 1.37 (1.16 - 1.63)
HDL-cholesterol (mmol/L) 1.26 (1.23 - 1.30) † 0.97 (0.88 - 1.06)
LDL-cholesterol (mmol/L) 3.22 (3.13 - 3.31) 3.46 (3.21 - 3.70)
Apolipoprotein B (mg/L) 947 (926 - 968) † 1117 (1058 - 1176)
K-value 0.07 (0.05 - 0.10) † -0.16 (-0.21 - -0.10)
non-HDL-cholesterol (mmol/L) 3.58 (3.48 - 3.68) † 4.32 (4.06 - 4.59)
Insulin (mU/L) 8.98 (8.39 - 9.60) 10.22 (8.62 - 12.12)
Glucose (mmol/L) 4.95 (4.89 - 5.01) † 5.34 (5.18 - 5.50)
HOMA-index 1.97 (1.83 - 2.12) 2.39 (1.99 - 2.87)
RLPc (mmol/L) 0.23 (0.22 - 0.24) † 0.45 (0.42 - 0.48)
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Plasma RLPc levels and CVD
In univariate analysis, a  plasma RLPc concentration above the standardized 90th 
percentile was associated with an increased risk for CVD in the non-FCH control group 
(OR = 2.38 [0.87 – 6.55]) and in FCH subjects (OR = 2.14 [0.75-6.12], reaching statistical 
signiﬁcance when the two groups were combined (OR 3.55 [1.97 - 6.39] (Table 5,
model I). When putting this in a model together with nonlipid risk factors including age, gender, 
smoking habits, HOMA, BMI, WHR and blood pressure, plasma RLPc concentration stayed an 
independent contributor to the prediction of CVD with an OR of 2.18 [1.02 - 4.66] for the total 
group. Both plasma levels of triglycerides and non-HDLc were also predictors of prevalent CVD 
in univariate analysis in both FCH and the control group as indicated in table 5 (model II for 
triglycerides and model III for non-HDLc). The independence of RLPc as a predictor of CVD 
Table 4     Correlation of plasma RLPc level with anthropometric and biochemical 
                 parameters in patients with familial combined hyperlipidemia (FCH) and
                 in the non-FCH control group.
FCH patients 
(n = 134)
Non-FCH controls 
(n = 448)
Age (years) 0.19 * 0.33 †
Cardiovascular disease 0.07  0.20 †
Body mass index (kg/m2) 0.20 * 0.35 †
Waist/hip ratio 0.34 * 0.40 †
Systolic blood pressure (mmHg) 0.13 0.28 †
Diastolic blood pressure (mmHg) 0.27 * 0.30 †
Total cholesterol (mmol/L) 0.20 * 0.45 †
Triglycerides (mmol/L) 0.76 † 0.67 †
VLDL-cholesterol (mmol/L) 0.78 † 0.68 †
VLDL-trglycerides (mmol/L) 0.73 † 0.65 †
HDL-cholesterol (mmol/L) 0.37 † -0.39 †
LDL-cholesterol (mmol/L) -0.25 * 0.40 †
Apolipoprotein B (mg/L) 0.12 0.55 †
K-value -0.46 † -0.37 †
Non-HDL-cholesterol (mmol/L) 0.29 † 0.57 †
Insulin (mU/L) 0.05 0.19 †
Glucose (mmol/L) 0.33 † 0.33 †
HOMA-index 0.13 0.23 †
Values are pearson correlation coeﬃcients; VLDL-cholesterol, very low-density lipoprotein cholesterol; VLDL-
triglycerides, very low-density lipoprotein triglycerides; K-value, a value ≤ -0.1 prepresents the presence 
of small dense LDL; HDL-cholesterol, high-density lipoprotein cholesterol; LDL-cholesterol, low-density 
lipoprotein cholesterol; HOMA-index, homeostasis model assessment-index; *, p-value < 0.05; †, p-value 
< 0.001.
High Remnant-like particles in patients with FCH
when including other lipid variables strongly correlated with RLPc, was explored in model A 
and B, as presentend in table 5. When putting triglyceride levels and RLPc levels together in one 
model to predict prevalent CVD (Model A, Table 5), the relative predictive power of RLPc levels 
for CVD was higher in the FCH group whereas triglycerides contribute more to the prediction 
of CVD in the control group.  For the total group, both plasma RLPc and triglycerides levels 
contributed independently to the risk of CVD. Adding non-HDLc to the model (model B, table 
5) showed that non-HDLc had the best predictive power for CVD in both the FCH and control 
group. 
Discussion
In this study we show that patients with FCH have two-fold elevated plasma RLPc levels 
compared to their normolipidemic relatives and spouses. In addition, high RLPc levels are 
associated with an 18-times increased risk for FCH. Therefore, assessment of plasma levels of 
RLPc completes the atherogenic lipid and lipoprotein proﬁle in FCH and may thus constitute 
an additional marker for the identiﬁcation of patients with FCH. 
Previous studies have demonstrated that lipoprotein metabolism in FCH patients is disturbed, 
leading to remnant accumulation in the circulation, using diﬀerent methodologies to isolate 
lipoprotein remnants 93, 269. Only one other study has reported plasma RLPc levels in FCH 269. 
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Table 5     Odds ratios for cardiovascular disease associated with elevated plasma levels of remnant-
                 like particles cholesterol (RLPc), triglycerides and non-HDL cholesterol above the 90th 
                 percentile in patients with familial combined hyperlipidemia and non-FCH control 
                 subjects.
FCH patients Non-FCH controls Total group
Univariate analyses for
I     RLPc 2.14 [0.75 - 6.12] 2.38 [0.87 - 6.55] 3.55 [1.97 - 6.39]
II    TG 1.44 [0.59 - 3.47] 6.27 [1.64 - 24.0] 4.63 [2.64 - 8.12]
III  Non-HDLc 3.14 [1.10 - 8.99] 3.59 [1.42 - 9.08] 5.66 [3.18 - 10.1]
Multivariate analyses model A
RLPc 2.20 [0.74 - 6.50] 1.76 [0.58 - 5.31] 2.35 [1.15 - 4.83]
TG 0.90 [0.33 - 2.44] 4.51 [1.07 - 19.05] 2.14 [1.02 - 4.49]
Multivariate analyses model B
RLPc 1.61 [0.50 - 5.22] 1.50 [0.49 - 4.62] 1.50 [0.69 - 3.30]
TG 1.20 [0.42 - 3.47] 6.37 [1.45 - 28.04] 1.85 [0.86 - 3.99]
Non-HDLc 2.47 [0.75 - 8.13] 4.14 [1.58 - 10.86] 3.15 [1.61 - 6.19]
Values are presented as odds ratios with 95% conﬁdence intervals (OR [95% CI]); FCH patients, patients 
with familial combined hyperlipidemia, including 24 patients with cardiovascular disease (CVD) and 110 
patients without CVD; Non-FCH controls, including 24 subjects with CVD and 424 subjects without 
CVD; RLPc, remnant-like particles cholesterol; TG, triglyceride levels; non-HDL-cholesterol, low-density 
lipoprotein cholesterol and very-low density lipoprotein cholesterol levels.
In this small study, 12 male FCH patients had a sixfold increased plasma RLPc concentration
(1.54 ± 1.84 mmol/l versus 0.24 ± 0.05 (n = 14) in controls) whereas the plasma RLPc 
concentration was only two-fold higer in female FCH patients (n = 11) as compared to controls 
(n = 13) (0.44 ± 0.42 versus 0.17 ± 0.04 mmol/l) 269. This is most likely the result of higher 
triglyceride levels compared to our population (TG 5.4 ± 5.2 mmol/l  versus TG 2.79 ± 1.6 
mmol/l). 
We show that men have higher RLPc levels compared to women in both FCH patients 
and controls. In addition, plasma RLPc levels increased with age in both males and females, 
conﬁrming earlier reports in other populations 261, 270.
In our non-FCH control group, elevated plasma RLPc levels are associated with obesity, 
insulin resistance and an atherogenic lipid and lipoprotein proﬁle characterized by elevated levels 
of plasma total cholesterol, triglycerides, apolipoprotein B, decreased levels of plasma HDLc, and 
more sdLDL. Similar associations have been reported previously 271, 272. We show that the major 
determinant of fasting RLPc were gender, plasma triglyceride level and non-HDL-cholesterol 
accounting for 72%  of the variance in fasting RLPc levels. 
Strikingly, in the FCH group no signiﬁcant correlation of RLPc levels with apoB levels and 
even a negative correlation with LDL-cholesterol was observed. This is most likely explained by 
the fact that RLPs are highly heterogenous in size and composition; in normolipidemic subjects 
RLPs are enriched in cholesterol and its plasma concentration was correlated with plasma LDL 
cholesterol concentration. However, when plasma triglyceride levels increase, as in FCH, then 
the elution proﬁle of RLP is shifted toward a larger-size particle, similar to that of a larger VLDL 
subfraction (VLDL1). So, the TG-rich component of RLPc is responsible for the increased RLPc 
concentration associated with hypertriglyceridemia as plasma triglycerides are then the major 
determinant of the size and composition of RLPs. Indeed the major determinant of plasma RLPc 
levels among FCH patients were plasma triglyceride levels.
The importance of plasma TG levels as an independent risk factor for CVD was recognized 
after the publication of a meta analysis by Austin et al. showing that plasma triglyceride levels 
predict relative risk for CVD mortality in relatives of FCH patients 8. Epidemiological data from 
Framingham study already showed that plasma TG is an important risk indicator of CVD in 
women 192. Additional evidence was obtained from by Yarnell et al. in a ten year follow up study 
273 and conﬁrmed in several other studies 274. However, triglycerides are not signiﬁcantly and 
independently associated with CVD in most prospective studies 275. The diﬃculty with using 
plasma or serum triglyceride measurements to assess CVD risk may stem from the variability 
within the subspecies of TRL particles, as well as the inverse association with HDL cholesterol. 
It is not possible to distinguish TRL that are atherogenic from those that are non-atherogenic 
simply by measuring plasma triglyceride levels. Therefore, in the present study we use a speciﬁc 
assay to measure atherogenic RLP as plasma RLPc levels have been associated with CVD and its 
risk factors. First, we show that increased plasma RLPc levels are associated with an increased risk 
for CVD in non-FCH subjects and in FCH patients, independently of nonlipid cardiovascular 
risk factors including age, gender, smoking, obesity, insulin resistance and blood pressure. Most 
importantly, we show that in the total group, RLPc levels conferred additional risk of CVD even 
when plasma TG levels are taken into account; subjects with RLPc levels above the 90th percentile 
have a 2.4 times increased risk of prevalent CVD, independent of plasma TG levels. Indeed, 
several clinical studies demonstrated that plasma RLPc oﬀered independent assessment for CVD 
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risk in addition to TG 276, 277. Furthermore we show that in patients with FCH the plasma RLPc 
level is a better predictor of CVD than plasma triglycerides; these results support the concept of 
identifying more atherogenic remnant particles by measuring RLPc instead of TG levels. However, 
in the control group, the plasma triglyceride level is a better predictor for prevalent CVD than 
the RLPc level. This could be related to the particle heterogeneity in RLP which could aﬀect 
the ability of RLPc concentration to predict atherosclerotic risk. Therefore, in controls with low 
plasma TG levels, plasma RLPc may not have the same clinical signiﬁcance as they do in patients 
with FCH with hypertriglyceridemia. Indeed, recently, in the Honolulu Heart Study, including 
normotriglyceridemic healthy men, RLPc levels did not provide additional information about 
risk of CVD over and above TG levels, whereas the association between RLPc and CVD was 
signiﬁcant for the group with elevated TG levels 278. Further studies should examine whether 
diﬀerence in RLP composition may reﬂect a diﬀerent risk on CVD in diﬀerent populations. 
So, RLPc levels predict CVD independent of plasma TG level, however, in our population the 
addition of non-HDL cholesterol into the model resulted in the loss of RLPc as an independent 
predictor of CVD. It remains, however, to be studied in large epidemiological studies to what 
extend the measurement of plasma RLPc provides additional knowledge for the treatment goals 
of the individual patients.
In summary, patients with FCH have two-fold elevated plasma RLPc levels. RLPc levels predict 
prevalent CVD independent of nonlipid cardiovascular risk factors. Most importantly, RLPc 
levels predicted prevalent CVD independently of plasma triglyceride levels, however, RLPc levels 
did not provide additional information about risk of CVD over and above non-HDL cholesterol 
levels in FCH.
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Elevated leptin levels in subjects with familial 
combined hyperlipidemia are associated with the 
increased risk for CVD
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Abstract
Background Familial Combined Hyperlipidemia (FCH) is characterized by hypercholesterolemia 
and/or hypertriglyceridemia and is associated with premature cardiovascular disease (CVD). Other 
features of FCH are obesity and insulin resistance. Serum leptin levels have been associated with 
obesity, insulin resistance and CVD. The aim of this study was to determine whether increased 
leptin levels contribute to the FCH phenotype and its increased risk for CVD. Methods The study 
population comprised 644 subjects, including 158 FCH patients. Leptin levels were determined, 
using a commercially available ELISA. Results For both males and females, the mean leptin 
level (ng/ml) was higher in FCH patients compared to normolipidemic relatives and spouses. 
However, after standardization for BMI and insulin resistance, these diﬀerences disappeared. 
The 90th percentile of the leptin level, standardized for BMI, insulin resistance and gender, was 
associated with an increased risk for CVD in FCH patients (odds ratio = 2.9, 95 % CI = 1.1 - 8.0) 
and in non-FCH subjects (odds ratio = 3.4, 95 % CI = 1.3 - 9.0). The overall increased risk for 
CVD, associated with a leptin level > 90th percentile, was 3.3 (95 % CI = 1.7 - 6.4). Conclusion 
We conclude that in patients with FCH, leptin levels are increased in proportion to their higher 
BMI and the presence of insulin resistance. These increased leptin levels are associated with an 
increased risk for CVD both in FCH patients and non-FCH subjects, independent of BMI, 
insulin resistance and gender.
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Introduction
Familial combined hyperlipidemia (FCH) is the most common genetic hyperlipidemia in 
humans and aﬀects 1 - 3 % of the general population. It is characterized by multiple lipoprotein 
phenotypes and is strongly associated with premature cardiovascular disease (CVD). Of the 
survivors of a premature myocardial infarction, up to 20 % are aﬀected with FCH 4. FCH is 
characterized by hypercholesterolemia and/or hypertriglyceridemia. Other phenotypes of FCH 
are elevated levels of apolipoprotein B (apoB) and low-density lipoprotein cholesterol (LDLc), 
decreased levels of high-density lipoprotein cholesterol (HDLc) and the presence of small dense 
LDL (sdLDL). In addition, FCH is associated with obesity and insulin resistance 9.
Obesity results in an increase in number and size of adipocytes. These adipocytes secrete leptin, 
a hormone, which is increased in obese subjects 279. Leptin is involved in the regulation of the 
energy expenditure and appetite via hypothalamic receptors 104. An increase of leptin level will 
lead to more energy expenditure and less appetite in normal persons via the hypothalamus. 
Obese persons have increased levels of leptin, but these high levels appear to fail to inﬂuence 
energy intake or expenditure to restore fat mass to normal. It is, therefore, believed that obesity 
is a state of leptin resistance. 
Leptin has direct eﬀects on insulin secretion by inhibiting insulin gene transcription 280 and 
insulin secretion 281. On the other hand, insulin increases leptin production indirectly via its 
eﬀects to increase glucose utilization and oxidative glucose metabolism in adipocytes at the 
transcriptional level 281, 282. Thus, high leptin levels are associated with insulin resistance 105.
Both obesity and insulin resistance are characteristics of FCH, and therefore, it is likely that 
leptin is elevated in persons with FCH. Furthermore, we hypothesize that leptin could be a 
marker for a disturbed adipocyte metabolism, one of the mechanisms proposed to play a role in 
the pathophysiology of FCH 9.
So far, only two small studies have studied the relationship between leptin concentrations and 
FCH, with conﬂicting results 247, 248. Jacobson et al. found a signiﬁcantly elevated leptin levels 
in young females with FCH 248, while Haluzik et al. observed no diﬀerences in a group of males 
with and without FCH 247. 
The aim of this study was to investigate whether leptin levels in our large cohort of well-deﬁned 
male and female patients with FCH were elevated, independent of their BMI, indicating that 
adipose tissue metabolism is disturbed in FCH. The second objective was to investigate whether 
leptin levels contribute to the increased risk for CVD in FCH. 
Methods
Study population
The study population existed of 37 families, comprising 644 subjects, of whom 158 subjects 
were diagnosed as FCH patients 16, 17. The normolipidemic relatives (n = 389) and unaﬀected 
spouses of both FCH patients and normolipidemic relatives (n = 90), also included in this study 
population, served as two independent reference groups. We separated the normolipidemic 
relatives and the spouses into two diﬀerent reference groups, because of the similar genetic 
background of the relatives with the FCH patients. The spouses were included in this study 
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as a separate control group, because they share environment, but are not genetically related to 
FCH. Seven subjects were not diagnosed because of missing values. For HOMA-index data were 
available for 143 FCH patients, 346 normolipidemic relatives and 87 spouses, due to technical 
errors in the insulin measurement. Information about the presence of CVD was gathered by 
personal interview and physical examination performed by the clinical investigator. CVD was 
deﬁned by angina pectoris (AP), myocardial infarction (MI), stroke, peripheral vascular disease 
or vascular surgery. When the presence of CVD was suspected by the clinical investigator, further 
details and conﬁrmation of the diagnosis were sought from the participants general practitioner, 
plus, if considered necessary from any relevant hospital records. In our study population 56 
subjects were identiﬁed with CVD, including 26 subjects with AP, 25 subjects with previous MI, 
10 subjects with peripheral vascular disease, 7 subjects with stroke and 23 subjects experienced 
vascular surgery. In total, 45 % (n = 25) of these subjects were diagnosed CVD based on the 
presence of two or more manifestations of CVD. Only 21 % of the subjects had only AP, so 79 
% of our subjects had well documented CVD. After withdrawal of lipid-lowering medication for 
4 weeks and an overnight fast, blood was drawn by venipuncture. The ethical committee of the 
Radboud University Nijmegen Medical Centre approved the study protocol and the procedures 
followed were in accordance with institutional guidelines. All subjects gave informed consent. 
The diagnosis FCH was based on absolute apoB levels in combination with triglyceride and 
total cholesterol levels adjusted for age and gender, using a nomogram, as recently described 17. 
Body mass index (BMI) was calculated as body weight (in kilograms) divided by the square of 
height (in meters). 
Table 1     Characteristics of patients with familial combined hyperlipidemia, normolipidemic 
                 relatives and spouses
FCH patients
(n = 158)
NL relatives
(n = 389)
Spouses
(n = 90)
Gender (males) * 76 (48.1%) 175 (45.0%) 44 (48.9%)
Age (years) 47.1 (16.3) ‡ § 37.8 (17.9) ¥ 52.3 (15.9)
Cardiovascular disease * 32 (20.3%) ‡ § 21 (5.4%) 3 93.3%)
Body mass index (kg/m2) 27.3 (4.4) ‡ 24.2 (5.2 ) ¥ 26.3 (4.2)
Total cholesterol (mmol/L) 6.5 (1.1) ‡ § 4.9 (1.2) ¥ 5.2 (1.0)
Triglycerides (mmol/L) † 2.8 (1.0) ‡ § 1.1 (1.0) 1.1 (1.0)
Apolipoprotein B (mg/L) 1371 (236) ‡ § 961 (249) 1001 (233)
HOMA-index † 2.9 (1.1) ‡ § 2.0 (1.0) 2.2 (1.1)
Values are presented as mean (SD); *, presented are number (%); †, presented are geometric mean 
(geometric SD); FCH, familial combined hyperlipidemia; NL relatives, normolipidemic relatives; HOMA-
index, homeostasis model assessment-index (missing values for HOMA-index in 15 FCH patients, 43 
normolipidemic relatives and 3 spouses; ‡, p-value based on GEE < 0.05, compared to normolipidemic 
relatives; †, p-value based on GEE < 0.05, compared to spouses; ¥, p-value based on GEE < 0.05, compared 
to spouses.
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Biochemical analyses
Plasma total cholesterol (TC) and total triglycerides (TG) were determined by enzymatic, 
commercially available reagents (Boehringer-Mannheim, Germany, catalog No. 237574 and Sera 
Pak, Miles, Belgium, catalog No. 6639, respectively). Total plasma apoB concentrations were 
determined by immunonephelometry, as recently described in detail 119. Glucose concentrations 
were measured in duplicate using the oxidation method (Beckman®, Glucose Analyser2, Beckman 
Instruments Inc., Fullerton, CA 92634, USA). Plasma insulin was assessed by radioimmunoassay 
(RIA) using 125I-labeled human insulin and anti-human insulin antiserum raised in guinea 
pig. Bound and free tracer were separated by sheep anti-guinea pig antiserum; human insulin 
(Novo Biolabs, Copenhagen, Denmark) was used for standards. The inter-assay coeﬃcient of 
variation for the insulin measurement was 10.3% at a level of 20.7 mU/l 170. Insulin resistance 
was assessed by the Homeostasis model assessment (HOMA). The HOMA-index was calculated 
from the fasting concentrations of insulin and glucose using the following formula: HOMA-
index = fasting serum insulin (µU/ml) x fasting plasma glucose (mmol/L)/22.5 171.
Serum leptin levels
For measuring leptin levels, serum samples were assayed in duplicate using enzyme-linked 
immunosorbent assay (R&D Systems, Minneapolis: Elisa Development System; Duoset® Human 
Leptin, Catalog No. DY398). This assay measured the total amount of leptin present in a sample, 
independent of the presence of leptin-binding proteins. Inter- and intra-assay coeﬃcients of 
variance were 6.4 and 3.5%, respectively. The detection limit was 0.1 ng/ml.
Statistical analyses
As it is well documented that, at a given BMI, females have a higher leptin level than males 283, 
284, all analyses were stratiﬁed or standardized for gender. Variables with a skewed distribution, 
including leptin levels, triglyceride levels and the HOMA-index, were logarithmically transformed 
before analysis.
Descriptive statistics, presented separately for FCH patients, normolipidemic relatives and 
spouses, are expressed as mean with standard deviation (SD), or geomatric mean with geometric 
SD for logarithmically transformed variables. Parametric Pearson correlation was used for 
correlation analysis. Diﬀerences in characteristics and leptin levels between subjects with FCH, 
normolipidemic relatives and spouses were tested by means of generalized estimating equations 
(GEE) because of possible correlated values within families. In the models used for the GEE 
analyses, with leptin levels and the other descriptive statistics as the dependent and FCH diagnosis 
as the independent variable, the link function ‘canonical’ was used and an equal-correlation 
population-averaged model was used as the working correlation matrix.  Also the odds ratios 
(OR), as an estimator of relative risk (RR), were calculated with logistic GEE. Within the model 
used for logistic GEE analysis, leptin represented the independent and CVD the dependent 
variable. To standardize the leptin level for BMI, HOMA-index and gender, for calculation of 
the 90th percentile, a GEE multiple linear regression model, with leptin as the dependent and 
BMI, HOMA-index and gender as the independent variable was used to calculate the predicted 
leptin level for each person. Subsequently, the predicted leptin level was substracted from the 
measured leptin level, to which the overall mean value of leptin levels was added, resulting in the 
value of the leptin levels standardized for these variables. The 90th percentile of the leptin levels, 
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standardized for gender, BMI and HOMA-index, is based on the group of non-FCH subjects 
without CVD, including spouses. Diﬀerences were considered statistically signiﬁcant at p-values 
< 0.05. All analyses were computed using the STATA 8.0 software. 
Results
Subject characteristics 
Descriptive statistics of anthropometric and metabolic characteristics of the study population 
are presented in table 1. FCH patients are older than normolipidemic relatives, but younger 
than the spouses. Evident is the higher prevalence of CVD in patients with FCH, compared to 
normolipidemic relatives and the spouses. The mean BMI of patients with FCH is signiﬁcantly 
higher compared to normolipidemic relatives. Compared to normolipidemic relatives and 
spouses, FCH patients have signiﬁcant higher levels of total cholesterol, triglycerides and apoB 
and are more insulin resistant, as reﬂected by a higher HOMA-index. Normolipidemic relatives 
are younger, have a lower BMI and have lower total cholesterol levels compared to the spouses 
(Table 1). 
Leptin levels and FCH
Both male and female FCH patients have higher mean leptin level compared to normolipidemic 
relatives and spouses, only not reaching statistical signiﬁcance in female FCH patients versus 
female spouses (Table 2).
Leptin levels show a strong signiﬁcant correlation with BMI in both males (r = 0.76) and 
females (r = 0.73). To determine whether the association of FCH with leptin concentration is 
dependent on BMI, we standardized the leptin concentration for BMI. After standardization, 
Table 2     Mean serum leptin levels in patients with familial combined hyperlipidemia, 
                normolipidemic relatives and spouses.
Leptin levels (ng/ml) FCH patients 
(n = 158 (48.1%)) *
NL relatives 
(n = 389 (45.0%)) *
Spouses 
(n = 90 44.3%)) *
Crude Males 8.9 [7.1 - 11.0] † ‡ 3.9 [34 - 4.5] § 5.5 [4.2 - 7.3]
Females 25.8 [21.7 - 30.7] † 18.4 [16.3 - 20.8] § 23.3 [18.6 - 29.2]
Standardized for BMI Males 6.2 [5.3 - 7.3] † ‡ 4.9 [4.4 - 5.4] 4.4 [3.6 - 5.4]
Females 20.3 [18.0 - 22.9] 20.3 [18.8 - 22.0] 21.7 [18.5 - 25.4]
Standardized for BMI
     and HOMA-index
Males 5.9 [5.1 - 7.0] 5.0 [4.5 - 5.6] 4.8 [3.9 - 5.8]
Females 19.1 [16.9 - 21.6] 20.7 [19.1 - 22.5] 21.9 [18.8 - 25.5]
Values are presented as means [95% conﬁdence interval] (calculated by GEE analyses); FCH, familial 
combined hyperlipidemia; NL relatives, normolipidemic relatives; BMI, body mass index; HOMA-index, 
homeostatis model assessment-index; *, percentage males; †, p-value < 0.05 , compared to normolipidemic 
relatives; ‡, p-value < 0.05, compared to spouses; §, p-value < 0.05, compared to spouses.
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no signiﬁcant diﬀerences in leptin levels among females with FCH, normolipidemic relatives 
and spouses are found. However, male FCH patients still show signiﬁcant higher leptin levels 
compared to normolipidemic relatives and spouses (Table 2). 
Patients with FCH are not only more obese than their normolipidemic relatives but they 
are also more insulin resistant. This is not completely contributable to their obesity, because 
after standardization of the HOMA-index for BMI, the diﬀerences in insulin resistance between 
patients with FCH and normolipidemic relatives and spouses remain signiﬁcant in our FCH 
population 9. Because leptin levels show a strong correlation with the HOMA-index for both 
males (r = 0.60) and females (r = 0.56), we also standardized leptin levels for the HOMA-index. 
After standardization of leptin levels for both BMI and HOMA-index, no signiﬁcant diﬀerences 
in leptin levels are found among FCH patients, normolipidemic relatives and spouses, although 
among males, a trend can be observed (Table 2). 
Leptin concentration in a multiple linear regression model
Multiple linear regression analyses showed that in the total study population, the variation in 
leptin concentration could be explained for approximately 70% by the variables gender and BMI. 
When including the HOMA-index in the model, 73 % of the variation in leptin concentration 
could be explained. 
Leptin concentration and CVD
Next, we determined whether elevated serum leptin levels (standardized for gender, BMI and 
HOMA-index) are associated with an increased risk for CVD. A serum leptin concentration 
above the standardized 90th percentile of leptin was associated with an increased risk for 
CVD in FCH patients (OR = 2.9, 95% CI = 1.1 - 8.0) and in non-FCH subjects (OR = 3.4, 
95% CI = 1.3 - 9.0). The overall OR for the total group is 3.3 with conﬁdence intervals ranging 
from 1.7 to 6.4 (Table 3). When performing the analysis with leptin levels as a continuous 
variable, we also obtained a signiﬁcant increased risk for CVD to be associated with a 1 SD 
change in leptin levels (OR = 1.6, 95% CI = 1.2 - 2.2).
Table 3     Odds ratios for cardiovascular disease associated with serum leptin levels above the 90th 
                 percentile.
FCH Non-FCH a Total group
Leptin
CVD+ 
(n = 29)
CVD- 
(n = 110)
OR 
[95% CI]
CVD+ 
(n = 29)
CVD- 
(n = 110)
OR 
[95% CI]
OR 
[95% CI]
    < 90th 21 
(72.4%)
98 
(89.1%) Reference
16 
(72.7%)
368 
(90.2%) Reference Reference
    > 90th 8 
(27.6%)
12 
(10.9%)
2.9
[1.1 - 8.0]
6 
(27.3%)
40 
(9.8%)
3.4 
[1.3 - 9.0]
3.3 
[1.7 - 6.4]
Values presented are total number (%) and the odds ratio's (calculated by logistic GEE analyses); serum 
leptin levels (ng/ml) are standardized for BMI, HOMA-index and gender;FCH, familial combined 
hyperlipidemia; CVD+, subjects with cardiovascular disease; CVD-, subjects without cardiovascular 
disease; a, non-FCH subjects include both normolipidemic relatives and spouses; < 90th, leptin levels < 90th 
percentile; > 90th, leptin levels > 90th percentile; 
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Discussion
In the present study, we report higher leptin levels in both male and female patients with FCH 
compared to their normolipidemic relatives and spouses. The extent of increase in leptin levels is 
in proportion to the degree of overweight and insulin resistance in these FCH patients. In females, 
the increased leptin levels were completely attributable to BMI, whereas in male FCH patients 
increased leptin levels were only partially attributable to overweight. However, the remaining 
diﬀerence in leptin levels in male patients with FCH seemed related to insulin resistance, since 
after correction for HOMA-index, leptin levels were no longer signiﬁcantly diﬀerent. So in both 
male and female FCH patients, leptin is not representing a defect in adipose tissue metabolism. 
The increased leptin levels in FCH were found to be associated with an increased risk for CVD, 
independent of gender, BMI and insulin resistance. 
So far, only two small studies investigated the relation of leptin concentrations and FCH. 
Haluzik et al. did not ﬁnd any diﬀerence in the leptin concentration between male subjects with 
familial combined hyperlipidemia and controls 247. Another study, performed in a small group of 
women by Jacobson et al., did show an increased concentration of leptin in females with FCH 
248. However, in this study they used subjects with familial hypercholesterolemia as a reference 
population and no healthy subjects. Our large study population, with both males and females, 
conﬁrmed at ﬁrst the results of Jacobson et al. but after standardization for BMI and insulin 
resistance, we report no diﬀerence in leptin levels of female FCH patients compared to their 
normolipidemic relatives and spouses, and only a non-signiﬁcant trend for male FCH patients. 
Because we did not ﬁnd a relation between FCH and leptin levels, independent of BMI 
and insulin resistance, adipose tissue metabolism with respect to leptin seems not disturbed in 
FCH. However, we cannot rule out the possibility of a disturbed adipose tissue metabolism in 
the pathophysiology of FCH because leptin is just one of the many markers of adipose tissue 
metabolism. Other markers of the adipose tissue, such as adiponectin and resistin 285, 286, need to 
be investigated before we can judge on involvement of disturbed adipose tissue metabolism in 
the pathophysiology of FCH indeﬁnitely. 
The rate of leptin production is mainly determined by obesity 279, 287-289, but there still is some 
inter-individual variability in plasma leptin concentration that is independent of body fatness. In 
our study, 70% of the individual variability in leptin levels could be accounted for by BMI and 
gender. However, after standardization of leptin levels for BMI only, we still found an association 
between FCH and leptin levels in men, not in women. Several studies have reported that leptin 
levels are also inﬂuenced by insulin resistance 290-294. Moreover, from literature, it is known that 
in men, but not in women, leptin levels correlate negatively with maximum glucose uptake rates 
and insulin sensitivity is related to serum leptin independently of percent body fat 295. Indeed, in 
our population we observed a strong correlation between leptin levels and the HOMA-index, as 
a measure of insulin resistance. This indicates that leptin levels should not only be standardized 
for BMI, but also for HOMA-index, as a measure of insulin resistance.  
From literature it is known that leptin is an independent risk factor for CVD 289, 292. So far, 
the relevance of high leptin concentrations as a risk factor for CVD associated with FCH has 
not been investigated. In the present study, we show that FCH subjects have elevated leptin 
levels, explained by the increased BMI and the presence of insulin resistance. Still it is possible 
that the elevated leptin levels contribute to the increased risk on CVD in FCH. Indeed, we 
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demonstrate that leptin levels above the 90th percentile are associated with an increased risk for 
CVD. Similar results were found among non-FCH subjects. This increased risk for CVD was not 
attributable to diﬀerences in gender, BMI and state of insulin resistance because the leptin level 
was standardized for these variables. Wallace et al. found an increased risk of approximately two-
fold on CVD in the highest two quintiles of leptin concentration compared to the lowest quintile 
289 in a prospective, nested, case control study of hypercholesterolemic men. Though our groups 
were not large enough to assess quintiles, the risk found for the 90th percentile in our study 
was comparable with the risks found for the highest two quintiles (60th and 80th percentile) by 
Wallace et al. 289. Moreover, when performing the analyses with leptin as a continuous variable, 
we also obtained an increased risk for CVD to be associated with higher leptin levels. In another 
study by Couillard et al., no signiﬁcant diﬀerences in serum leptin concentrations were observed 
between men with and without ischemic heart disease 287. This might be explained by the fact 
that obesity itself was not a risk factor for ischemic heart disease in this study. 
Several mechanisms are hypothesized to explain how leptin may increase the risk for 
cardiovascular events. The fact that leptin and its receptor are expressed in atherosclerotic plaques 
296, 297 indicates that leptin may be involved in the development of CVD. Leptin has many 
potentially atherogenic eﬀects, like stimulation of endothelial production of pro-atherosclerotic 
endothelin-1 298, induction of migration and proliferation of vascular smooth muscle cells 299, 
stimulation of inﬂammatory cells 300 and induction of calciﬁcation of vascular cells 296. So, leptin 
is involved in the process of atherosclerosis, which can also be concluded from our results that 
increased leptin levels are associated with an increased risk for CVD 
In summary, serum leptin levels are increased in patients with FCH in proportion to their 
obesity and state of insulin resistance. Elevated leptin levels are an independent risk factor for 
CVD in both FCH patients and in healthy controls.
Leptin levels in patients with FCH
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Abstract
Background Familial combined hyperlipidemia (FCH) is characterized by elevated levels of 
total cholesterol (TC), triglycerides (TG) and apolipoprotein B (apoB) and is associated with 
premature cardiovascular disease (CVD). Other features of FCH are obesity and insulin resistance. 
Serum leptin levels have also been associated with obesity, insulin resistance and atherosclerosis. 
Leptin exerts its eﬀect through the leptin receptor (LEPR). The aim of this study is to determine 
whether the Gln223Arg polymorphism in the LEPR gene contributes to FCH and its associated 
phenotypes. Methods The study population consists of 37 families, comprising 644 subjects, 
of whom 158 subjects were diagnosed as FCH. The FCH diagnosis was based on plasma TC 
and TG levels, adjusted for age and gender, and absolute apoB levels, according to our recently 
published nomogram. The Gln223Arg polymorphism was studied by PCR-restriction fragment 
length polymorphism. Results Carriers of one or two Arg alleles had an increased risk of FCH, 
compared to subjects homozygous for the Gln allele (OR = 1.6 [95% CI 1.0 – 2.4]). A diﬀerence 
in high-density lipoprotein cholesterol (HDLc) levels was present between carriers and non-
carriers of an Arg allele, 1.21 vs. 1.28 mmol/L, respectively (p = 0.04), but no diﬀerences in 
obesity, insulin resistance and other lipid parameters were found. Conclusion The Gln223Arg 
polymorphism in the LEPR gene is associated with FCH, which is supported by a signiﬁcant 
association between HDLc levels and the LEPR gene.
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Introduction
Familial combined hyperlipidemia (FCH) is the most common genetic hyperlipidemia in 
humans, with a prevalence of 5.7% in the general adult population 10. FCH is strongly associated 
with premature cardiovascular disease (CVD), reﬂected by the fact that up to 20% of the 
survivors of a premature myocardial infarction are aﬀected with FCH 8. FCH is characterized 
by hypercholesterolemia, hypertriglyceridemia and hyperapobetalipoproteinemia (hyperapoB). 
Other phenotypes of FCH are decreased levels of high-density lipoprotein cholesterol (HDLc) 
and the presence of small dense low-density lipoprotein (sdLDL) 13, 18, 116. In addition, patients 
with FCH are more obese and insulin resistant 9, 93. 
At present, the complex genetics of FCH, is still not fully understood 209, 301. The fact that FCH 
is a genetic heterogeneous disease complicates the identiﬁcation of major contributing genes. 
Based on the pathophysiology of FCH, several candidate genes have been evaluated, showing 
an association of FCH with lipoprotein lipase (LPL) 79, hepatic lipase (HL) 73, APOA1/C3/A4  50 
and APOE 69.
Linkage analyses have been performed in several study populations to unravel the genetic 
defects causing FCH. Several regions of linkage have been identiﬁed, including a region on 
chromosome 1q21-23 26, 28, 30. In this region, the upstream stimulatory factor 1 (USF1) gene has 
been suggested to be the gene associated with FCH 46. Other regions of linkage identiﬁed for 
FCH have been reported on several other chromosomes, including 2p, 6q, 8p, 9p, 10p, 11p, 
16q, 19q, 21q, 97 thereby underscoring the genetic heterogeneity of FCH. No other major gene, 
however, has been identiﬁed untill now.
In 2002, a genome scan in 18 Dutch families provided evidence that a locus on the human 
chromosome 1p31, harboring the leptin receptor (LEPR) gene, contributes to apolipoprotein B 
(apoB) levels in patients with FCH 38. This region segregated with plasma leptin levels, adiposity 
and body weight within these FCH families 302.  In the Pima Indians, markers near the LEPR gene 
have also been associated with obesity-related phenotypes 303. So, the LEPR gene is a potential 
candidate gene of FCH. The leptin receptor is responsible for transmission of the leptin signal 
in the hypothalamus to several signal transducers and transcription activators  and is the major 
leptin-binding protein in blood  304, 305. Leptin, mainly produced by the adipose tissue, is involved 
in the regulation of the energy expenditure and appetite via hypothalamic receptors 104, 306. Obese 
individuals have increased levels of leptin, which appear to fail to restore fat mass to normal. It 
is therefore believed that obesity is a state of leptin resistance 307.The leptin receptor is a class I 
cytokine receptor and has several isoforms, one of which is the soluble leptin receptor present 
in blood. In lean subjects the largest part (60 – 98%) of leptin in blood is present in the bound 
form; however, in obese subjects the majority of leptin is unbound 308. The leptin receptor is also 
present in peripheral tissues such as pancreatic beta cells, liver and skeletal muscle 309. In these 
tissues, leptin is capable of stimulating lipid oxidation via the LEPR with subsequent increase in 
insulin sensitivity 309-311.
The human LEPR gene is located on chromosome 1p31 104 and several single nucleotide 
polymorphisms (SNPs) have been described in this gene 312. Two polymorphisms have already 
been described in a population of FCH patients, and were not associated with any feature of 
FCH38}. A third polymorphism in the LEPR gene is Gln223Arg, located within the region 
encoding the extracellular domain of the leptin receptor and therefore present in all isoforms of 
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the receptor. The amino-acid change caused by Gln223Arg is associated with a change in leptin-
binding activity 313. The Gln223Arg polymorphism has been associated with body mass index 
(BMI), fat mass, leptin levels, and systolic and diastolic blood pressure in some studies; 309, 312, 314 
however, other studies did not ﬁnd these associations  315-317.  
The aim of this study was to investigate whether there is an association between the presence 
of the Arg allele deﬁned by the Gln223Arg polymorphism in the LEPR gene and FCH and its 
associated phenotypes. 
Methods
Subjects
The study population consisted of 37 families, comprising 644 subjects, of whom 158 subjects 
were diagnosed as FCH patients 16, 17. The diagnosis FCH was based on total cholesterol (TC) 
and triglycerides (TG) levels adjusted for age and gender in combination with absolute apoB 
levels, according to our nomogram, as recently published 17. The normolipidemic relatives 
(n = 390) and unaﬀected spouses of both the FCH patients and the normolipidemic relatives 
(n = 89), served as two independent reference groups, because of the similar genetic background 
of the relatives with the FCH patients. Seven subjects were not diagnosed because of missing 
values. Information about the presence of CVD was gathered by personal interview and physical 
examination performed by the clinical investigator. After withdrawal of lipid-lowering medication 
for 4 weeks and an overnight fast, blood was drawn by venipuncture. The ethical committee of the 
Radboud University Nijmegen Medical Centre approved the study protocol and the procedures 
followed were in accordance with institutional guidelines. All subjects gave informed consent. 
BMI was calculated as body weight (in kilograms) divided by the square of height (in meters). 
Waist circumference was obtained with use of a standard cloth tape measure, measured in mm 
at the level of the umbilicus in the late exhalation phase while standing. Systolic and diastolic 
blood pressure were assessed twice with an automated blood pressure device (Dinamap; Critikon, 
Tampa, Fl, USA) in the right arm in a sitting position after a 5-minute rest period, mean blood 
pressures were used in our analyses.
Biochemical analyses
Plasma TC and TG were determined by enzymatic, commercially available reagents (Boehringer-
Mannheim, Germany, catalog No. 237574 and Sera Pak, Miles, Belgium, catalog No. 6639, 
respectively). HDLc was determined by the polyethylene glycol 6000 method 267. Total plasma 
apoB concentrations were determined by immunonephelometry 119. LDL subfractions were 
separated by single spin density gradient ultracentrifugation. A continuous variable K represents 
the LDL subfraction proﬁle of each individual. A negative K-value (K ≤ -0.1) reﬂects a more 
dense LDL subfraction proﬁle, and a positive K-value (K > -0.1) reﬂects a more buoyant proﬁle 
120, 147, 268. Glucose concentrations were measured in duplicate using the oxidation method 
(Beckman®, Glucose Analyser 2, Beckman Instruments Inc., Fullerton, CA, USA). Plasma 
insulin concentrations were determined using a double antibody method 170. Insulin resistance 
was assessed by homeostasis model assessment (HOMA), a continuous, quantitative parameter 
where higher values indicate a more insulin resistant state. The HOMA-index was calculated 
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from the fasting concentrations of insulin and glucose using the following formula: HOMA-
index = fasting serum insulin (µU/ml) x fasting plasma glucose (mmol/L)/22.5 171. Leptin levels 
were measured in duplicate in serum samples using enzyme-linked immunosorbent assay (R&D 
Systems, Minneapolis: Elisa Development System; Duoset® Human Leptin, Catalog no. DY398) 
318. 
DNA extraction and genotyping
DNA was isolated from peripheral blood lymphocytes by a standard method. The Gln223Arg 
variant was genotyped by PCR-restriction fragment length polymorphism analysis. PCR was carried 
out in a total volume of 50 µl containing 50 ng of the forward primer 5’-GCCTAATCCAGTAT
TTTCATATCTG-3’ and 50 ng of the reverse primer 5’-GCCACTCTTAATACCCCCAGTAC-
3’, 200 µM each dNTP, 10 mM Tris-HCl (pH 8.30), 50 mM KCL, 1.5 mM MgCl2) and 1 unit 
Taq polymerase (Life Technologies). PCR conditions were: an initial denaturation step of 3 min 
Table 1     Characteristics of patients with familial combined hyperlipidemia, normolipidemic
                relatives and spouses.
FCH patients 
(n = 158)
NL relatives 
(n = 390)
Spouses 
(n = 89)
Gender (males) * 75 (47.5%) 175 (44.9%) 44 (439.4%)
Ager (years) 47.1 (16.3) ‡ § 37.7 (18.0) ¥ 52.6 (15.9)
CVD * 32 (20.3%) ‡ § 21 (5.4%) 3 (3.4%)
BMI (kg/m2) 27.3 (4.4) ‡ 24.2 (5.3) ¥ 26.4 (4.2)
Waist circumference (cm) 87.4 (14.2) ‡ § 77.6 (12.1) ¥ 82.9 (11.3)
Systolic BP (mmHg) 136.4 (17.7) § 128.0 (20.1) ¥ 134.3 (17.1)
Diastolic BP (mmHg) 85.2 (10.5) § 80.3 (12.1) ¥ 83.6 (10.1)
TC (mmol/L) 6.5 (1.1) ‡ § 4.9 (1.2) ¥ 5.2 (1.0)
TG (mmol/L) † 2.8 (1.6) ‡ § 1.1 (1.6) 1.1 (1.6)
ApoB (mg/L) 1372 (236) ‡ § 961 (249) 1001 (233)
HDLc (mmol/L) 0.97 (0.33) ‡ § 1.22 (0.36) ¥ 1.29 (0.32)
K-value -0.25 (0.24) ‡ § 0.04 (0.27) 0.06 (0.23)
HOMA-index † 2.9 (1.8) ‡ § 2.0 (2.0) 2.2 (1.8)
Leptin  (ng/mL) male † 8.9 (0.4) ‡ § 3.9 (0.4) ¥ 5.5 (0.4)
Leptin (ng/mL) female † 25.8 (0.4) ‡ § 18.4 (0.5) ¥ 23.3 (0.4)
Analyses are performed with GEE and results are presented as mean (sd); *, presented are number (%); 
†, presented are geometric mean (geometric SD); FCH, familial combined hyperlipidemia; NL relatives, 
normolipidemic relatives; CVD, cardiovascular disease; BMI, body mass index; systolic BP, systolic blood 
pressure; diastolic BP, diastolic blood pressure; TC, total cholesterol; TG, triglycerides; apoB, apolipoprotein 
B; K-value, a value below -0.1 represents the presence of small denxe low-density lipoprotein; HDLc, high-
density lipoprotein cholesterol; HOMA-index, homeostasis model assessment-index; ‡, p-value < 0.05, 
compared to normolipidemic relatives; §, p-value < 0.05, compared to spouses; ¥, p-value < 0.05, compared 
to spouses.
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at 94°C, followed by 40 cycles of 94°C, 1 min (denaturation), 53.7°C, 1 min (annealing), 72°C, 
30 s (extension), and a ﬁnal extension of 7 min at 72°C. The PCR ampliﬁcation resulted in a 
fragment of 416 bp, which was subjected to a MspI restriction enzyme analysis (New England 
Biolabs, Beverly, MA, USA) to detect the Arg variant; the Arg allele contains an MspI restriction 
site. Subsequent gel electrophoresis showed a fragment of 416 bp when the Gln allele was present 
and a fragment of 229 bp and 187 bp when the Arg allele was present.
Statistical analyses
Descriptive statistics, expressed as mean ± standard deviation (SD) or a geometric mean ± 
geometric SD, were presented for FCH patients, normolipidemic relatives and spouses. Variables 
with a skewed distribution, including HOMA-index, leptin and triglyceride levels, were 
logarithmically transformed. The frequencies of the genotypes were tested for Hardy-Weinberg 
equilibrium by chi-square analysis before the analyses. Diﬀerences in anthropometric and 
metabolic characteristics between the genotypes were tested by means of generalized estimating 
equations (GEE) because of possible correlated values within families. The odds ratio as an 
estimate of relative risk of FCH was calculated using logistic GEE. GEE analyses were used 
to adjust leptin levels for BMI. Diﬀerences were considered statistically signiﬁcant at p-values 
< 0.05. All analyses described above were computed using the STATA 8.0 software (StataCorp 
LP, College station, Texas, USA). 
Results
Subject characteristics 
Descriptive statistics of anthropometric and metabolic characteristics of the study population 
are presented in Table 1. FCH patients are on average older than normolipidemic relatives, but 
younger than spouses. Evident is the higher prevalence of CVD in patients with FCH, compared 
to normolipidemic relatives and spouses. The mean BMI and waist circumference of patients 
with FCH are signiﬁcantly higher, compared to normolipidemic relatives and spouses. The 
systolic and diastolic blood pressures are signiﬁcantly higher in patients with FCH compared 
to the normolipidemic relatives, but not compared to the spouses. By deﬁnition, FCH patients 
are characterized by increased plasma TC, TG and apoB levels compared to normolipidemic 
relatives and spouses. Furthermore, FCH patients have decreased HDLc levels, are more insulin 
resistant, as reﬂected by a higher HOMA-index and more sdLDL is present, as reﬂected by a 
Table 2     Risk on FCH associated with Gln223Arg polymorphism in the leptin receptor gene
FCH patients, n (%) Controls, n(%) OR [95% CI]*
Gln223Gln 41 (26.0%) 171 (35.8%) Reference
Gln223Arg/Arg223Arg 117 (74.0%) 307 (64.2%) 1.6 [1.0 - 2.4]
Analyses are performed with GEE; FCH, familial combined hyperlipidemia; OR, odds ratio; *, OR 
represents the risk associated with the presence of the Arg allele in patients with FCH compared to controls, 
which include both the normolipidemic relatives and spouses.
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lower K-value. Both male and female FCH patients have higher plasma leptin levels compared 
to normolipidemic relatives and, only within the males, compared to spouses. Normolipidemic 
relatives are younger, have a lower BMI, waist circumference, systolic and diastolic blood pressure, 
TC and HDLc levels, compared to the spouses (Table 1). 
LEPR polymorphism and FCH
The allele frequencies in the total group are 0.4 for the Arg allele and 0.6 for the Gln allele. 
The distribution of the alleles in the group of spouses was in Hardy-Weinberg equilibrium 
(p = 0.75). The Arg223Arg genotype is present within 31 FCH patients (20%), 66 normolipidemic 
relatives (17%) and 14 spouses (16%). No diﬀerences in lipid, lipoprotein and insulin resistance 
parameters were found between subjects with the Gln223Arg or Arg223Arg genotype, therefore, 
pooled analyses for the carriers of the Arg allele were performed 319. As normolipidemic relatives 
and spouses did not diﬀer in frequencies of the genotypes, they were pooled into one group of 
controls for further analyses.
Table 3     Mean values of obesity, lipid, lipoprotein and insulin resistance parameters for the 
                 carriers and non-carriers of the Arg allele in the control group.
Gln223Gln Gln223Arg/Arg223Arg P-value P-value *
Age (years) 36.7 (34.1 - 39.3) 42.4 (40.3 - 44.4) 0.000 -
BMI (kg/m2) 23.9 (23.3 - 24.6) 24.7 (24.2 - 25.2) 0.041 0.501
Waist (cm) 77.1 (75.4 - 78.9) 79.3 (78.0 - 80.7) 0.045 0.565
Syst. BP (mmHg) 127.5 (124.7 - 130.3) 129.7 (127.5 - 132.0) 0.161 0.303
Diast. BP (mmHg) 79.2 (77.6 - 80.9) 81.5 (80.2 - 82.8) 0.013 0.504
TC (mmol/L) 4.82 (4.66 - 4.98) 4.97 (4.85 - 5.10) 0.090 0.955
TG (mmol/L) † 1.01 (0.94 - 1.09) 1.09 (1.03 - 1.15) 0.094 0.422
ApoB (mg/L) 942 (909 - 976) 981 (956 - 1006) 0.061 0.782
HDLc (mmol/L) 1.28 (1.22 - 1.33) 1.21 (1.17 - 1.25) 0.033 0.041
K-value 0.05 (0.02 - 0.09) 0.04 (0.02 - 0.07) 0.589 0.896
HOMA-index † 2.04 (1.84 - 2.26) 2.01 (1.85 - 2.18) 0.795 0.671
Leptin (ng/mL)
Males † 3.9 (3.1 - 4.9) 4.3 (3.7 - 5.0) 0.517 0.906
Females † 18.7 (15.9 - 21.9) 19.1 (16.8 - 21.7) 0.801 0.875
Analyses are performed with GEE and results are presented as means (95% conﬁdence interval); BMI, body 
mass index; K-value, a value < -0.1 represents the presence of small dense low-density lipoprotein; HDLc, 
high-density lipoprotein cholesterol; HOMA-index, homeostasis model assessment-index; Syst.BP, systolic 
blood pressure; Diast. BP, diastolic blood pressure; * p-value corrected for age; †, geometric mean with 95% 
conﬁdence interval is presented.
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In table 2, the genotypic distribution is presented for both the patients with FCH and the 
controls. In the control group, 64.2% of the subjects were carrier of one or two Arg alleles 
for the Gln223Arg polymorphism in the LEPR gene. In the group of FCH patients, almost 
74.0% were carrier of an Arg allele. The presence of an Arg allele was associated with a 1.6 
[95% CI 1.0 – 2.4] times increased risk for FCH (Table 2).
LEPR polymorphism and FCH phenotypes
As shown in table 3, controls carrying one or two Arg alleles had a higher BMI, waist 
circumference and diastolic blood pressure and decreased levels of HDLc compared to control 
subjects with the Gln223Gln genotype. No diﬀerences in other lipid and lipoprotein or insulin 
resistance parameters were found. The mean leptin level in male and female control carriers of 
an Arg allele did not diﬀer signiﬁcantly from non-carriers (Table 3). Also after adjustment of 
leptin levels for obesity and insulin resistance, as represented by the BMI and HOMA-index, 
respectively, the leptin levels did not diﬀer between control carriers and non-carriers of an Arg 
allele (data not shown). Because a diﬀerence in age was observed between controls carrying an Arg 
allele and controls not carrying an Arg allele, analyses were adjusted for age. After adjustment for 
age, only the HDLc levels were signiﬁcantly diﬀerent between the two genotype groups. Within 
the group of FCH patients there were no signiﬁcant diﬀerences in obesity, blood pressure, lipid 
levels and insulin resistance parameters between carriers and non-carriers of one or two Arg 
alleles after adjustment for age (data not shown).
Discussion
In our population of 37 well-deﬁned FCH families, we found that carriers of one or two Arg 
alleles of the Gln223Arg polymorphism in the leptin receptor gene have a 1.6 times increased 
risk on FCH and have decreased levels of HDLc. 
There are several reasons, which suggest that the LEPR gene could be a good candidate gene for 
FCH. First of all, the LEPR gene is located on chromosome 1p31, within a segment to which a 
QTL for apolipoprotein B has been mapped in another Dutch FCH population 38. The authors 
also considered the LEPR gene as a candidate gene. However, genotyping two SNPs did not 
reveal evidence of an association between alleles of the LEPR gene and apoB levels in their study 
population. They did, however, not study the functional Gln223Arg polymorphism in the LEPR 
gene. We show that the Gln223Arg polymorphism is not associated with apoB levels. Most 
likely, another gene in this chromosomal region contributes to elevated apoB levels in FCH.  
Another reason, why the LEPR gene has been postulated to be a good candidate gene is the 
fact that the LEPR gene maps to a locus which segregates with adiposity, body weight and plasma 
leptin levels in pedigrees with FCH 302. Within these pedigrees with FCH, it was found that 
leptin levels are associated with two polymorphic markers in the LEPR gene 302. We now show 
that the Gln223Arg polymorphism is not associated with leptin levels in our population of 
patients with FCH. Recently, we showed that the increased leptin levels in patients with FCH 
are attributable to their increased adiposity and insulin resistance, suggesting that the increased 
leptin levels in FCH patients are not speciﬁc for FCH 318. Reasons for the apparent discrepancy 
in results between the two diﬀerent studies could be that van der Kallen et al. did not test a 
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functional polymorphism like we did, only polymorphic markers within the LEPR gene, and 
they used leptin levels as a surrogate marker of obesity, so the independent role of leptin in FCH 
was not investigated. 
The choice for the functional Gln223Arg polymorphism in the LEPR gene was based on 
previous studies, which suggested that the Gln223Arg polymorphism of the leptin receptor 
gene is associated with high blood pressure, obesity, lipids and insulin resistance 312, 313, 320, 321, all 
characteristics of FCH. However, data are conﬂicting, as there are also many studies reporting 
no association 317, 322-325. A recent paper by Heo et al., 322 in which data from nine distinct studies 
were pooled for analysis, stated that there was no compelling evidence for any of the LEPR 
polymorphisms tested, including the Gln223Arg and the two polymorphisms previously tested 
in another FCH population, 38 to be associated with BMI and waist circumference in the general 
population. Our results support the data from Heo et al., 322 as we did not ﬁnd an association 
between the Gln223Arg polymorphism in the LEPR gene and BMI and waist circumference. In 
the present study, we also did not ﬁnd an association with blood pressure, insulin resistance, or 
any of the lipid and lipoprotein parameters, except for HDLc, which was signiﬁcantly lower in 
carriers of the Arg allele.
The mechanistic implication of the association between FCH, decreased HDLc levels and the 
LEPR gene, found in this study, is unclear. It is possible that the association of the Gln223Arg 
polymorphism in the LEPR gene with HDLc originates from chance alone, as it is the only 
signiﬁcant association among several tests. However, previous studies in mice and humans 
support the association between HDLc and the LEPR gene. The ob/ob and db/db mice, which 
have speciﬁc mutations in the leptin and the leptin receptor gene, respectively, have elevated 
levels of HDLc, which can be reversed by treatment with leptin 326, 327. This suggests that leptin 
plays a role in the regulation of HDLc. Also a study performed in humans by Mendez-Sanchez 
et al., 328 found a negative correlation between leptin levels and HDLc. Mendez-Sanchez et al. 
328 hypothesized that in obese humans, as they have high leptin levels and are leptin resistant, 
elevated leptin levels could have direct peripheral actions on the liver, leading to accelerated 
hepatic degradation of HDLc. Alternatively, leptin is suggested to be capable of inﬂuencing 
several apolipoprotein genes and the hepatic lipase (HL) gene expression. Liang and Tall 326 
showed that the ob/ob mice have a down-regulated expression of genes encoding a variety of 
apolipoprotein and hepatic lipase with reversal upon leptin administration. In humans with 
FCH, it was recently reported by Soro et al. that HL plays a major role in determining HDLc 6 
and also plasma phospholipid transfer protein (PLTP), cholesteryl ester transfer protein (CETP) 
and lipoprotein lipase (LPL) activity have been suggested to contribute to HDLc in FCH 6, 136. 
Leptin or the Arg allele of the LEPR gene may thus contribute to low HDLc levels by modifying 
HL, PLTP, CETP or LPL levels. Recently, a genome-wide linkage analysis in hypertensive 
sibships indicated that a locus for HDLc levels was located on chromosome 1p, to which also 
the LEPR gene has been mapped 329. So, it is conceivable that there is an association between the 
Gln223Arg polymorphism in the LEPR gene and HDLc.
The association of the LEPR gene with HDLc in our study population is not supported by 
associations between the polymorphism in the LEPR gene and leptin levels or other serum lipid 
levels, while other studies, which also found an association between the Gln223Arg polymorphism 
and HDLc levels, do ﬁnd supportive associations with leptin or other lipid parameters 314, 320.
In conclusion, the Gln223Arg polymorphism in the leptin receptor gene is associated with 
FCH patients and Gln223Arg polymorphism in LEPR gene
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Abstract
Background Familial combined hyperlipidemia (FCH) is characterized by elevated levels of total 
cholesterol, triglycerides and/or apolipoprotein B. Other features of FCH are obesity and insulin 
resistance. Adiponectin is a secretory product of the adipose tissue. Low levels of adiponectin 
are associated with insulin resistance and accelerated atherosclerosis. The aim of this study was 
to determine whether decreased adiponectin levels are associated with FCH and its phenotypes. 
Methods The study population comprised 644 subjects, including 158 patients with FCH. 
Serum adiponectin levels were determined using a commercially available ELISA. Results For 
both males and females, the mean adiponectin level (µg/ml) was signiﬁcantly lower in FCH 
patients (2.0 (1.8 - 2.2) and 2.5 (2.3 - 2.8), respectively) compared to normolipidemic relatives 
(2.3 (2.2 - 2.5) and 3.1 (2.8 - 3.3), respectively), and spouses (2.4 (2.1 - 2.7) and 3.2 (2.8 - 3.6), 
respectively). These diﬀerences remain signiﬁcant after adjusting for waist circumference and 
insulin resistance. Low adiponectin level in FCH patients was a superior independent predictor 
of the atherogenic lipid proﬁle, including high triglyceride levels, low HDL-cholesterol levels 
and the amount of small, dense LDL present, compared to both obesity and insulin resistance. 
Conclusions Low adiponectin levels may contribute to the atherogenic lipid proﬁle in FCH, 
independent of insulin resistance and of obesity, as measured by waist circumference. This ﬁnding 
implies a role of adipose tissue metabolism in the pathophysiology of FCH. 
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Introduction
In the past, the adipose tissue was seen as an energy depot, storing energy in the form of 
triglycerides and not having a real function of its own. At present, we know that adipose tissue 
also secretes several signaling proteins, called adipokines 330. Adiponectin is one of the major 
adipokines derived from the adipose tissue and is abundantly present in human plasma, at 
concentrations ranging from 2 to 10 µg/mL in healthy subjects 106. Adiponectin production is 
inversely correlated with adipose tissue mass 107. 
Low adiponectin levels are found in subjects with obesity 331-333, diabetes mellitus 333, 334 and 
cardiovascular disease (CVD) 109, 112. These subjects with low adiponectin levels fail some of 
the protective actions of adiponectin, including the stimulation of fatty acid oxidation and the 
improvement of glucose metabolism, by increasing lipid oxidation both in pancreas and muscle, 
thereby increasing insulin sensitivity 107. Furthermore, adiponectin has an insulin-sensitizing 
eﬀect on hepatocytes, resulting in suppression of hepatic glucose output 108. In addition, 
adiponectin inhibits the inﬂammatory process and possibly atherosclerosis by suppressing tumor 
necrosis factor-alpha-induced adhesion molecule expression 109, the adhesion and migration 
of monocytes/macrophages, and their transformation into foam cells 110. Because of these 
properties, adiponectin is suggested to be the missing link between obesity, insulin resistance and 
atherosclerosis 106. 
Besides the eﬀects of adiponectin on whole body glucose metabolism and insulin sensitivity, 
adiponectin has also been reported to modulate plasma lipid levels, directly or indirectly 335. 
Several studies have reported a negative correlation of adiponectin levels with serum triglycerides 
(TGs) and small dense low-density lipoprotein (sdLDL) and a positive correlation with high-
density lipoprotein cholesterol (HDLc) 111, 336-341. Furthermore, Chan et al. recently showed that 
adiponectin regulates triglyceride-rich lipoprotein metabolism 337, 342. The mechanisms by which 
adiponectin modulates plasma lipid levels are unknown; however, several possibilities have been 
proposed. Adiponectin enhances fatty acid oxidation in the circulation and in the skeletal muscle 
through activation of AMP-kinase 107, so the accumulation of triglycerides occurs with low levels 
of adiponectin. Recent studies suggest a strong relationship between adiponectin and lipoprotein 
lipase (LPL) activity 343. Finally, the eﬀects of adiponectin on lipid levels may be related to the 
eﬀect of adiponectin on insulin sensitivity.
Familial combined hyperlipidemia (FCH) is the most common genetic hyperlipidemia in 
humans, aﬀecting 1 - 3% of the general population. It is strongly associated with premature CVD; 
of the survivors of a premature myocardial infarction, up to 20% are aﬀected with FCH 4. FCH is 
characterized by increased levels of plasma total cholesterol, triglycerides, and/or apolipoprotein 
B (apoB). Other phenotypes of FCH are decreased levels of HDLc and the presence of sdLDL 13, 
18, 116. In addition, FCH is associated with obesity and insulin resistance 9.
The pathophysiology of FCH is still unknown, although several metabolic abnormalities have 
been suggested, including the hypothesis that FCH is caused by disturbances in adipose tissue 9, 
93, 251. Quantitative and qualitative changes in adipose tissue contribute to fatty acid accumulation 
in the circulation, which drives apoB secretion in the liver, leading to increased lipid levels and 
insulin resistance 9, 344. On the other hand, alterations in adipose tissue can result in dysregulation 
of the secretion of adipokines. Because adiponectin is one of the major adipokines and, as 
described above, is associated with obesity, insulin resistance and dyslipidemia, all features of 
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FCH, adiponectin may play a role in the pathophysiology of FCH or may be a marker for a 
disturbed adipose tissue metabolism in FCH. Therefore, the inadequate storage and release of 
fatty acids alone or in combination with dysregulation of secretion of adipokines may contribute 
to the detrimental metabolic sequelae in FCH. 
Here, we address the question of whether in FCH the adiponectin levels are disturbed and 
whether disturbed adiponectin levels are associated with FCH and its associated phenotypes. 
Methods
Study population
Thirty-seven families, comprising 644 subjects (158 subjects diagnosed as FCH patients, 390 
normolipidemic relatives, and 89 spouses) were included in the study population, as previously 
described 16, 17. Seven subjects were not diagnosed because of missing values. The normolipidemic 
relatives and spouses are regarded as separate reference groups, because of the similar genetic 
background of the relatives with the FCH patients. The spouses of both the FCH patients and 
the normolipidemic relatives were included in this study as a separate control group, because 
they share environment but are not genetically related to FCH patients. All subjects ﬁlled 
out a questionnaire about their previous medical history. After withdrawal of lipid-lowering 
medication for 4 weeks and an overnight fast, blood was drawn by venipuncture. The ethical 
committee of the Radboud University Nijmegen Medical Centre approved the study protocol, 
and the procedures followed were in accordance with institutional guidelines. All subjects gave 
informed consent. 
The diagnosis FCH was based on the nomogram, as recently published by our group 17. Plasma 
triglyceride and total cholesterol levels, adjusted for age and gender, and absolute apoB levels 
were applied to the nomogram to calculate the probability of being aﬀected by FCH. In short, in 
the nomogram for each of the three variables, the corresponding number of points is read from a 
scale and then summed to give a total point score, which is translated into a probability of being 
aﬀected by FCH. The subjects is deﬁned as aﬀected by FCH when te probability is > 60%, when 
the diagnostic phenotype is also present in at least one ﬁrst-degree relative, and when premature 
CVD, before the age of 60 years, is also present in at least one individual in the family.
Body mass index (BMI) was calculated as body weight (in kilograms) divided by the square of 
height (in meters). The maximum hip circumference (cm) and waist circumference (cm) at the 
umbilical level were measured in the late exhalation phase while standing. The waist-hip ratio 
(WHR) was calculated.
Biochemical analyses
Plasma total cholesterol and total triglycerides were determined by enzymatic, commercially 
available reagents (catalog number 237574 (Boehringer-Mannheim) and catalog number 6639 
(Sera Pak), respectively). HDLc was determined by the polyethylene glycol 6000 method 267. 
Low-density lipoprotein cholesterol (LDLc) was calculated by subtraction of very low-density 
lipoprotein cholesterol (VLDL-c) and HDLc from plasma total cholesterol according to the 
method of Friedewald, Levy, and Fredrickson 345. Total plasma apoB concentrations were 
determined by immunonephelometry 119. LDL subfractions were separated by single-spin density 
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gradient ultracentrifugation. A continuous variable, K, represents the LDL subfraction proﬁle of 
each individual. A negative K-value (K ≤ -0.1) reﬂects a more dense LDL subfraction proﬁle, and 
a positive K-value (K > -0.1) reﬂects a more buoyant proﬁle 120, 147, 268. Glucose concentrations 
were measured in duplicate using the oxidation method (Beckman®, Glucose Analyser2, 
Beckman Instruments Inc., Fullerton, CA 92634, USA). Plasma insulin concentrations were 
determined using a double-antibody method. Insulin resistance was assessed by the homeostasis 
model assessment (HOMA). The HOMA-index was calculated from the fasting concentrations 
of insulin and glucose using the following formula: HOMA-index = fasting plasma insulin 
(µU/ml) x fasting plasma glucose (mmol/L)/22.5 171.
Serum adiponectin levels
To measure adiponectin levels, serum samples were assayed in duplicate using a commercially 
available enzyme-linked immunosorbent assay (catalog number DY1065; R&D Systems, 
Minneapolis, USA). This assay measures total circulating levels of adiponectin present in the 
serum. Interassay and intra-assay coeﬃcients of variance were 7.2% and 6.2%, respectively. The 
detection limit was 0.1 ng/ml. 
Table 1     Characteristics of patients with familial combined hyperlipidemia, normolipidemic 
                 relatives, and spouses.
Characteristics
FCH patients 
(n = 158)
NL relatives 
(n = 390)
Spouses
(n = 89)
Gender (males) 75 947.5%) 175 (44.9%) 44 (49.4%0
Age (years) 47.1 (16.3) * † 37.7 (18.0) ‡ 52.6 (15.9)
Cardiovascular disease 32 (20.3%) * † 21 (5.4%) 3 (3.4%)
Body mass index (kg/m2) 27.3 (4.4) * 24.2 (5.3) ‡ 26.4 (4.2)
Waist-to-hip ratio 0.88 (0.08) * † 0.83 (0.08) ‡ 0.85 (0.08)
Waist circumference(cm) 87.4 (14.2) * † 77.6 (12.1) ‡ 82.9 (11.3)
Total cholesterol (mmol/L) 6.5 (1.1) * † 4.9 (1.2) ‡ 5.2 (1.0)
Triglycerides (mmol/L) 2.8 (1.6) * † 1.1 (1.6) 1.1 (1.6)
HDLc (mmol/L) 0.97 (0.33) * † 1.22 (0.36) ‡ 1.29 (0.32)
LDLc (mmol/L) 4.2 (1.0) * † 3.2 (1.1) ‡ 3.5 (1.0)
Apolipoprotein B (mg/L) 1371 (236) * † 961 (249) 1001 (233)
K-value -0.25 (0.24) * † 0.04 (0.27) 0.06 (0.23)
Insulin (mU/ml) 12.7 (1.7) * † 9.1 (1.9) 9.5 (1.7)
Glucose (mmol/L) 5.2 (1.1) * 5.0 (1.1) ‡ 5.2 (1.1)
HOMA-index 2.9 (1.8) * † 2.0 (2.0) 2.2 (1.8)
Values presented are means (SD) except as indicated; Gender and CVD data are presented as number (%); 
TG, insulin, glucose, and HOMA-index data are presented as geometric means (geometric SD); FCH, 
familial combined hyperlipidemia; K-value, a value ≤ -0.1 represents the presence of small, dense low-
density lipoprotein (sdLDL); *, p-value < 0.05, compared to normolipidemic relatives; †, p-value < 0.05, 
compared to spouses; ‡, p-value < 0.05, compared to spouses.
Decreased adiponectin levels in patients with FCH
140
Statistical analyses
For any given degree of obesity, females have higher adiponectin levels than males. Therefore, 
all analyses were stratiﬁed, standardized, or corrected for gender. Variables with a skewed 
distribution, including adiponectin levels, triglyceride levels, and the HOMA-index, were 
logarithmically transformed before analysis.
Descriptive statistics, presented separately for FCH patients, normolipidemic relatives, 
and spouses, are expressed as a means with SD or geometric means with geometric SD for 
logarithmically transformed variables. Parametric Pearson correlation was used for correlation 
analysis. Diﬀerences in characteristics and adiponectin levels between patients with FCH, 
normolipidemic relatives, and spouses were tested by means of generalized estimating equations 
(GEEs) because of possible correlated values within families. GEE analyses were performed to 
standardize adiponectin levels for waist circumference and HOMA-index. Tertiles of adiponectin, 
standardized for gender, were calculated separately for FCH patients and controls. GEE regression 
models were used to calculate the prediction of the atherogenic lipid proﬁle in FCH patients and 
controls by adiponectin levels, HOMA-index and waist circumference, adjusted for age and 
gender. The standardized ß coeﬃcient is calculated by multiplying the ß coeﬃcient with the ratio 
of the standard deviations for the independent and dependent variables. The predicted change 
in several variables caused by a 25% model-based decrease in adiponectin or a 5% increase in 
waist circumference was calculated. The choice of a 25% change in adiponectin level and a 5% 
change in waist circumference were based on the fact that these changes are associated with a 3 to 
4 kg change in body weight 346-348. Diﬀerences were considered statistically signiﬁcant at p-values 
< 0.05. All analyses were computed using the STATA 8.0 software. 
Results
Subject characteristics 
Descriptive statistics of anthropometric and metabolic characteristics of the study population 
are presented in table 1. FCH patients were older than normolipidemic relatives but younger 
than the spouses. Evident was the greater incidence of CVD in patients with FCH compared to 
normolipidemic relatives and spouses. The mean BMI of patients with FCH was signiﬁcantly 
Table 2     Mean adiponectin levels in patients with FCH, normolipidemic relatives, and spouses.
Males Females
Subject
Adiponectin level
(ng/mL)
Diﬀerence 
versus 
Spouses
Adiponectin level
(ng/mL)
Diﬀerence 
versus 
Spouses
FCH patients 2.0 (1.8 - 2.2) * † -17% 2.5 (2.3 - 2.8) * † -22%
Normolipidemic relatives 2.3 (2.2 - 2.5) -4% 3.1 (2.8 - 3.3) -3%
Spouses 2.4 (2.1 - 2.7) Reference 3.2 (2.8 - 3.6) Reference
Values for adiponectin levels are geometric means with 95% conﬁdence interval (CI); *, p-value < 0.05, 
compared to normolipidemic relatives; †, p-value < 0.05, compared to spouses.
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higher than that of normolipidemic relatives. Mean WHR and waist circumference was 
signiﬁcantly higher in FCH patients compared with normolipidemic relatives and spouses. 
Compared with normolipidemic relatives and spouses, FCH patients had signiﬁcantly higher 
levels of total cholesterol, triglycerides, apoB and LDLc and signiﬁcantly lower levels of HDLc. 
Furthermore, FCH patients were characterized by the presence of sdLDL and insulin resistance, 
as reﬂected by a signiﬁcant lower K-value and a signiﬁcant higher HOMA-index, respectively. 
Normolipidemic relatives were younger and had lower BMI, WHR, waist circumference, total 
cholesterol, LDLc, and HDLc compared to the spouses (Table 1). 
Adiponectin level and FCH
As presented in table 2, both male and female FCH patients had signiﬁcantly lower mean 
serum adiponectin levels compared with both normolipidemic relatives and spouses. Mean 
adiponectin levels were 17% lower in male and 22% lower in female FCH patients compared 
with male and female spouses (Table 2). Adiponectin levels in normolipidemic relatives and 
spouses did not diﬀer signiﬁcantly. 
Within the total group, adiponectin levels were associated with BMI (males, r = -0.285; females, 
r = -0.311), WHR (males, r = -0.238; females, r = -0.306), and waist circumference (males, 
r = -0.246; females, r = -0.339). The correlations of adiponectin levels with markers of obesity were 
comparable for FCH patients and non-FCH control subjects. The correlations of adiponectin 
levels with waist circumference for both FCH patients and controls are shown in ﬁgure 1.
We adjusted the adiponectin levels for waist circumference because of the good correlation and 
because it is known from the literature that of these three markers of obesity, waist circumference 
is the best simple anthropometric predictor of abdominal visceral fat mass 349. The adiponectin 
levels remained signiﬁcantly lower in both male and female patients with FCH (2.1 (1.9 - 2.3) 
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Figure 1
Correlation between waist circumference and serum adiponectin levels in patients with familial combined 
hyperlipidemia (FCH) and controls. Open squares represent males and closed squares represent females.
Decreased adiponectin levels in patients with FCH
142
and 2.8 (2.5 - 3.0), respectively) when comparing with male and female spouses (2.5 (2.2 - 2.8) 
and 3.2 (2.8 - 3.6), respectively) and borderline signiﬁcant when comparing with male and 
female normolipidemic relatives (2.3 (2.1 - 2.4) and 3.0 (2.8 - 3.2), respectively). When we used 
BMI or WHR as markers for adiposity, the results remained unchanged (data not shown).
It is known that adiponectin is even more related to whole body insulin sensitivity than to 
adiposity. Indeed, in our population, we observed a correlation of adiponectin with HOMA-
index of -0.34 for males and -0.31 for females; therefore, we adjested adiponectin levels not only 
for waist circumference but also for the HOMA-index. This did not change the point estimates 
of adiponectin (data not shown). Adiponectin levels in normolipidemic relatives and spouses 
did not diﬀer signiﬁcantly, therefore they were combined into one group and referred to as 
controls.
Adiponectin and the atherogenic lipid proﬁle
FCH patients were stratiﬁed by gender-speciﬁc tertiles of adiponectin levels, as presented in 
table 3. FCH patients with low adiponectin levels were more obese, as reﬂected by a higher waist 
circumference, and more insulin resistant, as reﬂected by an increased HOMA-index, compared 
with FCH patients with intermediate or high adiponectin levels. Furthermore, low adiponectin 
levels in FCH patients were associated with an atherogenic lipid proﬁle characterized by higher 
triglyceride levels, low HDLc levels, and the presence of sdLDL. No relationships between 
adiponectin and total cholesterol, LDLc and apoB levels were found. Similar associations of 
adiponectin levels with obesity, insulin resistance and the atherogenic lipid proﬁle were found in 
controls (data not shown). 
Multivariate regression analyses showed that, in the total study population, gender, waist 
circumference, and HOMA-index could explain only 20% of the variation in adiponectin levels. 
Table 3     Obesity, insulin resistance, and lipid parameters in patients with FCH stratiﬁed by 
                 gender-speciﬁc tertiles of adiponectin levels.
Characteristics
First tertile 
(0 - 1.9 ng/mL)
Second tertile
(1.9 - 2.6 ng/mL)
Third tertile
(2.6 - ∞ ng/mL))
waist  (cm) 91.4 (88.0 - 94.9) * † 86.5 (83.0 - 89.9) 84.3 (80.8 - 87.6)
HOMA-index 3.9 (3.3 - 4.5) * † 2.9 (2.5 - 3.1) ‡ 2.3 (2.0 - 2.7)
TG (mmol/L) 3.2 (2.9 -3.6) * † 2.7 (2.5 - 3.1) 2.4 (2.2 - 2.7)
HDLc (mmol/L) 0.93 (0.86 - 1.00) † 0.96 (0.89 - 1.03) 1.03 (0.95 - 1.10)
K-value -0.33 (-0.41 - -0.26) † -0.24 (-0.31 - -0.16) -0.19 (-0.26 - -0.12)
TC (mmol/L) 6.5 (6.2 - 6.8) 6.4 (6.1 - 6.8) 6.5 (6.2 - 6.8)
LDLc (mmol/L) 4.07 (3.73 - 4.41) 4.18 (3.82 - 4.52) 4.31 (3.96 - 4.66)
ApoB (mg/L) 1378 (1304 - 1452) 1383 (1307 - 1459) 1358 (1284 - 1432)
Values shown are means and (95% conﬁdence intervals) except as indicated; HOMA-index and TG data are 
presented as geometric means (95% conﬁdence intervals); Waist, waist circumference; TG, triglycerides, K-
value, a value ≤ -0.1 represents the presence of sdLDL; TC, total cholesterol; LDLc, low-density lipoprotein 
cholesterol; ApoB, apolipoprotein B; *, p-value < 0.05, compared to second tertile; †, p-value < 0.05, 
compared to third tertile; ‡, p-value < 0.05, compared to third tertile.
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Expanding the model with age and smoking led to a further 4% of variation that was explained. 
A maximum of 30% of the variation in adiponectin levels could be explained when HDLc and 
K-value were also added to the model.
In table 4, the results of regression models are presented, including adiponectin, HOMA-
index and waist circumference, as predictors of the atherogenic lipid proﬁle, independent of each 
other and adjusted for age and gender. Among FCH patients, a reduction in serum adiponectin 
level was associated with a signiﬁcant increase in triglyceride levels, a decrease in HDLc level, 
and a decrease in the K-value (Table 4). A model-based reduction of 25% in serum adiponectin 
level resulted in a 6.2% increase in triglyceride level, a 3.7% decrease in HDLc level and a 0.06 
decrease in absolute value of parameter K, reﬂecting the presence of more sdLDL. An increase in 
waist circumference was also associated with a signiﬁcant increase in triglyceride level, a decrease 
in HDLc level, and a decreased K-value, indicating the presence of sdLDL. A model-based 
increase of 5% in waist circumference was associated with an increase in triglyceride level of 
3.2%, a decrease of 1.7% in HDLc level and 0.02 decrease in the absolute value of parameter K. 
A change in HOMA-index was not associated with an independent change in any of these lipid 
parameters (Table 4). The results found in the control group were comparable to those found in 
patients with FCH (Table 4). A signiﬁcant eﬀect for the HOMA-index on triglyceride level and 
K-value was only found in the controls.
 
Table 4     Adiponectin levels, HOMA-index, and waist circumference as predictors of the 
                 atherogenic lipid proﬁle in patients with FCH and controls.
Variable Predictor            FCH patients ß       Controls ß
TG (mmol/L) Adiponectin -0.219 * -0.114 *
Waist circumference 0.222 * 0.185 *
HOMA-index -0.066 0.167 *
HDLc (mmol/L) Adiponectin 0.222 * 0.273 *
Waist circumference -0.197 * -0.260 *
HOMA-index 0.081 0.050
K-value Adiponectin 0.329 * 0.129 *
Waist circumference -0.173 * -0.129 *
HOMA-index 0.124 -0.098 *
Values shown are standardized ß coeﬃcients of 1 SD change in adiponectin levels (ng/mL) (log-transformed), 
waist circumference (cm), and HOMA-index (log-transformed) independent of age and gender; TG, 
triglycerides; HDLc, high-density lipoprotein cholesterol; K-value, a value ≤ -0.1 represents the presence of 
sdLDL; *, p-value < 0.05.
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Discussion 
In this study, we show that patients with FCH have low serum levels of adiponectin, even after 
adjusting for their body adiposity and degree of insulin resistance. Furthermore, we show that the 
adiponectin level in patients with FCH is the strongest independent predictor of the atherogenic 
lipid proﬁle, including high triglyceride level, low HDLc level and the presence of sdLDL. 
Several metabolic pathways have been proposed to explain the dyslipidemia in FCH, including 
an increased production of VLDL, with or without impaired clearance of triglyceride-rich 
lipoproteins 97. The increased production of VLDL may be attributable to increased hepatic lipid 
supply and availability, associated with obesity 350, and to the intrinsic eﬀects of insulin resistance 
on the hepatic output of VLDL and catabolism of VLDL in peripheral tissue 97. Therefore, 
both obesity and insulin resistance are suggested to be involved in the cause of dyslipidemia of 
FCH. Recently, a defect in adipose tissue metabolism was proposed as the primary cause of this 
increased production of VLDL in FCH 97. Our ﬁnding that low adiponectin levels contribute to 
the atherogenic lipid proﬁle in FCH, independent of insulin resistance and obesity, as measured 
by waist circumference, supports the hypothesis of a role for a disturbed adipose tissue metabolism 
in the pathophysiology of FCH.
Adiponectin is one of the major adipokines produced by adipose tissue. There is a growing 
body of evidence that adiponectin is involved in the regulation of both lipid and carbohydrate 
metabolism. Chan et al. 337 showed that adiponectin exerts an independent role in regulating 
triglyceride-rich lipoproteins in healthy men. In fact, the mechanism that may underlie the 
association between serum adiponectin levels and dyslipidemia was recently investigated, and 
adiponectin was shown to be an independent predictor of VLDLapoB catabolism 342. We 
now show for the ﬁrst time that adiponectin level is decreased in patients with FCH and that 
low adiponectin levels in FCH, as in non-FCH populations 111, 336-341, are associated with the 
atherogenic lipid proﬁle, including high levels of triglycerides, low levels of HDLc, and the 
presence of sdLDL. Obesity and insulin resistance, both characteristic independent features of 
FCH 344, are also known to be associated with the atherogenic lipid proﬁle. Most importantly, 
we now demonstrate that in FCH, adiponectin is a superior independent predictor of the 
atherogenic lipid proﬁle compared with obesity and insulin resistance. Assuming a 3 to 4 kg 
increase in bodyweight, adiponectin levels will decrease by ~25% 348 and waist circumference will 
increase by ~5% 346, 347. This model-based 25% decrease in adiponectin levels resulted in a 2-fold 
higher increase in triglyceride levels, a 2-fold higher decrease in HDLc levels, and a 3-fold higher 
decrease in K-value with a 5% increase in waist circumference. In contrast, insulin resistance 
was not associated with a signiﬁcant change in these lipid parameters. Therefore, adiponectin 
has a greater impact on the expression of the atherogenic lipid proﬁle than obesity and insulin 
resistance. Recently, the increase in adiponectin after weight loss was found to be correlated with 
serum lipid improvement, independently of insulin sensitivity changes 336. These results support 
the role of adiponectin in the lipid phenotype expression of FCH. 
Adiponectin levels are linked to triglyceride, HDLc and sdLDL levels, but they do not relate 
to plasma apoB levels, a characteristic feature of FCH. We propose that the lack of association 
of adiponectin with apoB supports the concept of a separate, but additive, genetic origin of high 
apoB levels in patients with FCH 344. FCH is a multifactorial disease in which the phenotype 
develops over a lifetime. The most common expression of FCH in children involves high 
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apoB levels 220, 351, 352. Therefore, a primary (genetic) defect in FCH results in the hyper-apoB 
phenotype, supported by segregation and linkage analyses providing evidence of a major gene 
inﬂuencing apoB levels 18. The fact that the lipid phenotype of FCH is not fully expressed until 
the third decade of life is possibly associated with the accumulation of central abdominal fat, 
resulting from changes in adipocyte size and function with aging. Alternatively, as hypothesized 
by Cnop et al. 111, low adiponectin levels result in hepatic insulin resistance, and this, together 
with increased plasma nonesteriﬁed fatty acid concentrations, will shift the fate of apoB away 
from degradation towards secretion by the liver, resulting in increased triglyceride levels. 
FCH patients are obese, and with this increased body adiposity, large triglyceride-ﬁlled visceral 
adipocytes produce less adiponectin 250, yet the low adiponectin levels in patients with FCH are 
not completely attributable to the degree of insulin resistance or the degree of obesity, as measured 
by waist circumference. Even though waist circumference is the best simple anthropometric 
predictor of abdominal visceral fat mass, we cannot exclude the possibility that the apparent 
independence of adiponectin levels may be attributable to the fact that intra-abdominal fat was 
not measured with a more sophisticated technique. However; an intrinsic defect in the adipocytes 
may also contribute to this hypoadiponectinemia in patients with FCH. To further explore the 
decreased adiponectin levels in patients with FCH, expression studies of adiponectin in adipose 
tissue should be performed in patients with FCH. Lihn et al. 353 showed that adiponectin mRNA 
expression in both visceral and subcutaneous adipose tissue is 6-fold higher in lean individuals 
compared to obese individuals. Studying expression levels of adiponectin in adipose tissue of 
patients with FCH can contribute to unravel the cause of the decreased adiponectin levels in 
these patients that are unexplained by their adiposity and state of insulin resistance. 
Furthermore, we demonstrate in our FCH population that body adiposity, insulin sensitivity, 
HDLc, the presence of sdLDL, smoking and age explained only 30% of the variation in 
adiponectin levels. Therefore, other factors must contribute to the variation in adiponectin levels. 
Recent analyses in a predominantly northern European population suggested that variation 
in serum adiponectin levels had a strong genetic component (heritability estimate = 46%) 
and adiponectin concentrations were signiﬁcantly linked (logarithm of the odds  = 4.1) to a 
quantitative trait locus on chromosome 5p 354. Possibly, a large part of the remaining 70% of the 
variation in adiponectin levels in FCH could also be explained by a genetic component, which 
requires further research. 
In summary, adiponectin levels are decreased in patients with FCH, independent of their 
insulin resistance and body adiposity, as measured by waist circumference. Furthermore, low 
adiponectin level in FCH predicts the presence of the atherogenic lipid proﬁle. Our results 
support the concept of a disturbed adipose tissue metabolism in the pathophysiology of FCH.
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Abstract
Background Familial combined hyperlipidemia (FCH) is the most common genetic lipid 
disorder, characterized by elevated lipid and apolipoprotein levels. It is hypothesized that a 
disturbed adipose tissue metabolism plays an important role in the pathophysiology of FCH. 
Recently, we have shown that patients with FCH have decreased levels of adiponectin, one of 
the major adipokines produced by adipose tissue. The aim of the present study was to investigate 
the association of two variants in the ApM1 gene, encoding for adiponectin, with adiponectin 
levels and dyslipidemia in FCH patients. Methods The study population included 36 Dutch 
FCH families, including 157 FCH patients. Two polymorphisms in the ApM1 gene (45T>G 
and 639C>T) were genotyped with PCR-RFLP. The FBAT program was used to analyse the 
polymorphisms and their haplotypes. Results Variants in the ApM1 gene were not associated 
with FCH. The variants in the ApM1 gene were, however, associated with adiponectin levels, 
resulting in 19% lower adiponectin levels in FCH patients carrying the 45T allele. Subjects 
carrying the 639T allele presented a more atherogenic lipid proﬁle. Conclusions The association 
of the ApM1 gene with decreased adiponectin levels and an atherogenic lipid proﬁle was not 
speciﬁc for FCH. We did not ﬁnd any indication that genetic variations in the ApM1 gene are 
associated with FCH.
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Introduction
Familial combined hyperlipidemia (FCH, OMIM-144250) is the most common genetic 
lipid disorder, aﬀecting up to 5% of the general population 10. FCH is strongly associated 
with premature cardiovascular disease (CVD) and among survivors of a premature myocardial 
infarction, up to 20% is aﬀected with FCH 4. Major characteristics of FCH include elevated 
levels of apolipoprotein B (apoB), triglycerides (TG) and/or plasma total cholesterol (TC). 
Other FCH phenotypes are decreased levels of high-density lipoprotein cholesterol (HDLc), 
the presence of small, dense low-density lipoprotein (sdLDL), obesity and insulin resistance 97. 
Despite more than 30 years of research, the etiology of FCH is still not fully understood. Several 
metabolic defects have been proposed to underlie the disturbed lipid proﬁle, including a defect 
in adipose tissue metabolism 96, 97. 
Adiponectin is one of the major adipokines derived from the adipose tissue and is abundantly 
present in human plasma. The production of adiponectin is inversely correlated with adipose 
tissue mass 107. Adiponectin stimulates the oxidation of fatty acids, improves the glucose 
metabolism and inhibits the inﬂammatory process and thereby, possibly atherosclerosis 107, 109, 
110. Decreased adiponectin levels were previously found in subjects with obesity, type 2 diabetes 
mellitus and CVD 109, 112, 331-334. Based on this, adiponectin is suggested to play an important role 
in the pathophysiology of FCH 355.
We have recently shown that adiponectin levels are signiﬁcantly lower in patients with FCH, 
independent of their obesity and insulin resistance status 355. These low adiponectin levels were 
found to be an independent predictor of the atherogenic lipid proﬁle in FCH, including high 
triglyceride levels, low HDLc levels and the presence of sdLDL. 
The gene encoding for adiponectin is the adipose most abundant gene transcript 1 (ApM1) 
gene, located on chromosome 3q27. In total, 87 single nucleotide polymorphisms (SNPs) in 
this gene can be found the NCBI SNP database. SNPs in the ApM1 gene are found to be 
associated with decreased adiponectin levels, although results are conﬂicting as recently reviewed 
by Gable et al. 356. Associations of SNPs in the ApM1 gene with type 2 diabetes, insulin resistance, 
hypertension, CVD, obesitas and hyperlipidemia have also been reported 356-358.
The aim of the present study was to investigate the role of genetic variations in the ApM1 gene in 
determining adiponectin levels in patients with FCH. For this purpose, we sequenced the ApM1 
gene in 18 FCH patients and determined two common variants. Furthermore, the association of 
these two variants in the ApM1 gene with FCH and its associated phenotypes, including obesity, 
insulin resistance and increased risk of CVD, reﬂected by intima-media thickness (IMT) values 
and prevalence of CVD, were studied in our well-characterized Dutch FCH families, using a 
family-based SNP and haplotype approach. 
Methods
Study population
The study population consists of 36 families, comprising 611 subjects with known genealogic, 
phenotypic, and genotypic data, of whom 157 individuals were diagnosed as FCH patients 17. 
These families had a mean size of 24 members from multiple (between 2 and 4) generations. The 
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diagnosis of FCH was based on the nomogram, as recently published 17. The normolipidemic 
relatives (n = 390), unaﬀected spouses of both the FCH patients and the normolipidemic relatives 
(n = 64) and subjects without known phenotypic and genotypic data (n = 230) were included for 
the family-based analyses. After withdrawal of lipid-lowering medication for four weeks and an 
overnight fast, blood was drawn by venipuncture. The maximum waist circumference (cm) at the 
umbilical level was measured in the late exhalation phase while standing. 
Information concerning CVD was gathered through personal interviews and physical 
examinations performed by the clinical investigator. When the clinical investigator suspected 
the presence of CVD, further details and conﬁrmation of the diagnosis were sought from the 
participant’s general practitioner and hospital records. CVD was deﬁned by angina pectoris 
(AP), myocardial infarction (MI), stroke, peripheral vascular disease or vascular surgery. In our 
study population 56 subjects were identiﬁed with CVD, including 26 subjects with AP, 25 with 
previous MI, 10 with peripheral vascular disease, seven with stroke and 23 who underwent 
vascular surgery. In total, 45% (n = 25) of these individuals were diagnosed with CVD based on 
the presence of two or more manifestations of CVD. 
The ethical committee of the Radboud University Nijmegen Medical Centre approved the 
study protocol and the followed procedures were in accordance with institutional guidelines. All 
subjects gave written informed consent.
Biochemical analyses
Biochemical analyses were performed as previously described for this population 17. In short, 
plasma TC and TG were determined by enzymatic, commercially available reagents (Boehringer-
Mannheim, Germany, catalog No. 237574 and Sera Pak, Miles, Belgium, catalog No. 6639, 
respectively). Total plasma apoB concentrations were measured by immunonephelometry. HDLc 
was quantiﬁed by the polyethylene glycol 6000 method. LDL subfractions were separated by 
single spin density gradient ultracentrifugation. A continuous variable, K, represents the LDL 
subfraction proﬁle of each individual. A negative K-value (K ≤ -0.1) reﬂects a more dense LDL 
subfraction proﬁle, and a positive K-value (K > -0.1) reﬂects a more buoyant proﬁle. Glucose 
concentrations were analyzed, using the oxidation technique (Beckman®, Glucose Analyser2, 
Beckman Instruments Inc., Fullerton, CA 92634, USA). Plasma insulin concentrations were 
ascertained by a double antibody method. Insulin resistance was assessed by the homeostasis 
model assessment (HOMA) method. Adiponectin levels were measured in duplicate using a 
commercially available enzyme-linked immunosorbent assay (R&D Systems, Minneapolis: Elisa 
Development System; Human adiponectin/Acrp30 Duoset®, Catalog no. DY1065) 355. 
Carotid intima-media thickness measurements
Carotid intima-media thickness (IMT) was measured in 61 FCH patients and 155 
normolipidemic relatives who visited our outpatient clinic 200. An AU5 Ultrasound machine 
(Esaote Biomedica) with a 7.5 MHz linear-array transducer was used to measure the IMT of 
both common carotid arteries. Longitudinal images of the most distal 10 mm of both the far 
wall and the near wall of the common carotid artery were obtained in the optimal projection 
(anterolateral, lateral or posterolateral). The actual measurement of IMT was performed oﬄine 
by the sonographer using semi-automatic edge-detection software (M’Ath®Std version 2.0, 
Metris, Argenteuil, France) 201. All measurements were carried out in end-diastole using the 
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R-wave of a simultaneously recorded ECG as a reference frame. From each frame the mean IMT 
was calculated over at least 7.5 mm of the aforementioned 10 mm segment (yielding a minimum 
quality index of 75%). The outcome variable was deﬁned as the mean IMT of the near and far 
wall of both common carotid arteries.
Sequencing and genotyping of the ApM1 gene
DNA was extracted from peripheral blood lymphocytes using a standard technique 121. All 
exons and intron 2 of the ApM1 gene were ampliﬁed in 6 fragments by standard polymerase 
chain reaction (PCR) with an annealing temperature of 53.7 °C 149. The primer sequences, 
locations and product sizes of the 6 fragments are listed in table 1. The PCR products were 
column-puriﬁed using Roche High Pure PCR puriﬁcation kits (Roche Applied Science, 
Mannheim, Germany), and bi-directional sequencing analysis was performed on an ABI Prism 
3100 Genetic analyzer using the ABI Prism BigDye Terminator version 3 chemical sequencing 
kit according to the instructions of the manufacturer (PE Applied Biosystems, Nieuwerkerk 
a/d Yssel, The Netherlands). The sequences were aligned with the reference sequence to detect 
sequence variants. We selected 18 well-deﬁned unrelated FCH patients to sequence the ApM1 
gene. Anthropometric and metabolic characteristics of these 18 FCH patients are presented in 
table 2.
Genotyping of the 45T>G SNP (rs2241766) and the 639C>T SNP (rs3821799) were carried 
in a ﬁnal volume of 50 µl. Primerset 2 was used for the 45T>G SNP and primerset 4 was used 
for the 639C>T SNP. The PCR products were digested by either 10 U SmaI at 25°C (45T>G) or 
10 U BstEII at 60°C (639C>T) (New England Biolabs, Beverly, MA, USA) and, subsequently, 
the resulting fragments (369, 216 and 153 bp in heterozygotes for 45T>G or 473, 405 and 68 
Table 1     Primersets used for sequencing of ApM1.
Primer sequence (5' > 3') Position primer * (#bp) Product size (bp)
1  F GAAGTTTCTCCGTCAGATGC 493 - 512 422
1  R CAGCCTGGAACTTCACAGAA 895 - 914
2  F GAAGTAGACTCTGCTGAGATGG 1231 - 1252 369
2  R CAGTGTAGGAGGTCTGTGATG 1578 - 1601
3  F GTGATGGCAGAGATGGCAC 172 - 190 475
3  R GTAACCACCAACAGAGCCTTG 626 - 646
4  F GGCTCAGTCCTGCCTTTGG 574 - 592 474
4  R CCACTCACAACCTTCTTGAC 1028 - 1047
5  F GTGGGAGATATAGAAGGAGG 957 - 976 452
5  R GTGGTAGGCAAAGTAGTACAG 1388 - 1408
6  F CACTATGATGGCTCCACTG 1343 - 1361 501
6  R CAGGACTGGGAACATAGCAT 1824 - 1843
* According to GenBank Accession number AB012163S1 (exon 1), AB012163S2 (exon 2) and NT_
005962 (intron 2 and exon 3).
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bp in heterozygotes for 639C>T) were separated on agarose gels. The genotyping of the 45T>G 
and the 639C>T SNPs was successful in all individuals.
Statistical analyses
The characteristics of the study population are expressed as mean ± standard deviation (SD). 
Prior to further statistical analyses, extended Mendelian error-checking was performed with 
Pedcheck 122. For families with Mendelian inconsistencies, problematic genotypes were set 
to missing for the complete nuclear family or the isolated problematic individual (2%). The 
parental data for both SNPs were tested for Hardy-Weinberg equilibrium by use of a ﬁsher’s 
exact-test. Variables with a skewed distribution, including triglyceride levels, adiponectin levels, 
and the HOMA-index, were logarithmically transformed. Nonparametric linkage analysis of the 
ApM1 polymorphisms were carried out using the SOLAR 2.1.4 software 123. The presence of 
linkage was tested for FCH and the related phenotypes, including apoB, TC and TG levels and 
the presence of sdLDL, represented by the K-value. The HAPLOVIEW program 178 was used to 
estimate allele and haplotype frequencies, linkage disequilibrium and allelic association between 
the two SNPs. 
Table 2     Characteristics of patients with familial combined hyperlipidemia,
                 in whom the ApM1 gene was sequenced
FCH patients (n = 18)
Gender (males) 10 (55.6%)
Age (years) 58.7 (10.0)
Cardiovascular disease (n (%)) 8 (44.4%)
IMT (mm) 0.84 (0.13)
Waist circumference (cm) 87.1 (13.1)
Total cholesterol (mmol/L) 7.2 (0.58)
Triglycerides (mmol/L) 3.6 (1.4)
Apolipoprotein B (mg/L) 1561 (90)
LDLc (mmol/L) 4.4 (0.7)
HDLc (mmol/L) 0.96 (0.20)
K-value -0.40 (0.19)
HOMA-index 4.6 (2.8)
Adiponectin males (ng/mL) 1.9 (0.6)
Adiponectin females (ng/mL) 2.6 (1.5)
Bivariate variables are presented as number (%); continuous variables are presented 
as mean (SD); FCH, familial combined hyperlipidemia; IMT, mean common 
carotid intima-media thickness was measured in 7 FCH patients; LDLc, low-density 
lipoprotein cholesterol; HDLc, high-density lipoprotein cholesterol; K-value, a value 
≤ -0.1 represents the presence of small dense LDL; HOMA-index, homeostasis model 
assessment-index.
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Associations between the individual polymorphisms, 45T>G and 639C>T, or haplotypes with 
adiponectin levels, FCH and the related phenotypes, in our extended families were determined 
using the family-based association test (FBAT) software 179. An additive model of inheritance 
was used, as the mode of inheritance of FCH is unknown and this model is particularly robust. 
FBAT broke down the extended pedigrees into nuclear families (n = 219) and evaluated their 
contribution to the test statistics. The –e option of FBAT, which computes the test statistic using 
an empirical variance estimator, was implemented as the nuclear families were not independent. 
The –p option, which performs the Monte-Carlo permutation procedure, was used to correct 
for multiple testing. Adjustments for age and gender were done by calculation of the residuals. 
For the haplotype analysis, the haplotype-based association test (HBAT) command of the 
FBAT program was used, utilizing the –e and –p options. Generalized estimating equations 
(GEE) analyses were used to test diﬀerences between the diﬀerent genotypes for parameters 
standardized for age and gender. The subjects carrying wildtype alleles for both SNPs are referred 
to as 'wildtype individuals' while controls carrying a rare allele for both SNPs, are referred to as 
'compound individuals'. Diﬀerences were considered statistically signiﬁcant at p-value < 0.05. 
Table 3     Characteristics of patients with familial combined hyperlipidemia, normolipidemic 
                 relatives and spouses
FCH patients 
(n = 157)
NL relatives 
(n = 390)
Spouses 
(n = 64)
Gender (males) 75 (47.8 %) 177 (45.4 %) 31 (48.4 %)
Age (years) 47.0 (15.6) * † 37.9 (15.7) ‡ 56.0 (10.5)
CVD 32 (20.4 %) * † 20 (5.1 %) 4 (6.3 %)
IMT (mm) 0.80 (0.12) * 0.72 (0.12) -
Waist (cm) 87.2 (12.2) * 77.7 (10.9) ‡ 84.3 (12.5)
Total cholesterol (mmol/L) 6.5 (1.1) * † 4.9 (0.9) ‡ 5.2 (0.8)
Triglycerides (mmol/L) 3.1 (1.5) * † 1.2 (0.5) 1.3 (0.6)
Apolipoprotein B (mg/L) 1370 (264) * † 960 (220) 996 (175)
LDLc (mmol/L) 4.1 (1.2) * † 3.2 (0.9) ‡ 3.4 (0.7)
HDLc (mmol/L) 0.98 (0.26) * † 1.22 (0.30) 1.28 (0.40)
K-value -0.26 (0.26) * † 0.05 (0.19) 0.05 (0.25)
HOMA-index 3.4 (1.8) * † 2.3 (1.3) ‡ 2.7 (1.3)
Adiponectin males (ng/mL) 2.1 (0.9) * † 2.5 (0.9) ‡ 2.9 (1.3)
Adiponectin females (ng/mL) 2.7 (1.2) * † 3.3 (1.3) 3.4 (1.7)
Bivariate variables are presented as number (%); continuous variables are presented as mean (SD); 
FCH, familial combined hyperlipidemia; NL relatives, normolipidemic relatives; CVD, cardiovascular 
disease; IMT, mean common artery intima-media thickness was measured in 61 FCH patients and 155 
normolipidemic relatives; waist, waist circumference; LDLc, low-density lipoprotein cholesterol; HDLc, high-
density lipoprotein cholesterol; K-value, a value ≤ -0.1 represents the presence of small dense LDL; HOMA-
index, homeostasis model assessment-index; *, p-value < 0.05, compared to normolipidemic relatives; †, 
p-value < 0.05, compared to spouses; ‡, p-value < 0.05, compared to spouses.
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All above described analyses were computed using the SPSS 12.0.1, PedCheck 1.1, SOLAR 
2.1.4, HAPLOVIEW 3.2, FBAT 3.2 software and STATA 8.0. 
Results
Characteristics of the study population
Anthropometric and metabolic characteristics of FCH patients, normolipidemic relatives and 
spouses are presented in table 3. The FCH patients were older than the normolipidemic relatives, 
but younger than the spouses. FCH patients had a thicker IMT and a higher prevalence of CVD. 
FCH patients were characterized by a disturbed lipid proﬁle, including increased levels of TC, 
TG, apoB and LDLc levels and decreased HDLc levels. Furthermore, the presence of sdLDL, 
as reﬂected by a K-value ≤ -0.1, is also speciﬁc for patients with FCH. FCH patients were more 
obese, as reﬂected by a higher waist circumference and more insulin resistant, as reﬂected by a 
higher HOMA-index. Serum adiponectin levels, in both males and females, were signiﬁcantly 
lower in FCH patients compared to normolipidemic relatives and spouses (Table 3). 
Sequencing of variants in the ApM1 gene and linkage analyses
Sequencing all exons and intron 2 of the ApM1 gene in 18 unrelated FCH patients did not 
result in the identiﬁcation of new SNPs. Based on linkage disequilibrium (LD) between SNPs 
and previously reported associations 357, two SNPs, the 45T>G and the 639C>T, were selected 
for haplotype analyses of the ApM1 gene. 
In founders, minor allele frequencies for the 45T>G and 639C>T SNPs were 0.14 and 0.40, 
respectively. For both SNPs, the genotypic distributions were in Hardy-Weinberg proportions. 
Strong linkage disequilibrium (D’ = 0.83) with little correlation between the loci (R2 = 0.12) 
was present between the two SNPs. The wildtype haplotype (TC) had a frequency of 0.58. The 
frequencies of the haplotypes deﬁned by a 45T>G rare allele (GC), a 639C>T rare allele (TT) or 
a rare allele for both SNPs (GT) were 0.01, 0.31 and 0.10, respectively. The GC haplotype was 
not taken into account for the statistical analyses, because of the low frequency.
Linkage analyses of the two SNPs in the ApM1 gene did not show evidence for linkage with 
adiponectin levels (lod score = 0.0), the diagnosis of FCH (lod score = 0.0) or with any of the 
related phenotypes, including apoB, TC and TG levels and the presence of sdLDL (all two-point 
lod scores < 0.5). 
Haplotype analyses of the ApM1 gene and adiponectin levels
Family-based association analyses of the individual SNPs in the ApM1 gene did not result in a 
signiﬁcant association with adiponectin levels. When performing haplotype analyses, however, a 
signiﬁcant (p = 0.049) association with the wildtype haplotype (TC) was present (Table 4). 
The normolipidemic relatives and spouses were combined into one control group, as no 
diﬀerences in anthropometric and biochemical parameters, based on genotypes, were observed 
between the two groups (data not shown). As shown in table 5 for this combined control group, 
the lowest adiponectin levels were found in wildtype individuals (2.65 ng/ml) and individuals 
carrying only a rare allele of the 639C>T SNP (2.64 ng/ml). Compound individuals, carrying the 
rare allele for both SNPs, presented the highest adiponectin levels (2.90 ng/ml). So, adiponectin 
levels were approximately 9% lower, when a wildtype allele for the 45T>G SNP was present 
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(p = 0.042). In patients with FCH carrying a wildtype allele for both SNPs or a rare allele for 
the 639C>T SNP, mean adiponectin levels (ng/ml) were approximately 19% lower compared 
to compound individuals (2.08 [95% CI: 1.84 – 2.36] and 2.10 [95% CI: 1.86 – 2.36] versus 
2.59 [95% CI: 2.26 – 2.97]; p-values < 0.05). The decrease in adiponectin levels for the 
individuals with a wildtype allele for the 45T>G allele was not signiﬁcantly diﬀerent in FCH 
patients compared to the controls (p = 0.196). 
In our FCH population, 30% of the variation in adiponectin levels is explained by waist 
circumference, HOMA-index, HDLc, the presence of small dense LDL, smoking and age 355. In 
addition to these factors, the 45T>G SNP only explained 1.1% of the variation in adiponectin 
levels in our complete study population (p = 0.006).
The ApM1 gene and related phenotypes of FCH
Single SNP analyses for the related phenotypes of FCH resulted in a signiﬁcant association 
of the 639C>T SNP with apoB (p = 0.048) and HDLc levels (p = 0.049) (Table 4). Haplotype 
analyses showed that these associations were due to undertransmission of the wildtype 
haplotype (TC) to subjects with high apoB levels (p = 0.014) and to subjects with low HDLc 
levels               (p = 0.047). As presented in table 5,  this resulted, in normolipidemic relatives and 
Table 4     Association of the individual SNPs and haplotypes of the ApM1 gene with familial
                combined hyperlipidemia and its related phenotypes after correction for age and gender.
SNPs Haplotypes
N 45T>G 639C>T TC TT GT
Adiponectin * 611 0.749 0.126 0.049 0.135 0.384
FCH 611 0.098 0.243 0.170 0.783 0.136
CVD 611 0.459 0.504 0.574 0.679 0.570
IMT 216 0.086 0.526 0.587 0.089 0.212
Waist circumference 611 0.921 0.636 0.885 0.515 0.554
Total cholesterol 611 0.389 0.129 0.058 0.199 0.376
Triglycerides * 611 0.055 0.186 0.193 0.858 0.087
ApolipoproteinB 611 0.138 0.048 0.014 0.130 0.233
LDLc 608 0.483 0.111 0.048 0.163 0.397
HDLc 609 0.155 0.049 0.047 0.251 0.263
K-value 611 0.361 0.115 0.142 0.263 0.353
HOMA-index * 550 0.633 0.598 0.388 0.796 0.501
P-values for the individual SNPs (FBAT) and haplotypes (HBAT) corrected for age, gender and multiple 
testing are presented; *, Ln-transformec variable; N, number of subjects with available data for the relevant 
phenotype; FCH, familial combined hyperlipidemia was present in 157 subjects; CVD, cardiovascular 
disease was present in 56 subjects; IMT, mean common carotid intima-media thickness; LDLc, low-density 
lipoprotein cholesterol; HDLc, high-density lipoprotein cholesterol; K-value, a value ≤ -0.1 represents the 
presence of small dense LDL; HOMA-index, homeostasis model assessment-index.
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spouses, in signiﬁcant higher apoB levels in subjects carrying only a rare allele for the 639C>T 
SNP (1008 mg/L; p = 0.003) and a trend towards higher apoB levels in compound individuals 
(994 mg/L; p = 0.055), compared to the wildtype indivuals (946 mg/L). The lowest HDLc levels 
were present in subjects carrying only a rare allele for the 639C>T allele (1.19 mmol/L), this 
was signiﬁcantly diﬀerent from levels found in wildtype individuals (1.25 mmol/L; p = 0.043). 
The HDLc levels in compound individuals (1.24 mml/L) did not diﬀer from the levels found in 
wildtype individuals (Table 5).
Single SNP analyses also showed a trend towards signiﬁcance for the 45T>G SNP with TG 
(p = 0.055), haplotype analyses showed that this was due to undertransmission of the haplotype 
with a rare allele for both SNPs (GT) (p = 0.087). In normolipidemic relatives and spouses, 
this resulted in high TG levels in subjects carrying a rare allele for only the 639C>T SNP 
(1.18 mmol/L) compared to wildtype individuals (1.07; p = 0.028) and compound individuals 
(1.08 mmol/L; p = 0.072).
Furthermore, haplotype analyses showed an association of the wildtype haplotype with LDLc 
(p = 0.048) and TC (p = 0.058) levels. The highest LDLc levels were found in compound 
individuals (3.40 mmol/L [95% CI: 3.24 – 3.56), which were borderline signiﬁcant diﬀerent 
from the levels found in wildtype individuals (3.22 [95% CI: 3.08 – 3.36]; p = 0.077). No 
signiﬁcant diﬀerence in TC levels was found between the diﬀerent genotypes (Table 4 and 5).
Table 5     Characteristics of the normolipidemic relatives and spouses according to the ApM1 
                 gene 45T>G and 639C>T SNPs.
Wildtypes
n = 137 
(30.2%)
Rare allele 639C>T
n = 207
(45.6%)
Compounds
n = 104
(22.9%)
Adiponectin (ng/mL) * 2.65 (2.45 - 2.86) 2.64 (2.47 - 2.82) † 2.90 (2.66 - 3.16) §
CVD (n (%)) 6 (4.4%) 13 (6.3%) 4 (3.8%)
IMT (mm) 0.75 (0.72 - 0.77) 0.73 (0.71 - 0.75) 0.73 (0.71 - 0.76)
Total cholesterol (mmol/L) 4.91 (4.76 - 5.07) 5.03 (4.89 - 5.16) 5.07 (4.89 - 5.24)
Triglycerides (mmol/L) 1.07 (0.99 - 1.16) 1.18 (1.11 - 1.27 ) † ‡ 1.08 (1.01 - 1.15) §
Apolipoprotein B (mg/L) 946 (912 - 980) 1008 (979 - 1036) 994 (955 - 1033) §
LDLc (mmol/L) 3.22 (3.08 - 3.36) 3.33 (3.21 - 3.45) 3.40 (3.24 - 3.56)
HDLc (mmol/L) 1.25 (1.20 - 1.31) 1.19 (1.14 - 1.23) † 1.24 (1.18 - 1.30)
K-value ≤ -0.1 (n (%)) 53 (28.3%) 96 (35.6%) 56 (38.1%)
Bivariate variables are presented as number (%) and the continuous variables, standardized for age and 
gender, are presented as mean (95% conﬁdence interval); *, Ln-transformed variable; Wildtypes, subjects 
carrying only the common allele for both SNPs; Rare allele 639C>T; subjects carrying either 1 or 2 rare 
alleles for the 639C>T SNP; Compounds, subjects carrying a rare allele for both SNPs; CVD, cardiovascular 
disease; IMT, mean common carotid intima-media thickness; LDLc, low-density lipoprotein cholesterol; 
HDLc, high-density lipoprotein cholesterol; K-value ≤ -0.1 represents the presence of small dense LDL; †, 
p-value < 0.05, compared to wildtypes; ‡, p-value < 0.10, compared to compounds; §, p-value < 0.10, 
compared wildtypes.
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No associations were found for any of the other investigated lipid (K-value), obesity (waist 
circumference) or insulin resistance (HOMA-index) parameters (Table 4 and 5). Taking the 
non-independence of the families and the possible presence of linkage (-e option) into account, 
yielded in comparable results (data not shown). 
ApM1 gene in relation to FCH and CVD
The 45T>G SNP showed a trend towards an association with FCH (p = 0.098). The 639C>T 
SNP was not associated with FCH (p = 0.243). The possible association of the 45T>G SNP 
disappeared when performing haplotype analyses and did not result in a signiﬁcant increased risk 
of FCH, when carrying this allele (Table 4). 
For the 45T>G SNP we found a non-signiﬁcant trend towards an association with IMT values 
(p = 0.086), resulting from an overtransmission of the T allele to subjects with high IMT values. 
No diﬀerences in IMT values or prevalence in CVD were, however, found for carriers of the 
diﬀerent genotypes (Table 5). 
Discussion 
In the present study we show that variants in the ApM1 gene contribute to low adiponectin 
levels in patients with FCH. Adiponectin levels were 19% lower in FCH patients carrying the 
45T allele. The eﬀect of the ApM1 gene on adiponectin levels, was, however, not speciﬁc for 
FCH, as in normolipidemic relatives and spouses adiponectin levels were approximately 9% 
lower in carriers of the 45 T allele.
Initially we sequenced the ApM1 gene in 18 FCH patients in search for new variants. The 
ApM1 gene has previously been sequenced in several diﬀerent study populations, but not in FCH 
patients 358-362. Sequencing the ApM1 gene in FCH patients did not result in the identiﬁcation 
of new SNPs. 
The 45T>G SNP is one of the most common and widely studied SNPs of the ApM1 gene, 
however, reported associations for this SNP with adiponectin levels are controversial 356. In 
Caucasians, both alleles of the 45T>G SNP are reported to be associated with lower adiponectin 
levels 357, 358, 363, 364. The two largest studies, both in over 1,000 individuals, report that decreased 
adiponectin levels are associated with the wildtype T allele, which is in agreement with results of 
the present study 357, 358. 
For the other investigated SNP, the 639C>T, in the ApM1 gene, no association with 
adiponectin levels was found in our study of well-deﬁned FCH families. The 639C>T SNP 
has never been studied before, as it is in strong linkage disequilibrium (LD) with the 276G>T 
SNP and the 712G>A SNP 357. The results for these two SNPs are, however, conﬂicting as both 
alleles are reported to be associated with lower adiponectin levels 356. It is suggested that these 
conﬂicting results can be caused by the presence of another functional SNP for which these SNPs 
act as markers 356. We selected the 639C>T SNP for the haplotype analyses in our FCH study 
population. No association with adiponectin levels for either allele was found, so the results for 
the 639C>T SNP could not explain the conﬂicting results previously found for the 276G>T and 
the 712G>A SNPs.
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Despite the eﬀect of ApM1 gene on adiponectin levels, the ApM1 gene was not associated 
with FCH. This may be explained by the observation that variants in the ApM1 gene explain 
only 1.1% of the variation in adiponectin concentration. In the literature the combination of 8 
SNPs, including the 45T>G and the 276G>T SNPs, have been found to explain approximately 
8% of the variance of adiponectin levels 357. Patients with FCH have approximately 15 - 20% 
lower adiponectin concentrations than controls 355. Considering that this leaves a maximum of 
0.2% of the variation in the decreased adiponectin levels in FCH patients that can directly be 
explained by variants in the ApM1 gene, it is not surprising that we have missed a possible existing 
association. From this, and the fact that no association with FCH was found, we conclude that 
the ApM1 gene is not a candidate gene for FCH and there are other mechanisms contributing 
to the decreased adiponectin levels in patients with FCH. An intrinsic defect in the adipocytes, 
like the presence of more large triglyceride-ﬁlled adipocytes, can result in dysregulation of the 
secretion of adiponectin in patients with FCH 250.
Low adiponectin levels were recently found to be related with the atherogenic lipid proﬁle, 
including high levels of triglycerides, low levels of HDLc and the presence of small dense LDL, 
in our population of FCH patients 355. This association with an atherogenic lipid proﬁle has 
previously also been reported in other non-FCH study populations 111, 332, 336-339, 341. In the present 
study we show that variants in the ApM1 gene are also associated with a more atherogenic lipid 
proﬁle. The rare allele of the 639C>T SNP is associated with high apoB levels, high TG levels and 
decreased HDLc levels. The rare allele of the 45T>G SNP counteracts this eﬀect of the 639C>T 
SNP on TG and HDLc levels, resulting in normalized levels of TG and HDLc in compound 
individuals. However, in the present study, variants in the ApM1 gene explain, independent of 
age and gender, less than 1% of the variation in the atherogenic lipid proﬁle. So, the clinical 
relevance of these genetic variants on the atherogenic lipid proﬁle is low. A relation of variants in 
the ApM1 gene with a more atherogenic lipid proﬁle has previously been reported in other study 
populations 357, 365-367.
Despite the association with the atherogenic lipid proﬁle, no eﬀect of the ApM1 gene on 
IMT and CVD was found. Previously, decreased adiponectin levels were also not found to be 
associated with CVD in our population of FCH families 355. Although a negative association of 
adiponectin levels with IMT values has recently been reported, it was not supported by other 
studies 357, 368, 369. We now report that an association of variants in the ApM1 gene with IMT 
values or the prevalence of CVD is not present in our Dutch FCH families.
Linkage analyses performed with the variants in the ApM1 gene did not result in evidence 
of linkage for FCH or its related phenotypes. Previously, genome-wide linkage analyses did 
also not result in the identiﬁcation of a region on interest on chromosome 3q27, including 
the ApM1 gene. From the literature it is, however, known that linkage analyses have limited 
power to identify genes with moderate eﬀects for complex diseases 203, 370. Family-based SNP and 
haplotype association analyses, as performed in this study, have greater power to detect moderate 
eﬀects 203, 371, 372.
Limitations of the present study are the low number of subjects with CVD and the availability 
of IMT data in only a sub-set of the study population, resulting in limited power to fully exclude 
the relevance of the ApM1 gene in CVD and IMT values.
In summary, variants in the ApM1 gene were associated with decreased adiponectin levels 
and an atherogenic lipid proﬁle, in both FCH patients and healthy controls, but the clinical 
Chapter 11
signiﬁcance seems limited. Furthermore, no association was found with IMT values and the 
prevalence of CVD. So, we did not ﬁnd any indication that genetic variations in the ApM1 gene 
are associated with FCH.
Variations isn the ApM1 gene in patients with FCH
159

 
 
 Su
m
m
ary
Summary, 
discussion and 
future perspectives
162
Despite more than 30 years of research, the genetic and metabolic origin of familial combined 
hyperlipidemia is still not fully understood. The studies described in the present thesis contribute 
to the elucidation of the genetic basis and metabolic pathogenesis of FCH. In the ﬁrst part of 
the present thesis we have focused on the genetic origin of FCH (Chapter 1 – 5), and in the 
second part we have explored the role of adipose tissue in the metabolic origin of FCH (Chapter 
6 – 11).
Part 1: The genetic origin of familial combined hyperlipidemia
Linkage analyses
In chapter 1 we performed linkage analyses for two diﬀerent diagnostic criteria of FCH in our 
Nijmegen FCH study population. Genome-wide linkage analyses performed with the traditional 
diagnostic criteria, based on TC and/or TG above the age- and sex-related 90th percentile, did not 
result in the identiﬁcation of a chromosomal region of interest (lod score < 1.0). The nomogram, 
based on plasma TC and TG levels, adjusted for age and gender, and absolute apoB levels, was 
also used as a diagnostic criterion for FCH. This resulted in the identiﬁcation of two regions 
of interest (lod score > 1), on chromosome 6q25-27  (lod score = 1.30) and 12q23-24 (lod 
score = 1.02). Linkage analysis of two characteristic quantitative traits of FCH, including TG 
levels and sdLDL, supported chromosome 6q as potential loci for FCH (lodscore = 1.13 for 
sdLDL and lodscore = 1.92 for TG levels). Most interestingly, suggestive evidence of linkage 
for FCH on chromosome 6q has previously been reported in another Dutch FCH population 
31. Linkage analysis of the other quantitative traits of FCH showed four regions with suggestive 
evidence of linkage, including TG levels (10p14-q21 (lod score = 2.24)), total cholesterol 
levels (1p32-12 (lod score = 1.98) and 8p22-21 (lod score = 2.11)) and HDL-cholesterol levels 
(19q13 (lod score = 1.73)). 
The results of our linkage analyses are of main importance, as we show that the use of diﬀerent 
diagnostic criteria aﬀects the outcome of linkage analyses and that the analyses of the underlying 
traits are more powerfull. This may be one explanation for the fact that linkage analyses 
performed by various other research groups, all using diﬀerent diagnostic criteria for FCH, have 
resulted in the identiﬁcation of a diversity of loci spread over the entire genome 26-36, 42. Other 
possible explanations for the diversity of loci reported for FCH by diﬀerent study populations 
include ethnic admixture and population stratiﬁcation. Since FCH is a complex multifactorial 
lipid disorder, genetic heterogeneity is potentially present in diﬀerent FCH populations, which 
may aﬀect the outcome of linkage analyses and contribute to the fact that most studies are 
underpowered to resolve loci of interest.
Candidate genes
In literature two loci, on chromosome 1q and 11q, have repeatedly been reported as regions of 
interest for FCH 26-33. Until now, two candidate genes have been proposed to underlie the linkage 
signal on chromosome 1q, the TXNIP and the USF1 gene. On chromosome 11q, genes of the 
apolipoprotein A1/C3/A4/A5 gene cluster have been suggested to underlie the linkage signal for 
FCH. 
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The TXNIP gene 
Based on a mutant mouse strain with phenotypic similarities with FCH patients, the TXNIP 
gene has been proposed as a candidate gene underlying the linkage signal for FCH on chromosome 
1q 44. In chapter 2 we investigated the putative role of the TXNIP gene in our FCH families, by 
sequencing the coding region, the 5’UTR and all introns of the TXNIP gene in 10 well-deﬁned 
FCH patients and 5 healthy controls. We did not ﬁnd any sequence variants in the TXNIP gene 
in patients with FCH or controls. Other research groups have also sequenced the TXNIP gene in 
patients with FCH and although rare sequence variants have been identiﬁed in these FCH study 
populations, none of the variants were associated with FCH 46, 150. 
Complete exclusion of the TXNIP gene as a candidate gene was, however, not possible as the 
3’UTR, which is known to inﬂuence the expression levels of genes, has not been sequenced. In 
chapter 3 the role of the TXNIP gene in FCH patients was further explored by quantiﬁcation 
of TXNIP mRNA expression levels in peripheral blood mononuclear cells (PBMCs) of 30 FCH 
patients and 30 healthy controls. No diﬀerences in expression levels were found between FCH 
patients and controls. Based on both expression levels and sequence data, we can conclude that 
the TXNIP gene is not a major contributor to the FCH phenotype.
The USF1 gene
With the TXNIP gene excluded, another gene on chromosome 1q, the upstream stimulatory 
factor 1 (USF1) gene, has been suggested as a prime candidate gene for FCH 46. In a group of 
Finnish FCH families, two single-nucleotide polymorphisms (SNPs) in the USF1 gene showed 
evidence of linkage and association with FCH and multiple phenotypes of FCH 46. In chapter 4 
we performed family-based SNP and haplotype analyses of these two SNPs in the USF1 gene, to 
evaluate the putative role of this gene in Dutch patients with FCH. We show that the previously 
identiﬁed risk haplotype of USF1 is not associated with FCH deﬁned by the nomogram 
(p = 0.55) whereas suggestive associations were found when using the traditional diagnostic criteria 
for FCH (USF1s1: p = 0.08 and USF1s2: p = 0.07). Suggestive associations with important 
phenotypes of FCH, including total cholesterol levels (USF1s1: p = 0.05 and USF1s2: p = 0.04), 
apolipoprotein B levels (USF1s1: p = 0.06 and USF1s2: p = 0.04) and the presence of small 
dense LDL (USF1s1: p = 0.10 and USF1s2: p = 0.09) were found. Several other research groups 
have also tried to replicate the results found in the Finnish FCH families 42, 47. The results of 
these studies, performed in Mexican FCH families and in pedigrees from Utah, were supportive 
for the role of the USF1 gene in FCH, although the results were less conclusive than found in 
the Finnish FCH families 42, 47. Based on the regulatory function of USF1 on the transcriptional 
activation of important enzymes in the glucose and lipid metabolism, USF1 was thought to 
be a good candidate gene for FCH. In our study population, however, variants in the USF1 
gene only explain approximately 1% of the variations in total cholesterol, apolipoprotein B and 
small dense LDL. To further explore the role of USF1 in FCH, we measured the expression 
levels of USF1 mRNA in PBMCs of 30 FCH patients and 30 healthy controls and did not ﬁnd 
haplotype-dependent diﬀerences in expression of USF1. In conclusion, the previously identiﬁed 
risk haplotype of USF1 showed a suggestive association with FCH and its related lipid traits but 
explains only 1% of the variation in TC, apoB, sdLDL.
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The APOA5 gene
In chapter 5 of this thesis the association of the APOA5 gene, located on chromosome 11q, 
with FCH and its related phenotypes was evaluated. We have genotyped two SNPs in the 
APOA5 gene (-1131T>C and S19W) and analyzed the data by family-based SNP and haplotype 
analyses and the measured genotype method. We demonstrate that the S19W variant in the 
APOA5 gene is associated with an increased risk on FCH (OR = 1.6 [95% CI: 1.0, 2.6]) and a 
more atherogenic lipid proﬁle, including higher TG levels (+22%), higher apoB levels (+5%), 
decreased HDLc levels (-7%) and the presence of sdLDL (+10%). The S19W explained 1 - 3 % 
of the genetic variation in FCH and its related phenotypes. So, the APOA5 gene might be the 
gene underlying the linkage signal on chromosome 11q. Through both linkage and association 
analysis, the APOA5 gene has also been reported to be associated with FCH in other study 
populations 33, 50, 51. Despite the association of the variants in the APOA5 gene with a more 
atherogenic lipid proﬁle, in literature contradictory results for the possible association of the 
APOA5 gene with intima-media thickness (IMT) values and CVD in Caucasian populations 
have been reported 189, 193-197, 205. We show that the APOA5 gene does not contribute to a thicker 
intima-media thickness of the carotid artery or an increased prevalence of CVD in FCH families. 
This may be attributable to the low number of subjects with CVD.
Part 2: The metabolic origin of familial combined hyperlipidemia
The pathophysiology of FCH
In chapter 6 we review the pathophysiology of FCH in relation to the diagnostic criteria and 
its characteristic phenotypes. 
An important diagnostic criterion of FCH is elevated plasma TG levels, which reﬂect TG-rich 
lipoproteins. Triglyceride-rich lipoproteins are, however, a heterogeneous group of particles some 
of which are more atherogenic than others. The remnant-like particles (RLP) are characterized as 
the most atherogenic triglyceride-rich lipoproteins. In chapter 7 we explored the role of remnant-
like particles cholesterol (RLPc) as a characteristic phenotype of FCH and its contribution to the 
increased risk of CVD in patients with FCH. Patients with FCH were found to have two-fold 
higher RLPc levels (males 0.59 mmol/l; females 0.40 mmol/l) compared to normolipidemic 
relatives (males 0.27 mmol/l; females 0.22 mmol/l)  and spouses (males 0.27 mmol/l; females 
0.24 mmol/l). Previous studies have also demonstrated that lipoprotein metabolism in FCH 
patients is disturbed, leading to remnant accumulation in the circulation; however, diﬀerent 
methodologies to isolate lipoprotein remnants were used 93, 269, 373. These increased RLPc levels 
contribute to the increased prevalence of CVD in FCH patients of our study population, 
independently of nonlipid cardiovascular risk factors (OR 2.18 [1.02 - 4.66]). RLPc levels did, 
however, not provide additional information about prevalent CVD over and above non-HDLc 
levels. So, we conclude that patients with FCH have two-fold elevated plasma RLPc levels, 
which contribute to the increased risk for CVD but not independent of non-HDL cholesterol 
levels. It remains, however, to be studied in large epidemiological studies to what extent the 
measurement of plasma RLPc provides additional knowledge for the treatment goals of the 
individual patients.
Summary
165
Adipose tissue metabolism
In the pathophysiology of FCH, a disturbed adipose tissue metabolism is hypothesized to play 
an important role. Generally, it is thought that in patients with FCH, hepatic overproduction 
of VLDL, combined with a delayed clearance of atherogenic triglyceride-rich lipoproteins, 
are caused by inadequate FFA trapping in the adipose tissue, as reviewed in chapter 6 91, 92, 96. 
Besides impaired FFA trapping, adipose tissue may also contribute to the FCH phenotype and 
its increased risk of CVD by secretion of adipokines, which are involved in glucose and lipid 
metabolism and atherogenesis.
Adipokines
In the present thesis, the possibility that a disturbed adipose tissue metabolism is the culprit of 
FCH was approached by the evaluation of two adipokines, leptin and adiponectin.
Leptin
In chapter 8 we explored the role of leptin in FCH. We showed that leptin levels were increased 
in patients with FCH; however, these levels are higher, proportional to their increased adiposity 
and the presence of insulin resistance. Previously, leptin levels were also measured in two small 
independent FCH populations 247, 248. The results of these studies were contradictory. Leptin 
levels were, furthermore, only corrected for the presence of obesity 247, 248. We conclude that 
patients with FCH have increased leptin levels, however, this is not attributable to a speciﬁc 
defect in the adipose tissue metabolism in FCH, as leptin levels are higher in proportion to 
their obesity and insulin resistance state. In our study population, increased leptin levels are 
related to increased risk for CVD both in FCH patients and non-FCH individuals (overall; 
OR = 3.3 [1.7 - 6.4]). So, increased leptin levels in FCH do contribute to the increased risk of 
CVD. 
In chapter 9, the possible role of genetic variations in the leptin receptor (LEPR), which is 
the transporter of leptin, was explored. For this, we have genotyped the functional Gln223Arg 
SNP in our FCH study population. The Gln223Arg is located within the region encoding the 
extracellular domain of the leptin receptor and therefore associated with the binding activity of 
leptin 38, 313. The Gln223Arg SNP in the LEPR gene is associated with a 1.6 times increased risk 
of FCH. The association of the LEPR gene with FCH was further supported by the presence of 
decreased HDLc levels in control carriers of one or two Arg alleles (1.21 mmol/L) compared to 
controls with the Gln223Gln genotype (1.28 mmol/L; p = 0.041). However, as no signiﬁcant 
diﬀerences were found for other lipid and lipoproteins, it is possible that the association found for 
HDLc originates from chance alone. Previous studies also show an association of the Gln223Gln 
with HDLc levels, but always in combination with other lipid and lipoproteins 314, 320. So, the 
LEPR gene is a modiﬁer gene for FCH.
Adiponectin
In Chapter 10 we explore the role of adiponectin in FCH. We report signiﬁcant lower 
adiponectin levels in both male and female FCH patients (males 2.0 ng/ml (95% CI [1.8 – 2.2]; 
females 2.5 ng/ml (95% CI [2.3 – 2.8]), compared to normolipidemic relatives (males 2.3 ng/ml 
(95% CI [2.2 – 2.5]; females 3.1 ng/ml (95% CI [2.8 – 3.3]) and spouses (males 2.4 ng/ml 
(95% CI [2.1 – 2.7]; females 3.2 ng/ml (95% CI [2.8 – 3.6]). Based on the presence of obesity 
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and insulin resistance in patients with FCH, these decreased adiponectin levels could be expected 
374. The decreased adiponectin levels in patients with FCH were, however, independent of their 
body adiposity and degree of insulin resistance. In addition, decreased adiponectin levels were 
the strongest independent predictor of the atherogenic lipid proﬁle, including high triglyceride 
levels, low HDLc levels and the presence of small dense LDL. The relation of adiponectin with 
an atherogenic lipid proﬁle was not speciﬁc for FCH patients and has previously been reported in 
other non-FCH study populations 111, 336-341. The decreased adiponectin levels found in patients 
with FCH support the concept of a disturbed adipose tissue metabolism in the pathophysiology 
of FCH.
In chapter 11 we describe the screening of the gene encoding for adiponectin, the adipose 
most abundant gene transcript 1 (ApM1) gene. The association of two SNPs, the 45T>G and 
the 639C>T SNPs, with FCH and its associated atherogenic lipid proﬁle were studied by family 
based SNP and haplotype analyses. No association of variants in the ApM1 gene with FCH 
was found. Variants in the ApM1 gene were associated with decreased adiponectin levels and an 
atherogenic lipid proﬁle, however, these associations were not speciﬁc for FCH. Previously, the 
variants in the ApM1 gene were found to be associated with a more atherogenic lipid proﬁle 111, 
332, 336-339, 341. So, we conclude that the ApM1 gene is not a candidate gene for FCH and that other 
mechanisms have to contribute to the decreased adiponectin levels in patients with FCH. For 
example, an intrinsic defect in the adipocytes, like the presence of more large triglyceride-ﬁlled 
adipocytes, can cause the deregulation of adiponectin in patients with FCH 250. 
An association of the ApM1 gene with intima-media thickness (IMT) values has also previously 
been reported, but could not be replicated in another study 357, 368, 369. No association with IMT 
values and the prevalence of CVD was found in our FCH patients, normolidemic relatives and 
spouses. Based on these results, we have found no evidence for the ApM1 gene to be a candidate 
gene for FCH in our Dutch FCH families.
Conclusions
1. The use of diﬀerent diagnostic criteria for FCH aﬀects the results of linkage analyses.
2. Linkage analyses for FCH and its related phenotypes have resulted in the identiﬁcation of a 
locus on chromosome 6q.
3. The investigated candidate genes on chromosome 1q21-23, including TXNIP and USF1, 
have not resulted in the identiﬁcation of a major gene in our Dutch FCH population.
4. The minor allele of the S19W SNP in the APOA5 gene is associated with FCH and an 
atherogenic lipid proﬁle, but not with prevalent CVD.
5. Plasma leptin levels are increased in patients with FCH. This is, however, in proportion to the 
presence of obesity and insulin resistance. The increased plasma leptin levels in patients with 
FCH contribute to the increased risk of CVD. 
6. The Gln223Arg SNP in the LEPR gene is associated with an increased risk of FCH and 
decreased HDLc levels.
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7. Plasma adiponectin levels are decreased in patients with FCH, independent of obesity and 
insulin resistance, supporting a potential role of adipose tissue in the pathophysiology of 
FCH. Furthermore, adiponectin is  the strongest independent predictor of the atherogenic 
lipid proﬁle, including high triglyceride level, low HDLc level, and the presence of small 
dense LDL.
8. The two investigated SNPs in the ApM1 gene are not associated with FCH, but do contribute 
to low adiponectin levels and an atherogenic lipid proﬁle in FCH.
Future perspectives
Part 1: The genetic origin of familial combined hyperlipidemia
To further elucidate the genetic origin of FCH two major issues have to be addressed. First, 
worldwide consensus about the diagnostic criteria of FCH is obligatory, as the use of diﬀerent 
diagnostic criteria inﬂuences the outcome of linkage analyses. Secondly, most genome-wide linkage 
analyses published for FCH are underpowered to detect linkage, resulting in the identiﬁcation of 
discrepant loci. These two major issues can be resolved by initiating (inter)national collaborations 
between the diﬀerent FCH study groups. Linkage analyses of the combined datasets with the use 
of an uniform diagnosis of FCH will increase power to detect a major locus for FCH.
Linkage analyses are known to be successful in the discovery of causal genes for monogenetic 
disorders. From literature it is, however, known that linkage analyses have limited power to 
identify genes with moderate eﬀects for more complex diseases, like FCH. Association methods 
have been shown to be more powerful than linkage methods under a number of conditions that 
typically prevail in complex disease. The power of association methods further improved with 
the recognition that haplotypes typically provide substantially more power to detect association 
than individual SNPs. Family-based haplotype analyses in extended pedigrees, however, remain a 
challenge, as the current programs are not capable of handling extended pedigrees.
As future research probably will focus on the genotyping of many SNPs for every candidate gene, 
the application of high-throughput sequencing and SNP genotyping technologies are necessary. 
The recent development of the 500,000 SNP array will allow us to study thousands of SNPs at 
a time. Although great progress has already been made in genetic epidemiology the challenge 
remains to analyse these large amounts of data and to deal with the multiple comparison issue.
Part 2: The metabolic origin of familial combined hyperlipidemia
The evidence for an important role of the adipose tissue in the pathophysiology of FCH has 
become more apparent. In the present thesis we have shown that adiponectin levels in plasma, 
one of the major adipokines, are signiﬁcantly lower in patients with FCH, independent of obesity 
and insulin resistance. Therefore, a primary role of adiponectin in the pathogenesis of FCH is 
suggested. Because the origin of low plasma adiponectin levels in patients with FCH is still 
unclear, this should be a major focus for future research. 
Recently, diﬀerent complexes of adiponectin have been identiﬁed in the circulation with a 
diﬀerent eﬀect on insulin sensitivity and inﬂammaroty mediators. To further investigate the role 
of decreased adiponectin levels in patients with FCH, the diﬀerent complexes of adiponectin 
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have to be measured. Furthermore, the regulation of the production of diﬀerent isoforms of 
adiponectin takes place within the adipocyte, and it is of interest to see if this proces is disturbed 
in patients with FCH.
The next step to resolve the origin of low adiponectin levels in patients with FCH is to take 
adipose tissue biopsies to measure RNA and protein expression levels and study the signaling 
pathway involved in adiponecin production and secretion. In this respect it would be of great 
interest to explore the role of subcutaneous vs. visceral adipose tissue in adiponectin production 
and secretion. Furthermore, adipocyte size has been shown to inﬂuence cytokine production. 
These in vitro and ex vivo experiments should be complemented with in vivo studies, using 
labelled glucose and/or fatty acids in dynamic positron emission tomography (dPET) studies 
and CT-scan in combination with insulin clamp techniques. These studies will reveal the role of 
visceral and subcutaneous adipose tissue and the liver in the pathophysiology of FCH. 
To further elucidate the role of the adipose tissue in FCH, the expression of other proteins 
released by the adipose tissue should also be measured in the adipose tissue (e.g. adipsin, resistin, 
tumor necrosis factor alpha, interleukine 6 and plasminogen activator inhibitor 1). The relation 
of these proteins with FCH should be investigated not only by measuring protein levels in the 
circulation or genotyping variants in the encoding genes, but also by measuring expression levels 
in the adipose tissue. This can be done by expression arrays, which is a powerful tool to investigate 
many proteins at a time and detect proteins, monitor their expression levels, and investigate 
protein interactions and functions.
Patients with FCH share many features of patients with the metabolic syndrome (MS) and 
type 2 diabetus mellitus (DM2), including insulin resistance, obesity, dyslipidemia and increased 
risk of atherosclerosis. Also in patients with the MS or DM2, low adiponectin levels have 
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Figure 1 
Obesity is a common feature of three metabolic diseases with high prevalence in the general population, 
including familial combined hyperlipidemia (FCH), type 2 diabetus mellitus (DM2) and the metabolic 
syndrome (MS). The unique role of a disturbed adipose tissue metabolism in patients with FCH can be 
explored by evaluating adipose tissue metabolism in patients with FCH, type 2 diabetus mellitus, obesity and 
the metabolic syndrome.
been reported. To elucidate the unique role of a disturbed adipose tissue metabolism in the 
pathophysiology of FCH, in vivo and in vitro experiments of the adipose tissue have to be 
performed not only in patients with FCH and controls, but also in patients with obesity, the 
metabolic syndrome and type 2 diabetus mellitus (Figure 1).
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Hart- en vaatziekten
Al sinds vele jaren zijn hart- en vaatziekten de meest voorkomende doodsoorzaken in westerse 
landen. In 2004 zijn in Nederland 45.445 mensen ten gevolge hiervan overleden. Dit is gelijk 
aan 33% van het totale sterftecijfer van dat jaar 1. Voor hart- en vaatziekten zijn veel risicofactoren 
bekend, waaronder roken, diabetes mellitus, hoge bloeddruk, overgewicht, gebrek aan beweging 
en een hoog cholesterolgehalte in het bloed. Omdat tegenwoordig bijna 50% van de volwassen 
Nederlandse bevolking aan overgewicht lijdt, is overgewicht (BMI > 25 kg/m2) een belangrijke 
risicofactor voor het krijgen van hart- en vaatziekten. Bij ongeveer 4% van de patiënten met 
nieuw gediagnosticeerde hart- vaatziekten, was overgewicht te oorzaak 2, 3. De relatie van een 
verhoogde cholesterolspiegel met hart- en vaatziekten is echter nog sterker. Bij ongeveer 20% 
van deze patiënten was een te hoog cholesterol gehalte de oorzaak 3. Onder personen van de 
Nederlandse bevolking in de leeftijd van 20 jaar en ouder heeft ongeveer 10% een verhoogd 
cholesterol (> 6.5 mmol/L) en/of neemt cholesterolverlagende medicijnen 2. 
Familiaire gecombineerde hyperlipidemie
In 1973 werd Familiaire geCombineerde Hyperlipidemie (FCH) voor het eerst beschreven als 
een erfelijke vetstofwisselingsziekte, die gekenmerkt wordt door wisselend verhoogde cholesterol 
en/of triglyceridegehalte in het bloed. Andere karakteristieke kenmerken van FCH zijn lage 
spiegels van HDL-cholesterol, hoge apolipoproteïne B-spiegels en de aanwezigheid van veel 
kleine, dichte, zeer atherogene LDL-cholesteroldeeltjes. Ongeveer 1 tot 5% van de Nederlandse 
bevolking heeft FCH. FCH wordt niet alleen gekenmerkt door een verstoorde vetstofwisseling, 
maar de patiënten met FCH zijn ook vaak te dik en hebben een afgenomen gevoeligheid voor de 
werking van insuline (insuline-resistentie).
Bij mensen met FCH is de kans op hart- en vaatziekten sterk verhoogd. In vergelijking met de 
hele Nederlandse bevolking hebben mensen met FCH een 2 tot 5 maal verhoogd risico op het 
krijgen van hart- en vaatziekten voor het 60ste  levensjaar. 
Omdat de kans op het krijgen van hart- en vaatziekten groot is bij mensen met FCH, is 
het belangrijk om deze mensen goed te kunnen herkennen en op tijd te starten met de 
behandeling. Echter, de diagnose van FCH is erg lastig omdat meerdere genetische, metabole en 
omgevingsfactoren een rol spelen. 
Plasma cholesterol- en/of triglyceride-spiegels boven de leeftijd- en geslacht afhankelijke 90ste 
percentielen worden sinds 1973 als criteria voor de diagnose van FCH gebruikt (traditionele 
diagnose van FCH) 14, 15. De variërende cholesterol- en triglyceride-spiegels binnen een persoon 
zorgen er echter voor dat de diagnose van FCH niet consistent is in de tijd 16. Hierdoor kan een 
persoon op een bepaald tijdstip gediagnostiseerd worden als FCH-patiënt, terwijl op een ander 
tijdstip de persoon niet aan de diagnostische criteria voldoet. Om deze redenen hebben Veerkamp 
et al. het nomogram ontwikkeld 17. Dit nomogram is gebaseerd op verhoogde cholesterol-, 
triglyceride- en/of apolipoproteïne B-spiegels. De diagnose van FCH op basis van het nomogram 
is consistenter in de tijd.
Ondanks meer dan 30 jaar onderzoek op het gebied van FCH zijn de genetische, metabole en 
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omgevingsfactoren die een rol spelen bij FCH nog steeds niet in zijn geheel opgehelderd. Met het 
onderzoek, beschreven in dit proefschrift, hebben wij een bijdrage geleverd aan de verbreding van 
de kennis over de genetische en metabole factoren die een rol spelen bij de ziekte FCH. 
In het eerste gedeelte van dit proefschrift worden genetische factoren die mogelijk een rol 
spelen, belicht (hoofdstuk 1 – 5). In het tweede deel worden de metabole factoren beschreven 
die mogelijk een relatie hebben met het ontstaan van FCH (hoofdstuk 6 – 11).
Deel 1: Genetische factoren en FCH
Voor het ontrafelen van de genetische factoren die een rol spelen bij FCH, kunnen verschillende 
strategieën gebruikt worden: het zogenaamde koppelingsonderzoek en de associatieanalyses. 
Voor het koppelingsonderzoek worden genetische variaties (markers) op alle chromosomen 
getest binnen grote families met twee of meer personen met FCH. Door te onderzoeken of deze 
markers samen overerven met FCH, kunnen regio’s op het chromosoom geïdentiﬁceerd worden 
waar mogelijk genen liggen die betrokken zijn bij de ziekte FCH. 
Het doel van associatieanalyses is het opsporen van ziekte allelen in kandidaat-genen die meer 
(of minder) vaak voorkomen bij mensen met FCH, dan in mensen zonder FCH. 
Kandidaat-genen zijn genen die potentiëel betrokken zijn bij FCH op basis van het feit 
dat ze bijvoorbeeld liggen in regio’s op de chromosomen die gevonden zijn door middel van 
koppelingsonderzoek. Kandidaat-genen zijn ook genen waarvan we op basis van de bekende 
functie denken dat ze een rol spelen in de ontwikkeling of verloop van FCH. 
Bij associatiestudies wordt het mogelijke verband tussen een variatie in een gen en de ziekte 
(of de kenmerken van de ziekte) onderzocht. Bij associatiestudies kunnen ook meerdere variaties 
in een gen tegelijkertijd geanalyseerd worden. Dit noemt men haplotype-onderzoek. Doordat er 
meerdere variaties tegelijkertijd onderzocht worden, is met deze onderzoeken de kans groter om 
een bestaande associatie te vinden.
Linkage analyses
In hoofdstuk 1 beschrijven we de resultaten van het koppelingsonderzoek dat we hebben 
uitgevoerd voor twee verschillende diagnostische criteria van FCH in onze Nijmeegse FCH 
populatie. Het koppelingsonderzoek voor FCH waarbij de diagnose is gesteld volgens de 
traditionele criteria, heeft niet geresulteerd in de identiﬁcatie van een relevante regio op een 
chromosoom.
Het koppelingsonderzoek voor de diagnose van FCH gebaseerd op het nomogram heeft 
geresulteerd in de identiﬁcatie van relevante regio’s op chromosoom 6q25-27 en chromosoom 
12q23-24. Bij de koppelingsonderzoeken van twee karakteristieke kenmerken van FCH, verhoogde 
triglyceridespiegels en de aanwezigheid van kleine, dichte LDL-deeltjes, werd suggestief bewijs 
voor linkage gevonden voor dezelfde regio op chromosoom 6q. Ook in een andere Nederlandse 
populatie van FCH-families werd suggestief bewijs voor linkage in deze regio op chromosoom 6q 
gevonden 31. Het feit dat in deze regio op chromosoom 6q enkele potentiëel relevante kandidaat-
genen liggen, ondersteunt onze data dat chromosooom 6q mogelijk betrokken is bij FCH en 
zeker verder onderzocht dient te worden.
Het koppelingsonderzoek voor de verschillende kenmerken van FCH heeft geresulteerd in 
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vier regio's met suggestief bewijs voor linkage. Voor triglyceride-spiegels werd op chromosoom 
10p14-q21 een interessante regio gevonden, voor cholesterol-spiegels op chromosoom 1p32-12 
en 8p22-21, en voor HDL-cholesterol-spiegels op chromosoom 19q13. 
Met de door ons uitgevoerde linkage-analyses laten wij zien dat het gebruik van verschillende 
diagnostische criteria voor FCH van invloed is op de resultaten die gevonden worden met de 
linkage-analyses. Dit kan dus een verklaring zijn voor het feit dat de reeds eerder uitgevoerde 
linkage-analyses door andere onderzoeksgroepen hebben geresulteerd in de ontdekking van een 
grote verscheidenheid van mogelijk relevante  gebieden die verspreid liggen over de verschillende 
chromosomen 26-36, 42. Mogelijke andere verklaringen voor de diversiteit aan regio’s met suggestief 
of signiﬁcant bewijs voor linkage voor FCH in de verschillende populaties, zijn etnische 
verschillen en populatie-stratiﬁcatie. Omdat FCH een multifactoriële ziekte is, kan er sprake zijn 
van genetische heterogeniteit in de verschillende onderzoekspopulaties. Ook dit kan van invloed 
zijn op de resultaten die gevonden worden met de linkage-analyses en dragen bij aan het feit dat 
de meeste studies door relatief kleine groepen patiënten met FCH te weinig kans hebben om te 
leiden tot echt relevante regio’s met signiﬁcant bewijs voor linkage. 
Kandidaat-genen
In de literatuur worden twee regio’s, op chromosoom 1q en 11q, herhaaldelijk gerapporteerd 
als regio’s met signiﬁcant bewijs voor linkage met FCH 26-33. Tot op heden zijn er twee genen, het 
TXNIP-gen en het USF1-gen, aangewezen als kandidaat-genen voor de regio op chromosoom 
1q. Op chromosoom 11q worden de genen van het apolipoprotein A1/C3/A4/A5-gen cluster 
gesuggereerd als kandidaat-genen. 
Het TXNIP-gen 
Gebaseerd op resultaten, gevonden in een muizenmodel met kenmerken die overeenkomen 
met kenmerken van FCH-patiënten, werd het gen coderend voor ‘thioredoxin interacting protein’ 
(TXNIP) voorgesteld als kandidaat-gen in de regio met linkage voor FCH op chromosoom 
1q 44. 
In hoofdstuk 2 hebben we de mogelijke rol van het TXNIP-gen in onze FCH families 
bestudeerd. Dit hebben we gedaan door het coderende gedeelte, het 5’UTR, en alle intronen van 
het TXNIP-gen in tien FCH-patiënten en vijf gezonde personen na te kijken. Er werden geen 
variaties in de sequentie van het TXNIP-gen in de patiënten en gezonde personen gevonden. 
Ook andere groepen hebben het TXNIP-gen bestudeerd bij patiënten met FCH. Ondanks het 
feit dat deze onderzoeksgroepen wel enkele variaties in de sequentie van het TXNIP-gen vonden, 
was geen van deze variaties geassocieerd met FCH 46, 150. 
Volledige uitsluiting van het TXNIP-gen als een kandidaat-gen voor FCH was echter nog niet 
mogelijk omdat het 3’UTR niet bestudeerd is. Van het 3’UTR is bekend dat het invloed kan 
hebben op het expressieniveau van een gen. In hoofdstuk 3 hebben we de rol van het TXNIP-
gen in FCH-patiënten verder onderzocht door het expressieniveau van het TXNIP-gen in perifere 
bloedcellen van 30 FCH-patiënten en 30 gezonde personen te meten. Er werden geen verschillen 
in expressieniveau van het TXNIP-gen gevonden tussen de FCH-patiënten en gezonde personen. 
Gebaseerd op zowel de gegevens van de sequentie van het TXNIP-gen als het expressieniveau 
van het TXNIP-gen, concluderen wij dat het TXNIP-gen geen belangrijke bijdrage levert aan de 
kenmerken van de ziekte FCH. 
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Het USF1-gen
Op het moment dat het TXNIP-gen uitgesloten was als een belangrijk kandidaat-gen, werd 
een ander gen op chromosoom 1q, het ‘upstream stimulatory factor 1’ (USF1)-gen, als mogelijk 
kandidaat-gen voor FCH voorgesteld 46. In een groep van Finse FCH-families is door middel van 
linkage- en associatie-analyses bewijs geleverd voor de betrokkenheid van twee single-nucleotide 
polymorﬁsmen (SNPs) in het USF1-gen met FCH en enkele karakteristieke kenmerken van FCH 
46. In hoofdstuk 4 hebben we de mogelijke rol van deze twee SNPs in het USF1-gen in Nijmeegse 
patiënten met FCH onderzocht. Dit hebben we gedaan door analyses op basis van een enkele 
SNP en op basis van haplotypes. Met de resultaten van deze analyses laten wij zien dat het risico-
haplotype van het USF1-gen, zoals geïdentiﬁceerd in de Finse FCH-patiënten, niet geassocieerd 
is met FCH gebaseerd op het nomogram, terwijl een suggestieve associatie met FCH gebaseerd 
op de traditionele criteria aanwezig was in onze Nijmeegse FCH-families. Het risico-haplotype 
was tevens geassociëerd met verhoogde cholesterolspiegels, verhoogde apolipoprotein B-spiegels 
en de aanwezigheid van kleine, dichte LDL-deeltjes. Ook andere onderzoeksgroepen hebben 
geprobeerd om de resultaten van de Finse onderzoeksgroep te bevestigen 42, 47. De resultaten 
van deze studies, uitgevoerd in Mexicaanse FCH-families en families uit Utah, ondersteunen 
het feit dat variaties in het USF1-gen een rol spelen in FCH, hoewel de resultaten van deze 
studies minder duidelijk waren dan de resultaten van de studie in de Finse FCH-patiënten 42, 
47. USF1 is gesuggereerd als kandidaat-gen voor FCH op basis van zijn regulerende functie op 
de transcriptie-activatie van belangrijke enzymen, die betrokken zijn bij de glucose- en vet-
stofwisseling. In onze studie-populatie konden de twee bestudeerde variaties in het USF1-gen 
echter maar ongeveer 1% van de variatie in cholesterol, apolipoprotein B en kleine dichte LDL-
deeltjes spiegels verklaren. Om de rol van USF1 in FCH-patiënten nog verder te onderzoeken 
hebben we het expressieniveau van USF1 in perifere bloedcellen van 30 FCH-patiënten en 30 
gezonde personen onderzocht. Wij hebben geen verschillen in expressieniveau van het USF1-
gen gevonden tussen de verschillende USF1 haplotypes. Op basis van de gevonden resultaten 
beschouwen wij het reeds eerder geïndentiﬁceerde risico-haplotype van het USF1-gen niet als een 
belangrijk risico-haplotype voor FCH in onze Nijmeegse populatie van FCH-patiënten. 
Het APOA5-gen
In hoofdstuk 5 hebben we de mogelijke rol van het APOA5-gen, dat gelegen is op chromosoom 
11q, in FCH onderzocht. Wij hebben het genotype van twee variaties (-1131T>C en S19W) 
in het APOA5-gen bepaald. Deze data hebben we in de FCH-families met behulp van SNP- 
en haplotype-analyses geanalyseerd. Wij laten zien dat de S19W-variatie in het APOA5-gen 
geassocieerd is met een verhoogd risico op FCH en een meer atherogeen lipidenproﬁel. Tot 
dit atherogeen lipidenproﬁel behoren verhoogde triglyceridespiegels, verhoogde apolipoproteïne 
B-spiegels, verlaagde HDLc-spiegels en de aanwezigheid van kleine, dichte LDL-deeltjes.  De 
S19W variant in het APOA5-gen verklaarde 1 tot 3% van de genetische variatie in FCH en de 
karakteristieke kenmerken van FCH. Het APOA5-gen kan dus het gen zijn dat het gevonden 
bewijs voor linkage op chromosoom 11q kan verklaren. In andere FCH-studiepopulaties is ook 
gebleken dat het APOA5-gen geassocieerd is met FCH 33, 50, 51. Ondanks de gevonden associaties 
van variaties in het APOA5-gen met een meer atherogeen lipidenproﬁel, worden in de literatuur 
tegenstrijdige resultaten gevonden voor een mogelijke associatie van variaties in APOA5-gen met 
hart- en vaatziekten, dan wel met de dikte van de wand van de halsslagader (intima-media dikte 
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= IMT) als surrogaat marker voor hart- en vaatziekten 189, 193-197, 205. In onze studie is geen bewijs 
gevonden voor een bijdrage van het APOA5-gen aan dikkere IMT. Tevens vinden we geen bewijs 
voor een associatie van de variaties in het APOA5-gen met een verhoogd voorkomen van hart- en 
vaatziekten in onze families met FCH. Een van de verklaringen waarom geen bewijs voor een 
associatie met IMT of hart- en vaatziekten is gevonden, kan zijn dat maar van een klein aantal 
personen IMT-data beschikbaar waren en dat maar een klein aantal personen hart- en vaatziekten 
had.
Deel 2: Metabole factoren en FCH 
Verschillende metabole factoren dragen bij aan het tot expressie komen van FCH. Algemeen 
wordt aangenomen dat er bij patiënten met FCH sprake is van een overproductie van triglyceride-
rijke lipoproteïnen (VLDL-deeltjes) door de lever. Dit leidt tot stapeling van triglyceride-rijke 
lipoproteïnen (o.a. remnant deeltjes genaamd). Echter de oorzaak van de overproduktie van VLDL-
deeltjes is niet volledig opgehelderd. Een van de hypotheses is dat het vetweefselmetabolisme in 
patiënten met FCH is verstoord, hetgeen resulteert in onvoldoende opname van vrije vetzuren 
door het vetweefsel 91, 92, 96. De vrije vetzuren blijven in het bloed en bereiken de lever, alwaar de 
vetzuren de productie van VLDL stimuleren.
Anderzijds kan een gestoord vetweefselmetabolisme leiden tot verandering in de produktie en 
afgifte van eiwitten (adiponectinen) door het vetweefsel, die betrokken zijn bij het glucose- en 
lipidenmetabolisme en het ontstaan van hart- en vaatziekten.
De pathofysiologie van FCH
In hoofdstuk 6 wordt de pathofysiologie van FCH in relatie tot de verschillende diagnostische 
criteria en de karakteristieke kenmerken van FCH besproken. 
Een belangrijk diagnostisch criterium van FCH zijn de verhoogde triglyceridespiegels, welke 
de aanwezigheid van triglyceride-rijke lipoproteïnen reﬂecteren. Tot de klasse van triglyceride-
rijke lipoproteïnen behoort een grote verscheidenheid aan deeltjes, waarbij het ene deeltje meer 
atherogeen is dan de andere deeltjes. De remnant-like deeltjes (RLP) worden gekarakteriseerd als 
de meest atherogene triglyceride-rijke lipoproteïnen. 
In hoofdstuk 7 onderzoeken we de rol van remnant-like particles cholesterol (RLPc) als 
een karakteristiek kenmerk van FCH en de bijdrage van RLPc aan het verhoogde risico op 
hart- en vaatziekten van patiënten met FCH. De RLPc spiegels van patiënten met FCH bleken 
twee maal hoger te zijn in vergelijking tot de familieleden met een normaal lipidenproﬁel en 
de aangetrouwde familieleden. Eerdere studies hebben ook al laten zien dat het lipoproteïne-
metabolisme bij patiënten met FCH verstoord is, wat kan leiden tot een opstapeling van remnants 
in de bloedsomloop. De gebruikte methodes om de lipoproteïne remnants te isoleren verschilden 
echter van elkaar 93, 269, 373. Deze verhoogde RLPc-spiegels dragen bij aan het verhoogde risico op 
hart- en vaatziekten bij patiënten met FCH in onze studiepopulatie. Dit was onafhankelijk van 
andere, niet-lipiden risicofactoren voor hart- en vaatziekten. RLPc spiegels gaven echter geen 
extra informatie over het voorkomen van hart- en vaatziekten boven de non-HDLc-spiegels. 
Daarom concluderen wij dat patiënten met FCH twee maal hogere RLPc-spiegels hebben in het 
bloed, welke bijdragen aan het verhoogde risico op hart- en vaatziekten, maar niet onafhankelijk 
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van non-HDL-cholesterolspiegels. In welke mate de meting van RLPc-spiegels extra kennis biedt 
voor de behandeling van individuele patiënten moet echter nog onderzocht worden in grote 
epidemiologische studies.
Vetweefselmetabolisme
Het vetweefsel werd lang gezien als een relatief passief orgaan voor opslag van energie. 
Tegenwoordig is het duidelijk dat het vetweefsel niet alleen betrokken is bij de opslag van energie, 
maar ook endocrien actief is door het vrijmaken van verscheidene eiwitten. Deze eiwitten zijn 
betrokken bij ontstekingen, glucose- en lipidenmetabolisme en atherogenese 103. 
Adipokines
De mogelijke betrokkenheid van een verstoord vetweefselmetabolisme bij FCH hebben wij 
onderzocht aan de hand van twee belangrijke eiwitten, de zogenaamde adipokines. Deze twee 
adipokines zijn leptine en adiponectine. 
  
Leptine
Leptine is betrokken bij de regulatie van het energieverbruik en het hongergevoel door middel 
van receptoren in de hypothalamus, waaronder de leptine-receptor 104. Een verhoging van de 
leptine-spiegels zal leiden tot een hoger energiegebruik en een vermindering van het hongergevoel 
bij gezonde personen. Echter, bij dikke mensen lijkt de toename in leptine-spiegels te falen bij 
de beïnvloeding van de energie-inname of om de vetmassa te herstellen naar normale niveau's. 
Overgewicht wordt daarom gezien als een situatie waarin mensen immuun zijn voor de werking 
van leptine. Leptine is niet alleen geassociëerd met overgewicht, maar ook met insulineresistentie 
105. Dit komt door de directe werking van leptine op het vrijmaken van insuline. Leptine-spiegels 
zijn bovendien geassocieerd met hart- en vaatziekten.
In hoofdstuk 8 onderzoeken we de mogelijke rol van leptine bij patiënten met FCH. Wij tonen 
aan dat leptine-spiegels verhoogd zijn bij patiënten met FCH. Deze verhoogde spiegels zijn echter 
evenredig met de mate van vetzucht en de aanwezigheid van insulineresistentie bij patiënten met 
FCH. Leptine-spiegels werden al eerder in twee andere FCH-populaties onderzocht 247, 248. De 
resultaten van deze studies waren echter tegenstrijdig 247, 248. Wij concluderen dat patiënten met 
FCH verhoogde leptine-spiegels hebben. Deze verhoogde leptine-spiegels zijn echter niet het 
gevolg van een speciﬁek defect in het vetweefselmetabolisme bij patiënten met FCH, omdat de 
verhoogde leptine-spiegels gerelateerd zijn aan het overgewicht en de mate van insulineresistentie 
bij deze FCH-patiënten. In onze studiepopulatie laten wij tevens zien dat verhoogde leptine- 
spiegels bijdragen aan een verhoogd risico op hart- en vaatziekten zowel bij FCH-patiënten als 
bij mensen zonder FCH. Verhoogde leptine-spiegels dragen dus bij aan het verhoogde risico op 
hart- en vaatziekten. Dit is echter niet speciﬁek voor FCH.
In hoofdstuk 9, wordt het onderzoek naar de mogelijke rol van genetische variaties in het 
leptine-receptor (LEPR)-gen beschreven. De leptine-receptor zorgt onder andere voor het 
transport van leptine. Wij hebben de functionele variatie van de LEPR-gen, de Gln223Arg-SNP, 
in onze FCH-studiepopulatie bepaald. De Gln223Arg-variant ligt in de regio die betrokken 
is bij de binding van deze receptor met leptine, en is daarom mogelijk van invloed op de 
bindingsactiviteit met leptine 38, 313. De Gln223Arg variant in het LEPR-gen is geassocieerd met 
een 1,6 keer verhoogd risico op FCH. Deze associatie werd ondersteund door de aanwezigheid 
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van verlaagde HDLc-spiegels bij dragers van een of twee Arg-allelen door controlepersonen in 
vergelijking tot controlepersonen zonder een Arg-allel voor het Gln223Arg-variant in het LEPR-
gen. Het is echter ook mogelijk dat de gevonden associatie voor HDLc-spiegels berust op toeval, 
omdat er geen signiﬁcante verschillen werden gevonden voor de andere lipiden en lipoproteïnen. 
Eerdere studies hebben ook laten zien dat het Gln-allel van de Gln223Arg-variatie in het LEPR-
gen geassocieerd is met HDLc-spiegels, maar deze associatie werd in deze andere studies altijd 
in combinatie met andere associaties voor lipiden of lipoproteïnen gevonden 314, 320. Op basis 
van deze resultaten concluderen wij dat het LEPR-gen een gen is dat betrokken is bij het tot 
expressie komen van de karakteristieke kenmerken van FCH en het verhoogde risico op hart- en 
vaatziekten. 
Adiponectine
In tegenstelling tot leptine is de productie van adiponectine omgekeerd evenredig gerelateerd 
aan de hoeveelheid vetweefsel 107. Adiponectine stimuleert het oxidatie-proces van vrije vetzuren 
in de spieren, bevordert de insuline-sensitiviteit in de spieren en lever en remt ontstekingsactiviteit 
107-110. Adiponectine heeft bovendien direct en indirect invloed op lipidenbloedspiegels 111, 112. Op 
basis van deze eigenschappen van adiponectine is gesuggereerd dat adiponectine de ontbrekende 
schakel zou kunnen zijn tussen overgewicht, insulinresistentie en atherosclerose.
In hoofdstuk 10 onderzoeken we de rol van adiponectine in patiënten met FCH. Wij tonen 
aan dat zowel mannen als vrouwen met FCH signiﬁcant lagere plasma-adiponectinespiegels 
hebben in vergelijking met familieleden met een normaal lipidenproﬁel en aangetrouwde 
familieleden. Gebaseerd op het feit dat patiënten met FCH dikker en meer insulineresistent 
zijn, kunnen deze verlaagde spiegels van adiponectine verwacht worden 374. De verlaagde 
adiponectinespiegels bij de patiënten met FCH waren echter onafhankelijk van het overgewicht 
en de mate van insulinegevoeligheid. Tevens bleek dat de verlaagde adiponectinespiegel de 
belangrijkste voorspeller was van een atherogeen lipidenproﬁel. De relatie van adiponectine 
met een atherogeen lipidenproﬁel is waarschijnlijk niet kenmerkend voor patiënten met 
FCH en is ook al eerder gevonden in andere niet-FCH-populaties 111, 336-341. Het feit dat we 
verlaagde adiponectinespiegels hebben gevonden bij patiënten met FCH, onafhankelijk van 
overgewicht en de mate van insulinegevoeligheid ondersteunt de hypothese dat een verstoord 
vetweefselmetabolisme mogelijk een rol speelt in het ontstaan van FCH. 
In hoofdstuk 11 beschrijven we de rol van variatie in het ApM1-gen  in FCH. Het ApM1-gen 
codeert voor adiponectine. De associatie van twee variaties in het ApM1-gen, de 45T>G en de 
639C>T-SNPs, met FCH en het geassociëerde atherogeen lipidenproﬁel werd bestudeerd in de 
FCH-families met behulp van SNP- en haplotype-analyses. Er werd geen relatie van de variaties 
in het ApM1-gen met FCH gevonden. Variaties in het ApM1-gen bleken wel gerelateerd te zijn 
aan verlaagde adiponectinespiegels en een atherogeen lipidenproﬁel. Deze relaties waren echter 
niet speciﬁek voor FCH. In eerdere studies werd de relatie van de variaties in het ApM1-gen 
met verlaagde adiponectinespiegels en een atherogeen lipidenproﬁel ook gevonden 111, 332, 336-339, 
341. Wij concluderen dus dat het ApM1-gen geen kandidaatgen is voor FCH en dat er andere 
mechanismen zijn die bijdragen aan de verlaagde adiponectinespiegels die gevonden worden 
bij patiënten met FCH. Een voorbeeld van zo’n ander mechanisme is de aanwezigheid van 
een intrinsiek defect in de vetweefselcellen. De aanwezigheid van meer grote met triglyceride-
gevulde vetweefselcellen kunnen bijvoorbeeld de adiponectineproductie bij patiënten met FCH 
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beïnvloeden 250. De eerder gerapporteerde associatie met IMT werd  niet in een andere studie 
bevestigd 357, 368, 369. In onze FCH-populatie werd geen bewijs voor een associatie van variatie in het 
ApM1-gen met IMT-waarden of de prevalentie van hart- en vaatziekten gevonden. Gebaseerd op 
deze resultaten concluderen wij dat er geen bewijs is gevonden voor het ApM1-gen als kandidaat 
gen voor FCH in onze Nijmeegse FCH-populatie.
Conclusies
1. Het gebruik van verschillende criteria voor het stellen van de diagnose FCH is een mogelijke 
verklaring voor de verschillen in de gevonden resultaten bij koppelingsanalyses.
2. Koppelingsonderzoek voor de diagnose van FCH en de karakteristieke kenmerken van FCH 
hebben geresulteerd in de identiﬁcatie van een regio op chromosoom 6q waar mogelijk 
gen(en) ligt (liggen) die betrokken is (zijn) bij FCH.
3. De kandidaatgenen, TXNIP en USF1, op chromosoom 1q21-23 spelen geen belangrijke rol 
in FCH in de Nijmeegse FCH-populatie
4. Het W-allel van de S19W-variant in het APOA5-gen is geassocieerd met FCH en een 
atherogeen lipidenproﬁel.
5. Leptine-spiegels zijn verhoogd bij patiënten met FCH. Dit is echter in verhouding met de 
mate van overgewicht en insulineresistentie bij deze patiënten. De verhoogde leptine-spiegels 
in patiënten met FCH dragen bij aan het verhoogde risico op hart- en vaatziekten.
6. De Gln223Arg-variatie in het LEPR-gen is geassocieerd met een verhoogd risico op het 
krijgen van FCH en met verlaagde HDLc-spiegels. 
7. Plasma adiponectinespiegels zijn verlaagd bij patiënten met FCH, dit si echter onafhankelijk 
van de mate van overgewicht en de mate van insulineresistentie. Deze bevinding ondersteunt 
de potentiële rol van het vetweefsel bij de ontwikkeling en/of verloop van FCH. Bovendien 
is adiponectine de belangrijkste onafhankelijke voorspeller van het atherogeen lipidenproﬁel, 
waaronder hoge triglyceride-spiegels, lage HDLc-spiegels en de aanwezigheid van kleine, 
dichte LDL-deeltjes.
8. De twee onderzochte variaties in het ApM1-gen zijn niet geassocieerd met FCH, maar zijn 
wel geassocieerd met lage adiponectinespiegels en een atherogeen lipidenproﬁel.
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Dankwoord
Een promotieonderzoek was iets wat ik erg graag wilde doen na het afronden van mijn studie 
Biomedische gezondheidswetenschappen. Het is een cliché, maar het voltooien van een 
promotieonderzoek is een periode van vallen, opstaan en niet opgeven, en zonder al de mensen 
die mij gedurende deze periode hebben gesteund, was het me niet gelukt. Daarom vind ik het 
een eer dat ik al diegene in het dankwoord mag noemen.
Anton, bedankt dat je me de mogelijkheid gaf dit onderzoek te verrichten. Op sommige 
momenten was je naast promotor, ook een leraar Engels en Nederlands voor mij. Ik hoop dat 
ik zoveel van je heb geleerd dat er, nu ook zonder jouw hulp, geen spellingsfouten meer in dit 
dankwoord staan.
Henk, het is al meer dan vijf jaar geleden dat ik de eerste keer bij je kwam omdat ik graag 
een promotieonderzoek wilde doen. Ondanks het feit dat ik geen onderzoek deed naar ‘jouw’ 
homocysteine, was je zeer geïnteresseerd in mijn onderzoek en wilde je altijd weer weten hoever 
ik was met de linkage analyses. Ik denk dat we alle twee even blij zijn met het feit dat het na alle 
tegenslag toch nog een hoofdstuk in mijn proefschrift is geworden. 
Jacqueline, jou bedanken voor alles wat je hebt gedaan voor mij zou evenveel of meer pagina’s 
beslaan als dit proefschrift. Het is heel simpel, zonder jou was dit me niet gelukt. Toen ik aan dit 
onderzoek begon was het lipidenmetabolisme een grote ‘black box’ voor mij, maar jij hebt daar 
gedurende het gehele onderzoek jouw licht op laten schijnen. Daarnaast zal ik de congressen 
die wij samen hebben bezocht niet snel vergeten. Gezellig samen een luxe kamer delen, samen 
winkelen, samen uit eten met Allan en natuurlijk samen zenuwachtig zijn voor mijn eerste 
presentatie op de 'American Heart Association' en de vele presentaties die daar nog op volgden. 
O ja, we bezochten natuurlijk ook samen de vele lezingen tijdens de congressen.
Gedurende het eerste jaar van mijn promotieonderzoek werd ik bij het uitvoeren van de linkage 
analyses begeleid door Lodewijk Sandkuijl. Gedurende dat jaar was hij een zeer begaafde, 
enthousiaste en inspirerende leraar voor mij. Hij kreeg het altijd voor elkaar mij zelf te laten 
ontdekken wat het antwoord op mijn vraag was. Helaas is Lodewijk op 4 december 2002 
overleden. Dankzij de inspiratie die hij op mij over heeft weten te brengen, heeft hij ervoor 
gezorgd dat ik, ondanks alle tegenslagen bij de linkage analyses, stug door bleef gaan. 
Anneke, ik ben blij dat je mijn paranimf wilt zijn. Niemand verdient het meer dan jij om hier 
naast mij te staan. Want voor een groot gedeelte van datgene wat in het proefschrift staat heb jij 
het werk in het lab gedaan. Het was altijd weer leuk om met jou te praten en te bespreken wat we 
gingen doen en hoe we dat aan zouden gaan pakken. Wij waren een echt team. Ik ben nog steeds 
trots op je dat je daar ging staan voor die zaal bij de DAS en een presentatie in het engels gaf. Je 
deed het echt super en zorg er maar voor dat het niet bij die ene keer blijft!
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Berry, jij was de afgelopen periode mijn kamergenoot. Samen hebben we de temperaturen in onze 
kamer meer dan eens boven de 38 °C zien stijgen. Het was erg gezellig om jou als kamergenoot 
te hebben en samen te klagen, discussiëren, maar vooral samen te lachen. Het zal nu wel stil zijn 
op de kamer. 
De dames van het lab, wat was ik af en toe blij als de telefoon weer ging en er iemand zei dat het 
weer tijd was voor koﬃe of thee. Gezellig kletsen met z’n allen over van alles en nog wat. Magda, 
jij weet altijd raad en met vragen over bestellingen of andere zaken kon ik altijd bij jou terecht. 
Helga en Heidi, jullie hebben mij wegwijs gemaakt in de wereld van de ELISA. Samen met jullie 
heb ik vele plaatjes gecoat en gewassen. Johanna, samen zijn we, na een dag vol motiverende 
praatjes, met de boot door nachtelijk Amsterdam gevaren. Dit was erg leuk en gezellig. Ineke, 
Liesbeth en Trees, ook jullie wil ik bedanken voor alles, ook al hebben we qua werkzaamheden 
weinig samen gedaan. Emine, ook al werk je nu niet meer voor het lab, toch wil ik ook jou 
bedanken voor alles. Wij hebben samen, als de ‘broekies’ van het lab, veel plezier gehad en nu wij 
alle twee weg zijn is de gemiddelde leeftijd van de groep weer aardig gestegen. Pierre, de voor jou 
kenmerkende brede visie op het doen van onderzoek, heeft ervoor gezorgd dat je altijd in staat 
was om mij advies te geven. Lab algemeen interne geneeskunde, ik vond het een eer dat ik bij de 
groep heb mogen horen. 
Thomas, samen zijn we naar de AHA in Orlando geweest, waar je bij de douane misschien even 
op mij hebt moeten wachten, maar waar we een gezellige tijd hebben gehad. Het was altijd weer 
leuk om met je bij te kletsen over van alles en nog wat als je weer eens op bezoek was in Nijmegen 
of we elkaar zagen op een congres.
Bas, in 1994 ben jij begonnen met het verzamelen van de families met familiair gecombineerde 
hyperlipidemie. Mario, in 1999 heb jij deze families en nieuwe families opgeroepen voor de 
vervolgstudie na 5 jaar. Dus toen ik in 2002 begon aan mijn onderzoek waren alle families al 
verzameld en lagen er vele buisjes opgeslagen in de vriezer. Bedankt voor het verzamelen van al 
deze gegevens en buisjes. 
Ewoud, jij hebt in 2004 een gedeelte van de families naar het ziekenhuis laten komen voor de 
vervolgstudie na 10 jaar. Ook van deze data heb ik dankbaar gebruik gemaakt. Heel veel succes 
bij jouw komende promotie en je nieuwe baan in Groningen als eerste-hulp arts. 
Til, ook al hebben we niet direct samengewerkt, toch wil ik je bedanken voor je hulp. Zonder al 
die buisjes bloed die jij de afgelopen jaren voor het FCH onderzoek mede verzameld hebt, had 
ik mijn onderzoek niet kunnen doen. 
Hcy-groep, bedankt voor de steun in de periodes dat het onderzoek minder goed liep, maar ook 
voor de hulp die jullie mij hebben geboden als ik niet wist hoe ik iets moest doen. Er werden 
vele activiteiten georganiseerd door de groep, etentjes, BBQ’s en kerstmaaltijden, en deze waren 
altijd even gezellig. Leo, in de beginperiode van mijn onderzoek heb jij mij bijgestaan met jouw 
jarenlange kennis op het gebied van de genetica, bedankt hiervoor. Sandra, bedankt dat je altijd 
tijd had als Anneke en ik weer eens met vragen bij je kwamen. Henkjan, het was prettig om 
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iemand te hebben die ongeveer even ver was met het promotieonderzoek. En ondanks het feit 
dat je een aantal maanden na mij bent begonnen, ga je nu precies een week eerder promoveren. 
Yvon, als laatste overgebleven promovendus van Henk, wil ik je heel veel succes toewensen bij 
het afronden van jouw onderzoek.
Martin en Sita, dankzij jullie hulp heb ik de resultaten van de linkage analyses toch nog in een 
artikel kunnen verwerken. Cornelia van Duijn, bedankt dat je mij als oud-stagiaire verder hebt 
willen helpen bij het uitvoeren van de haplotype analyses. Aaron, thank you for your help with 
the haplotype analyses. It was always a pleasure for me to come to Rotterdam to perform the 
statistical analyses and to discuss the problems we had with these programs. The breaks in which 
we drank lots of cappuccino and espresso were always a welcome distraction. Philippa Talmud 
and Steve Humphries, thanks for the hospitality during my stay at your laboratory. Rune Frants, 
bedankt voor de samenwerking bij het uitvoeren en analyseren van de linkage analyses. Geesje 
Dallinga-Thie, bedankt voor het uitvoeren van de RLPc bepalingen in onze FCH populatie.
Ook mijn stagiaire Arianne en de studentes Femke, Karin en Uyen, die een scriptie over 
FCH hebben geschreven, wil ik bedanken voor de bijdrage die ze geleverd hebben aan mijn 
onderzoek.
Lieke, echt super dat je mijn paranimf wilt zijn. Het is ﬁjn om een vriendin te hebben waar je 
altijd bij terecht kunt. MSN is gewoon een superuitvinding waardoor we altijd even konden 
bijkletsen of bij elkaar klagen, als de dingen weer eens niet zo liepen zoals we gepland hadden. 
Rome, Barcelona, Turkije, Edinburgh en Lissabon; ik hoop dat we nog veel meer plaatsen aan dit 
rijtje van bestemmingen, die we samen hebben gezien, mogen toevoegen. 
Carolien, Femke, Josianne en Selva, we hebben elkaar leren kennen in het begin van onze studie, 
nu alweer bijna 10 jaar geleden. Ook al zijn we nu allemaal een andere richting opgegaan, we 
zijn nog steeds vriendinnen. Bedankt voor alle steun, belangstelling en gezelligheid de afgelopen 
jaren.
Eveline, tijdens de introductie heb ik je leren kennen toen wij samen in een mentorgroepje 
zaten. We zijn sindsdien vriendinnen en zijn regelmatig samen wezen stappen en op vakantie 
geweest. Ik hoop dat ook jij binnenkort je studie zult afronden. Lilian, we hebben elkaar via via 
leren kennen, maar ondanks de verschillen in studie zien we elkaar gelukkig nog geregeld als we 
samen eten of uit eten gaan. Laura, ondertussen ben jij al weer meer dan een jaar gepromoveerd, 
en hierdoor weet je wat het is. Bedankt voor het logeerbed dat altijd klaar stond voor mij als ik 
weer eens een cursus in Rotterdam had. Judith en Richard, de afgelopen 2 jaar hebben we samen 
op dansles gezeten. Dat was altijd gezellig en ik hoop dat we snel weer een nieuwe gezamenlijke 
activiteit kunnen bedenken zodat we elkaar regelmatig blijven zien. Adriënne en Femke, bedankt 
voor de vele gezellige rik-avonden. Ik hoop dat er nog vele gezellige avonden, waarbij ik met 
winst naar huis mag gaan, zullen volgen.
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